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The majority of chemotherapeutic agents in clinical use exert their antitumor activity 
through the production of cytotoxic lesions in the malignant cell population. This concept 
of tumor cell kill has been the driving philosophy behind the development of most 
anticancer compounds in the last few decades. However, such agents also produce similar 
cytodestructive lesions in normal cells, and the efficacy of clinically useful anticancer drugs 
is achieved only through the greater susceptibility of neoplastic cells to the agents’ cytotoxic 
effects (1). The difference in drug susceptibility between tumor cells and normal cells is 
often small, and this narrow therapeutic index limits the amount of drug which can be given 
to the patient. While such chemotherapeutic agents have been responsible for significant 
advances in the treatment o f several types of cancers, notably childhood leukemias, this 
therapeutic response is often achieved at the expense of significant toxicity to normal cells 
and considerable morbidity to the patient. Furthermore, conventional cytotoxic regimens 
have been much less successful in the treatment of most adult malignancies, and few of the 
currently available drugs have any clinically effective activity against the most common 
forms of adult cancer (2,3).
Continued development of new cytotoxic agents has not led to significant 
therapeutic improvement over available anticancer drugs, and the generation of cytotoxic 
compounds currently under clinical investigation offers few prospects of broader antitumor 
activity (3). Because of the clinical limitations of cytodestructive drugs, it is necessary to 
develop new kinds of therapeutic agents which do not require cytodestruction for antitumor 
action. One such alternative approach envisions the use of pharmacological inducers of 
tumor cell maturation as a possible new therapy (1,4-6).
Differentiation of neoplastic cells. The maturation of tumor stem cells to terminally 
differentiated forms has been shown to be inhibited or abnormally regulated in both
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hematological malignancies and solid tumors (5, 7-9). This loss of control o f cell 
differentiation contributes to an increased population of self-renewing stem cells and to 
consequent tumor growth. In normal proliferating tissues, such as bone marrow, testes 
and skin, the process by which fully differentiated mature cells are continuously lost and 
replaced by a pool of self-renewing stem cells is tightly regulated (10). The pool of 
pluripotent stem cells is capable of self-renewal or differentiation to transitional, committed 
progenitor forms. Mitotic division of a stem cell can yield two new stem cells (self-renewal 
or proliferation), two progeny cells committed to the maturation pathway (differentiation), 
or one new stem cell and one cell committed to maturation. In normal proliferating tissues, 
tight regulation of this delicate balance between self-renewal and differentiation is necessary 
for both growth control and continuous production of mature, functional end-stage cells. 
Committed progenitor cells are restricted to one lineage of development and have limited 
self-renewal potential. These progenitor, or precursor, cells can undergo further 
differentiation and give rise to end-stage cells of that specific lineage. Mature end-stage 
cells are terminally differentiated and have no proliferative capability, but are functionally 
effective for a finite life span (1,11).
This regulated program of differentiation, essential for physiological processes such 
as hematopoiesis, is aberrant in malignancy (12). Hematopoiesis is normally mediated by 
the interaction of cytokines, which include erythropoietin (EPO), colony stimulating factors 
(CSFs) and interleukins (ILs). These glycoprotein molecules determine whether stem cells 
undergo self-replication or commitment to the differentiation pathway. In contrast to 
noimal stem cells, neoplastic stem cells display an increased probability of generating two 
new stem cells upon mitotic division, with a concomitantly decreased probability of 
producing daughter cells committed to the maturation pathway. Consequently, the tumor 
grows as stem cells undergo increased self-renewal and proliferation, and there is a 
decreased progression of stem cells to terminally differentiated, functional cells (1,11).
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However, cancer is not an irreversible process (1). Experimental evidence in a 
variety of tumor types has demonstrated that malignant cells often retain the ability to 
undergo a program of terminal differentiation similar to that occurring in normal tissue cells 
from which they originate (13-17). The sporadically observed spontaneous remission of 
cancer may be due to progression of malignant stem cells to terminally differentiated forms 
without futher proliferative potential. For example, differentiation o f malignant 
neuroblastoma cells to benign ganglioneuroma cells has been documented in pediatric 
patients with stage IV-S neuroblastoma (18,19).
Pharmacological induction of the differentiation of neoplastic stem cells. The initial 
evidence that pharmacological agents can induce the commitment of neoplastic stem cells to 
a maturation pathway and progression to non-tumorgenic forms was reported twenty-five 
years ago. In this first observation, colony stimulating factor (CSF) was shown to enhance 
mature colony formation from murine myelomonocytic leukemia cells (17). Similar studies 
later demonstrated that human spleen conditioned medium can induce the maturation of 
human leukemic myeloblasts and that the polar solvent dimethylsulfoxide (DMSO) can 
induce the differentiation of Friend murine erythroleukemia (MEL) cells (20). In the last 
twenty-five years, a wide variety of chemical and biological agents have been demonstrated 
to induce terminal differentiation of malignant cells in a number of tumor cell systems. 
Pharmacological induction of differentiation has been achieved in tumor cell lines derived 
from all three germ layers and of germ cell origin (1). Thus, the potential use of 
physiological inducers or pharmacological agents to correct the imbalance between self- 
renewing stem cells and mature end-stage cells is a potential approach to cancer therapy 
which needs to be addressed.
Differentiation in vitro has been examined in a number of human and murine 
leukemia cell lines, including the Friend MEL, HL-60 human acute promyclocytic leukemia 
and M l murine myeloid leukemia cell lines (1, 20-23). DMSO was initially shown to 
induce tumor cell maturation in these cell lines, and other polar compounds have
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subsequently been demonstrated to have similar differentiation-inducing activity (24-26). 
While the ability of DMSO and similar chemical agents to induce leukemia cell 
differentiation has been known for two decades, the mechanism by which these 
compounds exert their activity remains unclear. Nonetheless, the ability of these agents to 
induce maturation of leukemia cell lines in culture has simplified in vitro studies of cell 
differentiation (1). One particular murine leukemia cell line that has been studied 
extensively and that is often used to investigate tumor cell maturation is the Friend MEL cell 
line (20).
FRIEND MURINE ERYTIIROLEUKEMIA CELLS
Friend murine ervthroleukemia (MEL) cells and the spleen focus-forming virus 
(SFFV). Friend MEL cells were derived from proerythroblast-like cells isolated from the 
spleens of mice infected with the Friend SFFV viral complex (27, 28). This retroviral 
complex, commonly referred to as the "Friend virus," was discovered by Charlotte Friend 
in 1957 and consists of two component viruses: the spleen focus-forming virus (SFFV), a 
replication-defective retrovirus, and the Friend murine leukemia virus (F-MuLV), a 
replication-competent helper virus (27,29,30). The SFFV is the component responsible 
for the acute erythroleukemia induced by the Friend virus upon infection of adult mice (27, 
31-34). The target cells for SFFV infection has been demonstrated to be relatively late 
committed erythroid precursor cells closely associated with colony-forming unit-erythroid 
(CFU-E) cells (27, 28, 35-37), as depicted in Figure 1. These committed erythroid 
progenitor cells are responsive to the glycoprotein hormone erythropoietin (EPO), the 
principal humoral regulator of erythrocyte production, and are dependent on EPO for both 
proliferation and terminal differentiation to functional erythrocytes (38). EPO has been 
shown to be necessary for colony formation from these cells in in vitro assays (28).
Two variants of the SFFV can be distinguished by their ability to induce 
polycythemia (SFFVp) or a mild anemia (SFFVa) in infected adult mice (27). Mice
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Figure 1. The Friend murineervlhroleukemia (MEL) cell system for studying the 
erythropoietin (EPO)-induced differentiationQtervthroitLcells
The burst-forming unit-erythroid (BFU-E) is an early, committed erythroid 
progenitor cell derived from the colony-forming unit-stem (CFU-S). Interleukin-3 
(IL-3) acts upon CFU-S and BFU-E cells to stimulate both self-renewal as well as 
progression to more mature stages of development. IL-3 induces the differentiation 
of the BFU-E to the more mature colony-forming unit-erythroid (CFU-E).
Erythropoietin (EPO) acts upon the CFU-E to induce both proliferation and 
differentiation to erythrocytes, or mature red blood cells (RBCs). Infection of 
CFU-E cells by Friend virus gives rise to Friend murine erythroleukemia (MEL) 
cells that are independent of EPO and are blocked in EPO-induced differentiation. 
Induction of MEL cell differentiation by dimethylsulfoxide (DMSO) restores 
sensitivity to the differentiating effects of EPO.
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infected with Friend SFFVp or SFFVa viral complexes develop greatly enlarged spleens 
due to a massive proliferation of proerythroblast-like cells in the spleen (27, 28). 
However, whereas erythropoiesis in SFFVa-infected mice remains sensitive to normal 
physiological controls, erythroid differentiation is apparently unregulated in SFFVp- 
infected mice. SFFVp-infected mice continue to produce mature red blood cells even in the 
absence of detectable levels of EPO (28,39-41). Unlike the erythroid progenitor cells that 
are the target of SFFVp infection and EPO-dependent MEL cells derived from SFFVa- 
infected mice, Friend MEL cells derived from mice infected with SFFVp are unresponsive 
to EPO (30,42). SFFVp infection confers extensive self-renewal capacity upon erythroid 
progenitor cells and abrogates their dependence on EPO (Figure 1). These transformed 
Friend MEL cells can grow in the absence of EPO in culture and can form colonies in the 
absence of EPO in in vitro assays (43, 44). In addition, these cells are blocked in their 
differentiation and do not progress down the developmental pathway to mature erythrocytes 
when exposed to EPO in culture (20,27).
Chemical induction of the differentiation of Friend MEL cells. A variety of 
chemical agents, including DMSO, can induce Friend MEL cells to undergo changes in 
cellular morphology and function similar to those occurring during the differentiation of 
proerythroid cells to orthochromatophilic normoblasts. These alterations include a decrease 
in cell size, induction of heme and hemoglobin synthesis, expression of erythrocyte 
antigens, and changes in protooncogene expression. More interestingly, the induction of 
Friend cell differentiation by DMSO is accompanied by a restoration of sensitivity to both 
the growth-stimulatory and differentiation-inducing effects of EPO (Figure 1). DMSO- 
pretreated MEL cells respond to EPO in culture with both increased proliferation and 
increased hemoglobin production, a marker of erythroid differentiation (20,45).
The mechanism by which DMSO induces the differentiation of MEL cells and 
restores sensitivity to EPO remains unclear. A number of second messenger systems have 
been implicated in the chemical induction of differentiation in MEL cells, including cAMP-
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dependent protein kinase (PKA), protein kinase C (PKC) and tyrosine dephosphorylation 
(46-53). A strong body of evidence suggests that PKC plays an important role in the 
chemical induction of differentiation. Depletion of cellular PKC in MEL cells by long-term 
exposure to 12-O-tetiadecanoylphorbol-13-acetate (TPA) blocked the ability of the cells to 
differentiate in response to hexamethylene bisacetamide (HMBA) (51). The introduction of 
murine PKC-p, but not PKC-a, into permeabilized vincristine-resistant MEL cells 
accelerated HMB A-induced differentiation (52). Treatment of MEL cells with TPA or PKC 
inhibitors, such as H7 and sphingosine, blocked subsequent DMSO-induced 
differentiation. In addition, although PKC activity declined during MEL cell maturation, 
continued PKC activity was necessary for completion of the differentiation process (53).
Tyrosine dephosphorylation has also been implicated in the erythroid differentiation 
o f MEL cells (48). Several protein tyrosine kinase inhibitors, including ST638 and 
genistein, have been shown to effectively induce MEL cell differentiation (47,48). It was 
recently reported that most cellular phosphotyrosine-containing proteins were either 
decreased or disappeared very early in erythroleukemia cells induced to differentiate by 
exposure to DMSO. The phosphotyrosine phosphatase (PTP) inhibitor, sodium 
orthovanadate (Na3V0 4 ), prevented the alterations in phosphotyrosine-containing proteins, 
as well as the cellular differentiation produced by DMSO (49). In addition, mutant MEL 
cells resistant to the induction of differentiation by DMSO did not exhibit changes in 
phosphotyrosine-containing proteins (49). While both PKC activity and tyrosine 
dephosphorylation have been implicated in the maturation of MEL cells, the relative 
importance of each event remains unclear. Thus, it is not known whether PKC activity and 
tyrosine dephosphorylation are two separate, yet both necessary, pathways for the 
commitment to differentiate in response to DMSO or whether both activities are part of the 
same pathway, with one activity being upstream or downstream of the other. In addition, it 
is not known whether the tyrosine dephosphorylation seen in MEL cells undergoing
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maturation results from a decrease in tyrosine kinase activity, an increase in PTP activity, 
or a combination of both (49).
ERYTHROPOIETIN RECEPTOR
Erythropoietin (EPO). Erythropoietin (EPO) is a 34 kilodalton (kDa) glycoprotein 
hormone which is the primary humoral regulator of erythrocyte production. EPO is 
produced primarily by interstitial cells adjacent to proximal convoluted tubules in the 
kidney, although a small amount of EPO production occurs in the liver (38, 54). After 
synthesis and release by the kidney, EPO circulates to bone marrow where the hormone 
increases red blood cell production through the stimulation of committed erythoid 
progenitor cells (55, 56). EPO primarily stimulates CFU-E cells, which are highly 
responsive to EPO and give rise to erythroblast colonies (38,54). As erythroid progenitor 
cells differentiate beyond the nondividing late basophilic erythoblast stage, they become 
independent of EPO for continued maturation (57).
Unlike other hematopoietic growth factors, EPO production is regulated by a classic 
negative feedback control system. EPO production and consequent erythrocyte production 
increase in response to hypoxia, and hyperoxia acts as a negative regulator of EPO, as well 
as of erythrocyte, production (54). Recombinant human EPO (rhEPO) has been used 
clinically as a pharmacological inducer of red blood cell production in anemia resulting 
from renal failure with consequent inadequate production of endogenous EPO. 
Administration of rhEPO to anemic patients with renal failure results in a rapid and dramatic 
rise in patients’ hematocrits (58,59).
Erythropoietin receptor fEPORL The complementary deoxyribonucleic acid 
(cDNA) for the murine erythropoietin receptor (EPOR) has been cloned from an MEL 
cDNA library using a COS cell expression system (60). This cDNA encodes a 507 amino 
acid polypeptide with a single membrane-spanning domain. The EPOR is a type I 
transmembrane protein, with the amino terminus oriented on the luminal face and the
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carboxy terminus oriented on the cytoplasmic face. The human EPOR cDNA has also been 
cloned and encodes a 508 amino acid polypeptide (61). The human and murine receptors 
share 82% homology in both cDNA and amino acid sequences, and both polypeptides have 
a predicted molecular weight of 55 kDa based on the amino acid sequences. A newly 
synthesized polypeptide of human or murine EPOR has a moleculer size of 62 kDa as 
determined by protein gel electrophoresis (57, 60, 61), and this polypeptide undergoes 
post-translational glycosylation and oligosaccharide processing. The mature EPOR is 
expressed on the cell surface as a 66 kDa glycoprotein, as determined by protein gel 
electrophoresis.
The EPOR belongs to the cytokine receptor superfamily, which also includes the 
receptors for granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage- 
colony stimulating factor (GM-CSF), interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-7, 
interferon (IFN)-a, IFN-y, prolactin (PRL) and growth hormone (GRH) (62-69). The 
members of the cytokine receptor superfamily share a conserved tryptophan-serine-X- 
tryptophan-serine (WSXWS) motif just proximal to the transmembrane domain, as well as 
four spaced cysteine residues near the amino terminus (55). In contrast to the receptor 
protein tyrosine kinases, the cytokine receptors do not contain an intrinsic protein kinase 
domain. However, phosphorylation of cytoplasmic proteins seems to be important for 
EPO-induced proliferation, and the membrane-proximal region of the cytoplasmic domain 
of EPOR has been shown to be necessary for this proliferation (57,70-73). EPO binding 
induces tyrosine phosphorylation of the EPOR and association of the receptor with the 
cytoplasmic tyrosine kinase JAK2. This association leads to activation of JAK2 kinase 
activity, although it is not known whether JAK2 phosphorylates the EPOR (72,74,75).
Extensive crosslinking studies were conducted to identify the EPOR prior to 
isolation of the human and murine receptor cDNAs, and further studies have been 
performed to examine proteins which may be involved in the EPOR complex. However, 
the results of these experiments have not led to a clear model of the EPOR complex.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
10
Radioiodinated EPO has been crosslinked primarily to 85 and 100 kDa polypeptides in a 
variety of cell lines, but these proteins have not been shown to be immunologically related 
to the cloned EPOR (55,76-81). It is unclear what role, if any. these two proteins play in 
the EPOR complex, or if these proteins are really associated with the receptor. 
Surprisingly, no immunologically related protein of 66 kDa, the known molecular weight 
of EPOR expressed from cloned cDNA, has been shown to be crosslinked to 
radioiodinated EPO.
A point mutation resulting in the change of an arginine to a cysteine at residue 129 
of the exoplasmic domain produces a constitutively active, ligand-independent EPOR 
mutant, R129C (82). The mutant receptors form disulfide-linked homodimers, 
independent of EPO, in the rough endoplasmic reticulum (RER) and are transported to the 
plasma membrane (83). The constitutive activity of these disulfide-linked homodimers of 
R129C suggests that EPO-induced dimerization of wild-type EPOR may be necessary for 
signal transduction to occur in response to EPO. Several other members, including the 
GRH receptor, of the cytokine receptor superfamily have been shown to undergo ligand- 
induced homodimerization, and residue 129 of the EPOR maps to the dimer interface 
region of the GRH receptor (57, 84). Thus, homodimerization of the EPOR is thought to 
be necessary for the receptor to transduce its mitogenic signal. Whether such 
homodimerization is also required for transduction of the differentiation-inducing effect of 
EPO is unclear.
Binding studies of the EPOR. Radioiodinated EPO has been used to examine 
EPOR expression on a number of cell lines derived from the erythroid lineage, including 
normal erythroid progenitors, Friend MEL cells, other murine and human erythroleukemia 
cells, and cells from human fetal liver (55,76-78,80, 81, 85-92). The number of specific 
binding sites per cell and the affinity constants, or dissociation constants (kds), have been 
determined for many cell lines, and the values vary from cell line to cell line. The values 
for a number of murine cells and cell lines are summarized in Table 1. Erythroid progenitor
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Table 1. Cell receptor numbers and binding affinities of erythropoietin receptors 
(EPORs) expressed on murine cells or cultured murine cellJings
Murine cells or cell lines Receptor number per cell Binding affinity (nM)
EPOindependent cell lines









Rauscherred 1 160 2.7




FDC-P2 ‘ 20-60 0.8-1.4
IC-2 20-60 0.8-1.4
Murine cells
Friend cells 180-1000 0.09 (20%)
0.60 (80%)
CFU-E 370 0.07 (40%)
0.81 (60%)
Fetal liver cells 400-1200 0.1-0.4 (75%)
3.1 (25%)
This table is taken from information presented in D’Andrea, A. D. and Zon, L. I., 
Erythropoietin receptor: subunit structure and activation, J. Clin. Invest. 86:681- 
687 (1990) and the appropriate references therein.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
12
and erytholeukemia cells express from 100 to over 1000 EPO receptors per cell, and 
independent investigators have often reported very different numbers of receptors for the 
same cell line. The relatively low number of surface receptors for EPO is also typical for 
other members o f the cytokine receptor superfamily, such as the G-CSF, GM-CSF, IL-3 
and IL-6 receptors (93-95).
Some cell lines express both high- and low-affinity receptors, with an affinity 
constant of less than 100 pM for the high-affinity receptor and an affinity constant of 400 
pM to over 1 nM for the low-affinity EPOR. Many erythroid cells, including MEL cells, 
express receptors of only a single binding affinity, generally of low affinity (kd > 400 pM). 
Affinity constants of 100 pM to greater than 1 nM have been determined for these 
receptors, and widely varying values for several cell lines have been obtained by different 
laboratory groups studying the same line. It is interesting that such a wide range of both 
receptor numbers and affinity constants have been reported for the EPOR, as only one 
murine and one human receptor have been cloned to date. O f particular note are cell lines 
that express receptors of two binding affinities, as only one EPOR cDNA has been isolated 
in both mice and humans (60,61).
Effect of the induction of differentiation upon expression of the EPOR in Friend 
MEL cells. As mentioned above, the induction of Friend MEL cell differentiation by 
DMSO is accompanied by a restoration of sensitivity to both the growth-stimulatory and 
differentiation-inducing effects of EPO. Whereas uninduced Friend cells are independent 
of EPO and are blocked in their capacity to differentiate in response to EPO, DMSO- 
pretreated Friend cells respond to EPO with increased cellular proliferation and increased 
hemoglobin production (20,45). However, it remains unclear whether the expression of 
the EPOR in Friend MEL cells changes with chemical induction of differentiation or 
whether this induction is accompanied by expression of an EPOR of a different binding 
affinity from the receptor expressed in the uninduced state. DMSO treatment of Rauscher 
MEL cells, which are EPO-responsive (96), resulted in increased hemoglobin production
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and induction of a new population of high-density receptors (2 0 ,0 0 0  per cell) that displayed 
marked positive cooperativity with a Hill coefficient of 6.75 (97, 98). This positive 
cooperativity was interpreted as evidence that the receptors in Rauscher cells interact with 
each other through the formation of oligomers (98).
However, such cooperativity has not been demonstrated in EPO-nonresponsive 
Friend MEL cell lines. Treatment of MEL cell clone B8 with 1% (v/v) DMSO has been 
reported to increase specific binding of radioiodinated EPO by 200% after one day of 
exposure, although binding decreased to 100% over baseline by day 2  and gradually 
decreased to 50% over baseline after 4 days of exposure to DMSO (90). A single class of 
EPORs with a binding affinity of 1.2-1.4 nM was observed, and DMSO induction did not 
significantly change the binding affinity for EPO and did not result in positive cooperativity 
or expression of a second class of higher-affinity receptors. Thus, Rauscher and Friend 
MEL cells appear to have different responses in EPOR expression when induced to 
differentiate with DMSO.
Despite this work, further studies are needed to examine the changes in EPOR 
expression upon chemical induction of differentiation in Friend MEL cells. It is unclear 
whether the results reported with MEL cell clone B8 can be generalized to all Friend MEL 
cell lines or are specific to that particular line. Of note, the reported affinity constant of 1.3 
nM for clone B8 is a relatively high value compared to other reported dissociation constants 
for the low-affinity EPOR. DMSO acts in some manner to remove the block in EPO 
responsiveness of Friend cells, and it is necessary to examine whether DMSO removes this 
block at the level of the cytokine receptor, rather than at a downstream signal transduction 
site. If such modulation of EPOR expression does occur, possible mechansims may 
include a change in receptor number, appearance of a high-affinity receptor not present in 
uninduced cells, dimerization, or oligomerization of the receptor with positive binding 
cooperativity.
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ENVELOPE GLYCOPROTEIN OF THE SFFV
Unique oncogene of the SFFV. The vast majority of acutely transforming 
retroviruses carry an oncogene which is derived from a normal cellular protooncogene and 
whose protein product is responsible for cellular transformation and tumorigenicity (30). 
Many of these protooncogenes encode a component of the normal cell proliferation 
pathway such as a growth factor or a growth factor receptor. An activating mutation or 
aberrant expression of such a protooncogene can result in uncontrolled cell growth and 
malignancy. For example, leukemia in mice can arise from transforming mutations in 
hematopoietic growth factor receptors such as the CSF-1 receptor and the EPOR (99,100).
However, the Friend SFFV is unique among leukemogenic retroviruses, in that its 
oncogene is derived, not from a transduced cellular protooncogene but, from a viral 
envelope glycoprotein (30, 101-103). The viral envelope glycoprotein of the 
polycythemia-inducing strain of the SFFV, SFFVp gp55, binds to and constitutively 
activates the EPOR in murine erythroid progenitor cells, resulting in growth independence 
from EPO (104). In order to understand this crucial interaction between SFFVp gp55 and 
the murine EPOR, as well as the ability of this interaction to constitutively activate the 
receptor, the structure of SFFVp gp55 has been examined by a number of investigators.
Genome of the SFFV. The SFFV seems to have originated by deletion and 
recombination between its natural helper virus, the F-MuLV, and endogenous murine 
genetic sequences (27, 102, 105). The endogenous murine sequences contained in the 
SFFV are highly homologous to the envelope (env) genes of the mink cell focus-forming 
(MCF) viruses, so that the SFFV and MCF viruses appear to have originated from a 
common genetic source (27). The SFFV genome lacks a gene for a functional RNA- 
dependent DNA polymerase, resulting in replication defectiveness and dependence upon its 
helper virus (101). The SFFV does encode for a truncated gag-related protein, which 
varies in size from 15 to 45 kDa, depending on the particular SFFV strain (27,42, 101). 
In comparison, the prototype gag precursor has a molecular weight of 65 kDa.
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Gp55, the envelope glycoprotein of the SFFVp. The env gene of the SFFV 
encodes a 55 kDa glycoprotein, gp55, which is immunologically related to gp70, the MCF 
viral envelope glycoprotein (106-108). Unlike the gag protein, whose molecular weight 
varies from strain to strain and which is not even expressed in some MEL cell lines, gp55 
is highly expressed in all SFFV strains and is highly conserved from strain to strain (27). 
More importantly, the env gene alone is sufficient for pathogenecity o f the SFFVp, 
although a replication-competent helper virus is necessary to cause actual disease in mice 
(109).
As mentioned above, the SFFV env gene appears to be related to the env genes of 
the MCF viruses. Several nucleotide sequences of the SFFV env gene have been 
published, and these reports have shown that the amino-terminal two-thirds o f the SFFV 
env gene is nonhomologous to the corresponding region of the F-MuLV env gene but does 
share a high degree of homology with the env genes of the MCF viruses (110-112). The 
homology between the SFFV and the Friend MCF or Moloney MCF viruses in this region 
of the env gene is more than 90-95%, and there is a 67 amino acid sequence, beginning 
with amino acid residue number 60, which is identical for all SFFV and MCF viral 
envelope glycoproteins (27, 113,114). In contrast, the carboxy-terminal one-third of the 
SFFV env gene is homologous to the corresponding region of the F-MuLV env gene 
(114).
The SFFV env gene product, gp55, has several unique characteristics which can 
only be appreciated in comparison to the env gene products of other retroviruses, such as 
MuLV gp70, the prototypical retroviral envelope glycoprotein. The env gene of MuLV 
encodes an 80-90 kDa primary translation product which is glycosylated with high 
mannose-containing oligosaccharides. This precursor polyprotein is then cleaved to yield 
gp70, the envelope glycoprotein, and Prl5E, a smaller polypeptide which is further cleaved 
into pl5E and an R peptide (27).
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In the SFFV, however, a 585 base pair deletion in the middle of the env gene has 
removed the cleavage site between gp70 and Prl5E with resultant fusion of the amino- 
terminal gp70 sequences and the carboxy-terminal p l5E  sequences. This genetic deletion 
has resulted in the loss of 195 amino acids surrounding the gp70-Prl5E cleavage site and 
in the generation of a unique fusion protein, gp55 (27,110-112). In addition, a single base 
pair insertion near the 3' end of the p l5E  domain has caused a frame shift with resultant 
premature termination of translation. While the base pair insertion and its exact location 
vary from SFFV isolate to isolate, the results in each case have been the shortening of the 
reading frame by 99 base pairs, or 33 amino acids, and the generation of a unique sequence 
of 5 or 6  amino acids at the carboxy-terminus of gp55. Both the 585 base pair deletion and 
the single base pair insertion are conserved in all SFFV isolates, indicating that both 
mutations play a role in the pathogenecity of the virus (27).
Defective oligosaccharide processing and transport of SFFVp gp£>. The resultant 
SFFVp env gene product is a 409 amino acid polypeptide that has a molecular weight of 45 
kDa and is defective in carbohydrate processing and transport to the cell surface (27, 111, 
115). The large deletion in the SFFVp env gene has removed three putative asparagine- 
linked glycosylation attachment sites, and the carbohydrate processing that occurs at the 
remaining four N-linked glycosylation sites is incomplete (27, 113, 114, 116). The 
predominant form of the SFFVp env gene product that accumulates intracellularly is a 55 
kDa glycoprotein which remains ir. an immature, high mannose oligosaccharide, 
endoglycosidase H (endo H)-sensitive state within the RER (27,107,108,115).
This endo H-sensitive fraction, which accounts for 95% of the SFFVp env gene 
product, is blocked in its passage into the Golgi apparatus, where final N-linked 
oligosaccharide processing of glycoproteins to mature glycosylation patterns occurs. 
However, 2-5% of the SFFVp env gene product is transported to the cell surface, where it 
exists in an endo H-resistant 65 kDa form which undergoes homodimerization through the 
formation of disulfide bonds (27, 107, 115, 117). In addition, the large deletion in the
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SFFVp env gene has generated a transmembrane glycoprotein with only a two amino acid 
cytoplasmic tail. Thus, SFFVp gp55 is a unique integral membrane protein that consists of 
an exoplasmic domain, a putative 29 amino acid transmembrane domain, and an almost 
non-existent cytoplasmic domain (111 , 112).
Differences between the transmembrane regions of SFFVa gp55 and SFFVp gp55. 
The env genes of the SFFVa and SFFVp have been sequenced to determine differences 
between the anemia- and polycythemia-inducing strains of the SFFV, as the env gene has 
been shown to determine the biological activity of the SFFV (118). The major amino acid 
differences between SFFVa gp55 and SFFVp gp55 reside in the transmembrane domains 
of the two glycoproteins. There are 10 amino acid differences between SFFVa gp55 and 
SFFVp gp55, all within or proximal to the transmembrane region, and there is also a 2 
amino acid insertion in the transmembrane region o f SFFVp gp55 (115, 119). These 
amino acid differences have been shown to be responsible for the differences in 
responsiveness to and dependence upon EPO between MEL cells derived from mice 
infected with the Friend SFFVa and SFFVp viral complexes (119,120). While MEL cells 
derived from SFFVa-infected mice are EPO-dependent, Friend MEL cells derived from 
SFFVp-infected mice are EPO-independent and are unresponsive to the growth-stimulatory 
and differentiation-inducing properties of the cytokine (27).
GP55 AND THE NON-RESPONSIVENESS OF FRIEND MEL CELLS TO EPO
Interaction between the EPOR and SFFVp gp55. The env gene of the SFFVp has 
been identified as the part of the retroviral genome that is responsible for the EPO 
independence of SFFVp-infected erythroid progenitor cells (109). The initial studies were 
carried out using IL-3-dependent murine Ba/F3 cells that had been stably transfected with a 
plasmid expressing the cDNA for the murine EPOR. The resultant Ba/F3-EPOR cells were 
able to grow in the presence of IL-3 or EPO but still required one of the two factors for cell 
viability (104). Subsequent transfection of Ba/F3-EPOR cells with a retroviral vector
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expressing the cDNA for SFFVp gp55 conferred factor independence upon these cells, and 
coimmunoprecipitation experiments demonstrated that gp55 and the EPOR physically 
associated with resultant constitutive activation of the receptor. Transfection of Ba/F3 cells 
with a retroviral vector expressing the SFFVp gp55 cDNA did not result in IL-3- 
independent growth, and gp55 did not coimmunoprecipitate with the IL-3 receptor in these 
cells (104).
These and similar studies with other members of the cytokine receptor superfamily 
demonstrated the specificity of the interaction between SFFVp gp55 and the EPOR, as 
gp55 has not been shown to be physically associated with other members of the cytokine 
receptor superfamily or to induce growth independence from other cytokines (115). In 
addition, somewhat different studies in an in vivo experimental system demonstrated that 
expression of SFFVp gp55 was sufficient for tumorigenicity in erythroid cells and that this 
tumorigenicity was specific for erythroid cells. In these studies, transgenic mice 
expressing the SFFVp env gene, but no other part of the SFFVp genome, developed 
erythroleukemia but no other malignancies, confirming that the expression of gp55 resulted 
in the specific transformation of cells of the erythroid lineage (109).
Interaction between the transmembrane regions of the EPOR and SFFVp  gp55. 
Because the cytoplasmic tail of SFFVp gp55 consists of only two amino acids, the 
interaction of gp55 with the EPOR must occur between the exoplasmic or transmembrane 
domains of the two proteins (115). Mutations within either the exoplasmic or 
transmembrane region can cause a loss of tumorgenicity, suggesting that both regions may 
be necessary for interaction with the EPOR (121). Considerable additional evidence 
suggests that interaction of the transmembrane domains is important for the capacity of 
SFFVp gp55 to constitutively activate the EPOR (115, 119, 120). The amino acid 
differences between the transmembrane domains of SFFVa gp55 and SFFVp gp55 have 
been previously discussed in this section. These amino acid differences have been shown 
to determine the biological activity of the SFFV. In particular, the transmembrane region of
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SFFVp gp55 has been demonstrated to be necessary for growth independence from EPO in 
erythroid progenitor cells infected with the SFFV genome (119).
Similarly, the transmembrane region of the EPOR has been shown to be necessary 
for activation of EPO-independent growth by SFFVp gp55 in transfection studies of Ba/F3 
cells expressing chimeric receptors containing regions of the EPOR and the IL-3 receptor 
(70, 115). While a chimeric polypeptide containing the exoplasmic region of the EPOR 
and the transmembrane and cytoplasmic regions of the IL-3 receptor was able to physically 
associate and coimmunoprecipitate with gp55, this association did not result in EPO- 
independent cell growth. In contrast, a chimera of the exoplasmic and transmembrane 
domains of the EPOR and the cytoplasmic domain of the IL-3 receptor was bound and 
constitutively activated by SFFVp gp55. Thus, while the exoplasmic domain of the EPOR 
is involved in binding of the cytokine receptor to gp55, the transmembrane region is 
necessary for activation of the receptor by gp55 (115). The same studies also excluded the 
possibility that gp55 acts through the same binding site on the EPOR as does the natural 
ligand, EPO. First, there is no homology between the amino acid sequences of gp55 and 
EPO. More importantly, the first chimeric receptor was able to confer EPO-dependent 
growth upon Ba/F3 cells, demonstrating the capacity of the chimera to recognize EPO, but 
could not be constitutively activated by gp55.
SFFVp gp55-EPOR interaction, in the RER and at the cell surface, and activation of 
the EPOR bv gp55. Interestingly, SFFVp gp55 has been shown to associate with the 
EPOR primarily in the RER (122). This association in the RER interrupts normal 
carbohydrate processing and intracellular transport of the EPOR. As discussed previously, 
gp55 is defective in oligosaccharide processing and transport to the cell surface; instead, 
95% of the viral envelope glycoprotein is retained in an endo H-sensitive form within the 
RER (27, 107, 115,116). Expression of SFFVp gp55 in Ba/F3-EPOR cells resulted in 
retention of the EPOR in a high mannose, endo H-sensitive 64 kDa form within the RER 
and inhibited processing of the receptor to its mature, endo H-resistant 6 6  kDa form. The
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presence of gp55 also inhibited degradation of synthesized EPORs and prolonged the half- 
life of the cytokine receptors. Additionally, the intracellular gp55 form of the SFFVp env 
gene product, and not the cell surface gp65 form of the envelope glycoprotein, 
coimmunoprecipitated with the EPOR in cellular lysates of Friend MEL cells (122). 
Because of these results, as well as the observation that 95% of SFFVp gp55 and, in 
probable likelihood, a similar percentage of gp55-EPOR complexes remain in the RER, it 
was postulated that a novel mechanism, by which a mitogenic signal was generated from 
within the cell, could be responsible for the constitutive activation of the EPOR by gp55 
(115, 122).
However, more recent studies have suggested that the mitogenic signal is generated 
by the interaction of SFFVp gp55 and the EPOR at the cell surface. Radioiodinated EPO 
was chemically crosslinked to the cell surface gp65 form of gp55 in Friend MEL cells, 
demonstrating that a detectable amount of the SFFVp env gene product is associated with 
the EPOR at the cell surface of Friend cells (123). Interestingly, this set of experiments, as 
in all other reported crosslinking studies with radioiodinated EPO, did not observe 
crosslinking of radiolabeled EPO to its own receptor. Secondly, five SFFVp env mutants 
encoding glycoproteins that were expressed on the cell surface conferred factor 
independence upon Ba/F3-EPOR cells, whereas three mutants whose products were not 
transported out of the RER were not able to confer EPO independence upon Ba/F3-EPOR 
cells. The presence of the five pathogenic SFFVp env mutants in EPOR complexes on the 
cell surface was confirmed by crosslinking studies (124). Therefore, while the majority of 
the interaction between SFFVp gp55 and the EPOR occurs intracellularly within the RER, 
the small amount of interaction (2-5% of total gp55-EPOR complexes) between the fully 
processed gp65 form and the EPOR at the cell surface appears to be responsible for 
constitutive activation of the EPOR in Friend MEL cells.
Use ofchemical crosslinking to study SFFVp_gp55-EPQR interaction at the Friend 
MEL cell surface. As summarized above, a number of investigators have demonstrated that
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SFFVp gp55(gp65) and the EPOR are expressed on the cell surface of Friend MEL cells in 
very small numbers (27,55,107,115). It is possible that previous studies may have been 
unable to detect the small amount of cell surface complexes between the two glycoproteins. 
Because of the experimental limitations imposed by the small numbers of EPORs and 
gp55(gp65)-EPOR complexes on the cell surface of Friend cells, many of the studies that 
have examined the cell surface interaction of the two proteins have employed chemical 
crosslinking as an experimental tool (61, 74, 76-81, 89, 90, 123, 125). Chemical 
crosslinking has often been used to identify cell surface receptor proteins for which cDNA 
clones were not yet available or to characterize receptor expression in particular cell types or 
culture lines (126-128). While such studies have been used to identify crosslinked proteins 
as the receptors for other radiolabeled ligands, all attempts to crosslink radiolabeled EPO to 
its receptor have been unsuccessful. No immunologically related protein of 6 6  kDa, the 
molecular weight of the cloned mEPOR, has been reported to be crosslinked to 
radioiodinated EPO.
In addition to the actual cell surface receptor, however, chemical crosslinking can 
also identify proteins that are associated with the receptor. As mentioned above, 
radioiodinated EPO was crosslinked to the cell surface gp65 form of gp55 in Friend MEL 
cells, demonstrating that the SFFVp env gene product is associated with the EPOR at the 
Friend MEL cell surface (123). Interestingly, crosslinking of labeled EPO to gp55(gp65) 
was observed even in the absence of crosslinking of labeled EPO to the EPOR. These 
experiments demonstrated that the cell surface form of SFFVp gp55 is in close enough 
physical approximation to the EPOR to be crosslinked to radiolabeled EPO upon binding of 
EPO to its receptor. The close physical proximity of gp55(gp65) to the EPOR strongly 
suggests that the cell surface form of gp55 is associated with the EPOR complex at the 
Friend MEL cell surface.
Use of coimmunoprecipitation to study SFFVp pp55-EPOR interaction. The other 
experimental tool which has been frequently used in investigations of EPOR complexes and
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the interaction between gp55 and the EPOR is coimmunoprecipitation by antibodies which 
recognize SFFVp gp55 and the murine EPOR. This method was used to report the first 
evidence of the physical association between gp55 and the EPOR (104, 122). The 
intracellular location of the SFFVp gp55-EPOR association may be determined in several 
ways. First, the size of the immunoprecipitated form of gp55 is informative. The RER 
form of the SFFVp env gene product has a lower molecular weight, 52-55 kDa, than the 
cell surface form, which has a size of 65 kDa (27, 107, 116). In contrast, the EPOR 
undergoes a smaller increase in molecular size, from 62 kDa to 6 6  kDa, upon carbohydrate 
processing and transport to the cell surface. Secondly, endoglycosidase H treatment may 
be used to determine if the proteins in the gp55-EPOR complex have been transported 
through the Golgi (122). Lastly, careful cell fractionation and purification of membranes 
may allow determination of the amounts of gp55-EPOR complex in each membrane 
compartment, although this method has not been a commonly employed approach.
Coimmunoprecipitation, however, does have limitations. First, SFFVp gp55- 
EPOR complexes in the RER are more readily detected then cell surface complexes due to 
the greater number o f such complexes in the RER (122). Consequently, cell surface 
complexes may be difficult to detect due to their much lower numbers. Secondly, physical 
association of gp55 and the EPOR after formation of a cellular lysate can not be 
distinguished from actual association within the living cell. Thus, the two glycoproteins 
may be located in physically separate intracellular, or membrane, compartments in the 
living cell and may only associate when the cell undergoes lysis during in vitro 
manipulation of experimental cell samples. While these drawbacks should not exclude the 
use of this very useful experimental tool, the inherent limitations of coimmunoprecipitation 
studies must be kept in consideration when interpreting results from these types of studies.
Effect of DMSO upon the cell surface interaction of SFFVp gp55 and the EPOR. 
Of particular interest to this laboratory were the role of SFFVp gp55 in blocking the EPO- 
induced differentiation of MEL cells and the effect of DMSO induction of MEL cell
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
23
differentiation on the cell surface interaction between SFFVp gp55(gp65) and the EPOR. 
EPO both stimulates cell growth and induces differentiation of normal committed erythroid 
progenitor cells (38,54). SFFVp gp55 associates with the EPOR in Friend MEL cells, and 
this association constitutively activates a mitogenic signal from the receptor but does not 
result in activation of a differentiation signal (104). Moreover, although the EPOR 
expressed on Friend cells can bind EPO, a signal for the cell to differentiate is not 
transduced upon binding of EPO by the receptor. Thus, while activation of the EPOR by 
gp55 has been shown to be responsible for EPO-independent growth, it is unclear whether 
the presence of gp55 is responsible for the inability of Friend cells to differentiate in 
response to EPO.
As has been previously discussed above, exposure to DMSO induces Friend MEL 
cell maturation and restores EPO responsiveness to these cells (20). Given the importance 
of the cell surface interaction between gp55(gp65) and the EPOR in the constitutive 
activation of the cytokine receptor by gp55, it is conceivable that this interaction may also 
result in a block in EPO-induced differentiation. Such a block could occur through 
prevention by gp55 of an association between the EPOR and a third protein necessary for 
transduction o f a differentiation signal. Alternatively, the constitutive activation of a 
proliferation signal by gp55 may be sufficient to block any EPO-induced differentiation 
signal. Given the importance of the gp55-EPOR interaction, it is also conceivable that 
induction of maturation by DMSO may result in an interruption or perturbation of this 
association. It would, therefore, be quite interesting to determine whether induction of 
differentiation by DMSO is accompanied by dissociation of the EPOR from the cell surface 
form of gp55, thus allowing the receptor to transduce both a mitogenic and a 
differentiation-inducing signal upon binding EPO.
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MATERIALS AND METHODS
Materials. Recombinant human erythropoietin (rhEPO) for use in tissue culture 
studies was obtained through the generous gift of Dr. Marc Weisberg, R. W. Johnson 
Pharmaceutical Research Institute, Raritan, NJ. This tissue culture-grade rhEPO (10,000 
units/ml in a sterile buffered solution containing 2.5 mg/ml of human serum albumin; lot N- 
6985) was divided into 100 pi aliquots and stored at 4°C (129-131). Purified, serum 
albumin-free rhEPO for use in radioiodination and binding studies was also kindly donated 
by Dr. Weisberg. This iodination-grade rhEPO (200,000 units/ml in a sterile solution of 
50% [v/v] glycerol and 25 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid] buffer [pH 7.2]; lot N-7310) was divided into 10 pi aliquots and stored at -20°C. All 
other reagents were purchased from commercial sources as noted.
Cell culture. Friend murine erythroleukemia (MEL) PC4 cells, a subclone of the 
Friend MEL cell line 745, were obtained through the generous gift of Dr. David E. 
Housman, Massachusetts Institute of Technology, Cambridge, MA (132). Cells were 
maintained in suspension culture in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 15% (v/v) fetal bovine serum (FBS; Sigma Chemical Co., S t  Louis, 
MO, or GIBCO BRL /  Life Technologies, Gaithersburg, MD) and 2 mM L-glutamine 
(Sigma) at 37°C in a 90% air /  10% CO2 NAPCO 6300 humidified incubator (National 
Appliance Co., Portland, OR). For all experiments, as well as passages, cells were seeded 
at 4 x 104 cells/ml, and passaged cells were maintained in logarithmic growth.
A dimethylsulfoxide (DMSO)-resistant subline of MEL cells, DMSO/R1, was 
obtained without mutagenesis by passaging MEL cells in growth medium (DMEM, 15% 
[v/v] FBS, 2 mM L-glutamine) containing progressively higher concentrations of DMSO 
(Sigma), up to 1.5% (v/v) DMSO. DMSO/R1 was then cloned by single cell sorting using 
a FACS IV flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA).
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Unless otherwise noted, DMSO/R1 cells were continuously passaged in growth medium 
containing 1.25% (v/v) DMSO in a humidified air atmosphere containing 10% CO2.
Ba/F3-EPOR cells were derived from murine lymphoid Ba/F3 cells (133) which 
had been stably transfected with the eukaryotic expression vector p75/15-EPOR, which 
contains the complementary deoxyribonucleic acid (cDNA) for the murine erythropoietin 
receptor (EPOR) (60). Unlike parental Ba/F3 cells, which are dependent upon 
interleukin(IL)-3 for cellular growth, Ba/F3-EPOR cells can grow in the presence of IL-3 
or EPO (104). Ba/F3-EPOR cells were the generous gift of Dr. Kimiko Ishiguro, Yale 
University, New Haven, CT. Cells were maintained in suspension culture in R PM I1640 
medium supplemented with 10% (v/v) FBS and 0.3 units/ml of rhEPO at 37°C in a 95% 
air /  5% CO2 humidified incubator. Cells were seeded at approximately 4 x 104 cells/ml for 
passage, and passaged cells were maintained in exponential growth.
Chemical inducers of erythroid differentiation. Sterile filtered, tissue culture-grade 
(Hybri-Max) DMSO was purchased from Sigma and divided into 500 pi aliquots, which 
were stored at room temperature. A sterile stock solution of 500 mM HMBA (N,N‘- 
hexamethylene bisacetamide; Sigma) was made by filtering an aqueous solution through a 
0.22 pm Millex filter unit (Millipore Corp., Bedford, MA). Stock HMBA solution was 
wrapped in aluminum foil and stored at room temperature.
Differentiation-induced erythropoietin (EPO) responsiveness. MEL or DMSO/R1 
cells were seeded at 4 x 104 cells/ml in the presence of 1.25% (v/v) DMSO, 2 mM HMBA, 
4 mM HMBA, or no inducer. Cells were incubated for 3 days at 37°C in a humidified air 
atmosphere containing 10% CO2 . Cell numbers were determined on day 3, and cells were 
reseeded at 4 x 104 ceils/ml in the absence or presence of 0.5 unit/ml of tissue culture-grade 
rhEPO in growth medium containing the same type and concentration of inducer as before. 
Cells were incubated for 3 more days at 37°C in a humidified air atmosphere containing 
10% CO2. Cell densities were assayed on day 6  as a measure of proliferation, and cellular 
hemoglobin content was determined as a marker of erythroid differentiation (2 0 ).
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To determine whether the DMSO-resistant phenotype of DMSO/R1 was dependent 
upon continuous passage in DMSO-containing growth medium, DMSO/R1 cells were 
passaged for 1 week or 1 month in the absence of DMSO. Cells were then assayed for the 
ability of DMSO to induce differentiation and for EPO responsiveness, as described above.
Cell density. Cell numbers were determined using a Sampling Stand II (Coulter 
Corp., Hialeah, FL) and a Coulter ZM particle counter. Cell sizes were ascertained with a 
Coulter Channelyzer 256 multichannel analyzer.
Determination of hemoglobin content. A modification of a previously described 
method was used to measure hemoglobin content (134). Five x 106  cells were collected by 
centrifugation in an IEC Centra-7 centrifuge (International Equipment Co., Needham 
Heights, MA) and washed with 1 ml of ice-cold Hanks’ balanced salt solution (HBSS; 
GIBCO). Cells were lysed in 100 pi of ice-cold extraction buffer (20 mM Tris-HCl [pH 
7.5], 10 mM MgCh, 30 mM KC1,0.5% [w/v] Triton X-100), and nuclei were removed by 
centrifugation at 16,000 g for 5 minutes in an Eppendorf 5415C microcentrifuge 
(Brinkmann Instruments, Westbury, NY). The resulting supernatant was designated the 
nuclei-free cellular lysate. Fifty pi of nuclei-free cellular lysate were added to 2 ml of a 
freshly prepared solution of 0.033% (w/v) TMB (3,3',5,5'-tetramethylbenzidine; Aldrich 
Chemical Co., Milwaukee, WI) and 0.083% (v/v) H2O2 (J.T. Baker Chemical Co., 
Phillipsburg, NJ) in 10% (v/v) acetic acid (J.T. Baker), and the sample was mixed by 
gentle vortexing. After incubation at room temperature for 7 minutes, the absorbance was 
measured at 515 nm (OD515) in a Beckman Model 25 spectrophotometer (Beckman 
Instruments, Fullerton, CA). A standard curve was constructed from OD515 measurements 
of standards made with Type IV human hemoglobin (Sigma), and the hemoglobin contents 
of samples were quantified using the standard curve.
Isolation of total ribonucleic acid (RNAf. Total cellular RNA was isolated by 
extraction with guanidinium thiocyanate (Fluka Chemical Corp., Ronkonkoma, NY) 
followed by sedimentation through a cesium chloride (CsCl; American Bioanalytical,
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Natick, MA) gradient, as previously described (135*138). Five to fifteen x 107 cells were 
collected by centrifugation, and cells were resuspended in 10 ml of growth medium and 
transferred to a 15 ml conical tube. Cells were collected by centrifugation, and the 
supernatant was decanted. Cells were broken by vigorously vortexing the pellet at 
maximum speed for 30 seconds. Four ml of homogenization buffer (4 M guanidinium 
thiocyanate, 25 mM sodium citrate [pH 7.0], 0.5% [w/v] sodium lauryl sarcosinate, 100 
mM 2-mercaptoeihanol) were added, and the cellular lysate was homogenized by vigorous 
vortexing at maximum speed for 30 seconds.
The homogenate was carefully layered onto a 2.5 ml cushion of 5.7 M CsCl, 0.1 M 
EDTA (pH 7.0) in a Beckman 14 x 89 mm polyallomer centrifuge tube, and 3.5 ml of 
guanidinium thiocyanate homogenization buffer were added to the tube. The homogenate 
was centrifuged for 16-18 hours at 20°C and 32,000 rpm using an SW40 swinging-bucket 
rotor and a Beckman L5-75B ultracentrifuge (137). The resulting supernatant, including 
protein and DNA, was carefully removed by aspiration and decantation. The pellet, 
containing total cellular RNA, was washed twice with 70% (v/v) ethanol and allowed to 
dry at room temperature. The pellet was resuspended in 50-150 pi of sterile water, 
depending on the number of cells originally harvested. The RNA concentration of the 
resulting solution was determined by measuring the ultraviolet (UV) absorbance at 260 nm 
(OD260) using a Beckman Model 25 spectophotometer. The UV absorbance at 280 nm 
(OD280) was measured, and the ratio of OD26O to OD28O was determined to ensure the 
absence of protein contamination. Sterile water was added to dilute the RNA solution to 
approximately 3 mg/ml, and the final RNA concentration was determined by repeating UV 
absorbance measurements.
Electrophoresis of RNA through formaldehyde gels. Ten pg of total RNA were 
prepared for electrophoresis as previously described (139-141). RNA was dissolved in 20 
pi of a solution containing lx MOPS buffer, 2.2 M formaldehyde (J.T. Baker) and 50% 
(v/v) formamide (J.T. Baker, deionized by mixing with Bio-Rad AG 501-X8 mixed resin
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beads followed by filtration). MOPS buffer (lx ) consisted of 20 mM MOPS (3-[N- 
morpholino]propanesulfonic acid; American Bioanalytical), pH 7.0,5 mM sodium acetate 
and 1 mM EDTA (pH 8.0). Samples were incubated at 65°C for 15 minutes to denature 
RNA and were then chilled on ice. Four pi of 6x gel-loading buffer (1 mM EDTA [pH
8.0], 0.25% [w/v] bromophenol blue, 0.25% [w/v] xylene cyanol, 40% [v/v] glycerol) 
were added, and the samples were mixed. Samples were subjected to electophoresis 
through a 1.0% (w/v) Agarose (American Bioanalytical) gel containing 0.66 M 
formaldehye and 0.5 pg/ml of ethidium bromide (Sigma) in lx  MOPS buffer. An IBI 
Model MPH electrophoresis unit (International Biotechnologies, New Haven, CT) was 
employed, and lx  MOPS was used as the running buffer. A Model 3-3000 UV illuminator 
(Fotodyne, New Berlin, WI) was used to visualize 18S and 28S ribosomal RNA (rRNA) 
bands, and a photograph was taken with a Polaroid MP-4 Land Camera (Polaroid Corp., 
Cambridge, MA).
Transfer of RNA to nitrocellulose membranes. RNA was partially hydrolyzed by 
soaking the gel in 0.05 N NaOH under gentle agitation on a Model G2 Laboratory Rotator 
(New Brunswick Scientific Co., New Brunswick, NJ) for 20 minutes. The gel was then 
soaked in lOx SSC transfer buffer (150 mM sodium citrate [pH 7.0], 1.5 M NaCl) under 
gentle agitation for 15 minutes. RNA was transferred to an Immobilon-NC nitrocellulose /  
cellulose acetate membrane (Millipore) using lOx SSC as the transfer buffer and a TE80 
TransVac vacuum transfer unit (Hoefer Scientific Instruments, San Francisco, CA) as 
previously described (142-144). The membrane and gel were examined by UV 
illumination to assess the efficiency of transfer, and transferred RNA was crosslinked to 
the membrane using a Stratalinker UV crosslinker 1800 (Stratagene Cloning Systems, La 
Jolla, CA).
Purification of cDNA fragments for use as Northern hybridization probes. A probe 
for murine erythropoietin receptor (EPOR) messenger RNA (mRNA) transcripts was 
obtained by Kpnl-digestion of pXM-EPOR. pXM-EPOR, a mammalian expression vector
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containing an ampicillin resistance {amp1) gene and the murine EPOR cDNA, was the 
gracious gift o f Dr. Alan D'Andrea, Children's Hospital, Boston, MA (60). 
Logarithmically growing E. coli, strain DH5a (a gift of Dr. Jianming Li, Yale University, 
New Haven, CT), were collected by centrifugation and made permeable to DNA by 
incubation in ice-cold 50 mM CaCl2 for 30 minutes (140,145, 146). These competent 
bacteria were transformed with pXM-EPOR by incubation on ice for 30 minutes followed 
by heat shock at 37°C for 5 minutes. Bacteria were plated on LB (Luria broth) agar 
containing 50 pg/ml of ampicillin (Boehringer Mannheim Corp., Indianapolis, IN) and 
allowed to grow overnight at 37°C. Transformants were selected for partial purification of 
plasmid DNA by a previously described "mini-prep" method (147, 148), and DNA was 
analyzed by digestion with the restriction endonuclease Kpnl (Boehringer Mannheim). A 
large scale plasmid preparation was performed using a previously described alkaline lysis 
method (137, 147).
A 1.8 kb EPOR cDNA insert was excised by digestion with Kpnl and separated 
from Kpnl-linearized pXM by 1.0% Agarose gel electrophoresis using lx  Tris-borate 
buffer (90 mM Tris-HCl [pH 8.0], 90 mM boric acid, 2 mM EDTA) as the running buffer 
(140). The EPOR cDNA insert was recovered by electrophoresis onto a diethylaminoethyl 
(DEAE)-cellulose membrane (Schleicher & Schuell, Keene, NH) as previously described 
(137). The membrane was washed with low-salt buffer (50 mM Tris-HCl [pH 8.0], 150 
mM NaCl, 10 mM EDTA), and DNA was eluted with high-salt buffer (50 mM Tris-HCl 
[pH 8.0], 1 M NaCl, 10 mM EDTA). The eluate was extracted with an equal volume of 
salt-saturated (SS)-phenol (Boehringer Mannheim): chloroform: isoamyl alcohol (25:24:1, 
v/v), and the aqueous layer was extracted with an equal volume of chloroform: isoamyl 
alcohol (24:1, v/v). After addition of 0.1 volume of 3 M sodium acetate (pH 5.2) and 
ethanol precipitation, the DNA pellet was resuspended in TE80 buffer (10 mM Tris-HCl, 
0.1 mM EDTA, pH 8.0) (140).
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A probe for mRNA transcripts of the mouse myeloblastosis oncogene c-myb was 
obtained by EcoRl-digestion of pMCl (American Type Culture Collection [ATCC], 
Rockville, MD) to excise a 2.5 kb murine c-myb cDNA insert. The c-myb cDNA insert 
was electrophoretically separated from vector and recovered by electrophoresis onto a 
DEAE-cellulose membrane as described above. A 1.4 kb probe for mRNA transcripts of 
the mouse myelocytomatosis oncogene c-myc was derived from the cDNA of MEL cells 
and was the generous gift of Dr. Ishiguro.
Northern hybridization. A membrane containing crosslinked, transferred total RNA 
was incubated with prehybridization buffer containing 50 mM Tris-HCl (pH 7.5), 1 M 
NaCl, 0.1% (w/v) sodium pyrophosphate, 0.2% (w/v) bovine serum albumin (BSA), 
0.2% (w/v) polyvinyl-pyrrolidone, 0.2% (w/v) Ficoll, 1% (w/v) sodium dodecyl sulfate 
(SDS), 10% (w/v) dextran sulfate, 50% (v/v) deionized formamide and 0.1 mg/ml of heat- 
denatured salmon sperm DNA at 42°C for several hours. Twenty-five ng of a DNA probe 
were radiolabeled using a random primer extension kit (GIBCO) and a previously 
described protocol (149,150). Reaction buffer and [a-32P]-deoxycytidine 5’-triphosphate 
(dCTP) (3000 Ci/mmol in 10 mM Tricine [pH 7.6], 10 mCi/ml; Du Pont NEN Research 
Products, Boston, MA) were added to the heat-denatured probe to a total volume of 49 ml 
containing 0.02 mM deoxyadenosine 5’-triphosphate (dATP), 0.02 mM deoxyguanosine 
S'-triphosphate (dGTP), 0.02 mM deoxythymidine 5'-triphosphate (dTTP), 200 mM 
HEPES, 50 mM Tris-HCl (pH 6.8), 5 mM MgCh, 10 mM 2-mercaptoethanol, 0.4 mg/ml 
of BSA and 5.5 OD26O units/ml of oligodeoxyribonucleotide primers (hexamers). One ul 
of Klenow fragment (large fragment of DNA polymerase I, 3 units/pl in 100 mM 
potassium phosphate buffer [pH 7.0], 10 mM 2-mercaptoethanol, 50% [v/v] glycerol) was 
added, and the reaction mixture was incubated at room temperature for 60 minutes.
The radiolabeled probe was heat-denatured and hybridized to the membrane by 
incubation at 42°C for 14-18 hours. The membrane was rinsed and then washed with 2x 
SSC (30 mM sodium citrate [pH 7.0], 300 mM NaCl) containing 0.1% (w/v) SDS at room
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temperature. The membrane was then washed with 0.2x SSC (3 mM sodium citrate [pH
7.0], 30 mM NaCl), 0.1% (w/v) SDS once at room temperature and twice at 68°C. The 
membrane was exposed to X-Omat RP scientific imaging Film (Eastman Kodak Co., 
Rochester, NY) at -70°C.
Radioiodination of erythropoietin. Recombinant human erythropoietin (rhEPO)
was labeled with NaI2^i using the IODO-GEN reagent (1,3,4,6-tetrachloro-3o,6o-
diphenylglycouril; Pierce Chemical Co., Rockford, 1L) (151-153), as previously described
(78). Four pg of IODO-GEN were coated on the bottom of a 12 x 75 mm borosilicate
tube. Five hundred units of pure, iodination-grade rhEPO in 45 pi of HBSS containing
0.01% (w/v) Tween 20 (Fierce) were added to the reaction tube. Five pi (500 pCi) of
Na125I (100 mCi/ml in NaOH solution, pH 7-11; Amersham Corp., Arlington Heights, IL)
were added to bring the reaction volume to 50 pi, and the mixture was incubated at room
temperature for 10 minutes. The iodination reaction was quenched by the addition of 100
pi of an aqueous solution of 1.6 M KI (Sigma). 125I-rhEPO was purified from unreacted 
N a 125[ using an Excellulose GF-5 Desalting Column (Pierce). The column was 
equilibrated with two volumes of elution buffer (HBSS, 0.1% [w/v] BSA, 0.01% [w/v] 
Tween 20), and the quenched reaction mixture was applied to the column. An initial 
fraction of 300 pi and subsequent fractions of 5 drops (approximately 60 pi) were collected 
in 1.7 ml Eppendorf tubes. One pi was removed from each fraction, and radioactivity was 
determined using an LKB 1282 Compugamma universal gamma counter (Wallac Inc., 
Gaithersburg, MD).
Analysis of radioiodination products bv sodium dodecvl sulfate-polvacrylamide gel 
electrophoresis (SDS-PAGET One pi was removed from each eluted fraction and added to 
19 pi of extraction buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5% 
[w/v] Nonidet P-40, 0.2 mM phenylmethanesulfonyl fluoride, 5 pg/ml of aprotinin). 
Twenty pi of 2x SDS-PAGE sample buffer (125 mM Tris-HCl [pH 6.8], 4% [w/v] SDS, 
40% [v/v] glycerol, 10% [v/v] 2-mercaptoethanol, 0.002% [w/v] bromophenol blue) were
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added, and the samples were boiled for 5 minutes and then cooled (154). The samples 
were subjected to 7.5% SDS-PAGE using an SE600 vertical slab electrophoresis unit 
(Hoefer) and a 1.0 mm thick gel. The stacking gel consisted of 5% (w/v) acrylamide, 
0.13% (w/v) N,N'-methylene-bis-acrylamide (bis), 125 mM Tris-HCl (pH 6.8), 0.1% 
(w/v) SDS, 0.1% (w/v) ammonium persulfate and 0.1% (v/v) N,N,N’,N'- 
tetramethylethylenediamine (TEMED). The resolving gel consisted of 7.5% (w/v) 
acrylamide, 0.2% (w/v) bis, 375 mM Tris-HCl (pH 8.8), 0.1% (w/v) SDS, 0.1% (w/v) 
ammonium persulfate and 0.06% (v/v) TEMED. The running buffer consisted of 25 mM 
Tris, 192 mM glycine and 0.1% (w/v) SDS. All reagents were molecular biology grade; 
Tris buffer was purchased from American Bioanalytical, and all other materials were 
purchased from Bio-Rad Laboratories, Richmond, CA. Molecular weights were 
determined using prestained SDS-PAGE standards (Bio-Rad). The gel was soaked for 60 
minutes in a fixing solution of 10% (v/v) trichloroacetic acid (Brand-Nu Laboratories, 
Meriden, CT), 10% (v/v) acetic acid and 30% (v/v) methanol (J.T. Baker). The fixed gel 
was dried under heat and vacuum for 90 minutes using a Bio-Rad Model 443 slab dryer, 
and the dried gel was exposed to X-Omat AR scientific imaging film (Eastman Kodak) at 
-70°C.
Determination of the biological activity of radioiodinated erythropoietin. The 
biological activity of radioiodinated erythropoietin was assessed using a previously 
described quantitative colorimetric assay for cellular proliferation (155). Ba/F3-EPOR cells 
were seeded at 1 x 104 cells per well in a 96-well plate (Becton Dickinson Lab ware, 
Lincoln Park, NJ) in a volume of 100 pi of RPMI 1640 medium supplemented with 10% 
(v/v) FBS and varying amounts of 125I-rhEPO. Ba/F3-EPOR cells were also seeded at the 
same cell density in 100 pi per well of RPMI 1640, 10% (v/v) FBS, containing varying 
amounts of tissue culture-grade or iodination-grade (albumin-free) rhEPO. Cells were 
incubated for 2 days at 37°C in a humidified air atmosphere containing 5% C02- Ten pi of 
stock MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Sigma)
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solution (10 mg/ml; sterile filtered) were added to each well, and the cells were incubated at 
37°C in 95% air /  5% CO2 for 4 hours. One hundred-fifty nl of acid-isopropanol (0.04 N 
HC1 in 2-propanol) were added to each well, and the contents of each well were thoroughly 
mixed to dissolve crystals of the MTT formazan product. The 96-well plate was read in a 
Titertek Multiskan MCC/340 eight-channel vertical photometer (Row Laboratories, 
McLean, VA), using a test wavelength of 550 nm and a reference wavelength o f750 nm.
Determination of erythropoietin receptor (EPOR) number and binding affinity. 
Logarithmically growing MEL or DMSO/R1 cells were collected by centrifugation, and the 
supernatant was decanted. Cells were resuspended in binding medium (DMEM, 15% [v/v] 
FBS, 2 mM L-glutamine, 20 mM HEPES, pH 7.4) at a density of 6 x 106 cells/ml. Cells 
were transferred to Eppendorf tubes by pipetting 500 pi (3 x 106 cells) into each tube. 
Cells were collected by centrifugation, and the supernatant was removed by aspiration. 
Cells were resuspended in the absence or presence of 50-fold excess rhEPO in 100 pi of 
binding medium containing varying amounts of 12̂ I-rhEPO. Cells were incubated at 10- 
12°C for 4 hours to allow binding of 12̂ I-rhEPO to cell surface EPO receptors. Cells and 
bound ,2^I-rhEPO were collected by centrifugation and were washed twice with 500 pi of 
ice-cold PBS (phosphate-buffered saline, pH 7.5). Eppendorf tube tips containing cell 
pellets were severed and placed in 12 x 75 mm borosilicate tubes, and radioactivity was 
determined using an LKB 1282 gamma counter.
Metabolic labeling. Cells were seeded at 4 x 104 cells/ml, or 1 x 105 cells/ml when 
cells were to be labeled the next day, in growth medium containing 1.5% (v/v) DMSO, 5 
mM HMBA or no inducer. Cells were incubated for 1,2 or 3 days at 37°C in a humidified 
air atmosphere containing 10% CO2 . Three x 106 cells were collected by centrifugation 
and washed once with 1 ml of methionine-free DMEM (GIBCO) supplemented with 15% 
(v/v) FBS and 2 mM L-glutamine, which had been prewarmed to 37°C. Cells were 
resuspended at a density of 1.5 x 107 cells/ml in 200 pi of methionine-free medium, and 
100 pCi of L-[35S]-methionine (10 mCi/ml in an aqueous solution containing 10 mM 2-
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mercaptoethanol; Du Pont NEN) were added to attain a final concentration of 500 pCi/ml 
(156-158). Cells were incubated at 37°C for 60 minutes.
Immunoprecipitation of cellular lvsates. Cells were collected by centrifugation and 
washed twice with 1 ml of ice-cold HBSS. Cells were lysed in 200 pi of ice-cold 
extraction buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5% [w/v] 
Nonidet P-40,0.2 mM phenylmethanesulfonyl fluoride, 5 pg/ml of aprotinin), and nuclei 
were removed by centrifugation. The supernatant, designated the nuclei-firee cellular 
lysate, was transferred to a new Eppendorf tube. Five pi of goat a-MuLV gp70 polyclonal 
antiserum (lot # 81S000127, 86 mg/ml of protein; Quality Biotech Inc., Camden, NJ), 
which cross-reacts with SFFVp gp55, were added to each cellular lysate sample for a 
dilution of 1:40, and immunoprecipitation was conducted overnight at 4°C. Twenty-five pi 
of Protein A-Agarose (Pierce) were added to each sample, and the samples were incubated 
for 20 minutes at room temperature under agitation (159-165). The immunoglobulin- 
Protein A complexes were washed 6 times with 500 pi of ice-cold extraction buffer.
Analysis by SDS-PAGE and autoradiography. The immunoglobulin-Protein A 
complexes were resuspended in an equal volume (50 pi) of 2x SDS-PAGE sample buffer 
and boiled for 5 minutes. The samples were cooled to room temperature and were then 
centrifuged at 16,000 g for 30 seconds. Twenty pi of supernatant were removed from each 
sample and subjected to 7.5% SDS-PAGE, and molecular weights were determined using 
prestained SDS-PAGE standards (154). The gel was soaked under gentle agitation in a 
fixing solution of 10% (v/v) trichloroacetic acid, 10% (v/v) acetic acid and 30% (v/v) 
methanol for 60 minutes. The fixing solution was decanted, and the gel was impregnated 
with EN3HANCE fluorescent autoradiography enhancer (Du Pont NEN) by soaking the 
gel under gentle agitation in EN3HANCE solution for 60 minutes. The used enhancer 
solution was discarded, and an excess of ice-cold water was added to precipitate the 
fluorescent material inside the gel. The gel was soaked under gentle agitation in cold water
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
35
for 60 minutes and then dried under heat and vacuum for 90 minutes. The dried gel was 
exposed to Kodak X-Omat RP scientific imaging film at -70°C.
Endoglvcosidase H fendo H) treatment of metabolicallv labeled SFFVp gp55 
immunoprecipitates. MEL or DMSO/R1 cells were seeded at 4 x 104 cells/ml in the 
presence or absence of 1.5% (v/v) DMSO and were incubated for 2 days at 37°C in a 
humidified air atmosphere containing 10% CC>2. Three x 106 cells were collected by 
centrifugation, resuspended in 200 pi of methionine-free medium, and labeled with 100 pCi 
of L-[35S]-methionine for 15 minutes (156-158). Cells were collected by centrifugation, 
washed twice with regular growth medium containing methionine, and resuspended in 200 
pi of DMEM, 15% (v/v) FBS, 2 mM L-glutamine. Cells were incubated in regular growth 
medium for 0, 3 or 6 hours (chase period). Cells were then collected by centrifugation, 
washed twice with ice-cold HBSS, and lysed in 200 pi of extraction buffer as described 
above. The nuclei-free cellular lysates were subjected to immunoprecipitation by 5 pi of 
goat a-MuLV gp70 polyclonal antiserum (1:40 dilution) as desribed above.
After washing the immunoglobulin-Protein A complexes with ice-cold extraction 
buffer as described above, the immunoglobulin-Protein A complexes were resuspended in 
25 pi of endo H extraction buffer (50 mM Tris-HCl [pH 8.0], 0.5% [w/v] SDS, 0.5% 
[v/v] 2-mercaptoethanol). The samples were boiled for 5 minutes, allowed to cool to room 
temperature, and then centrifuged at 16,000 g for 30 seconds. Ten pi of supernatant were 
removed and added to 40 pi of endo H incubation buffer to bring the total volume of the 
reaction mixture to 50 pi. The final incubation mixture consisted of 10 mM Tris-HCl (pH
8.0), 100 mM sodium citrate (pH 5.5), 0.1% (w/v) SDS, 0.7% (v/v) 2-mercaptoethanol, 
and 4% (v/v) Nonidet P-40 with or without the presence of 5 mU of endoglycosidase H (1 
mU/pl in 50 mM sodium phosphate, 0.05% [w/v] sodium azide, pH 7.0; Boehringer 
Mannheim) (166-168). The samples were incubated overnight at 37°C, and 50 pi of 2x 
SDS-PAGE sample buffer were then added (154). The samples were boiled for 5 minutes
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and allowed to cool to room temperature. Fifty pi were removed from each sample and 
analyzed by 7.5% SDS-PAGE and autoradiography as described above (154).
Nuclei-free cellular lysates. Cells were seeded at 4 x 104 cells/ml, or 1 x 10s 
cells/ml when cells were to be harvested the next day, in the presence or absence of 1.25% 
(v/v) DMSO. Cells were incubated for 1, 2 or 3 days at 37°C in a humidified air 
atmosphere containing 10% CO2 . Three x 106 cells were collected by centrifugation and 
washed twice with 1 ml o f ice-cold HBSS. Cells were lysed in 200 pi o f ice-cold 
extraction buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5% [w/v] 
Nonidet P-40,0.2 mM phenylmethanesulfonyl fluoride, 5 mg/ml of aprotinin), and nuclei 
were removed by centrifugation.
Determination of the protein concentrations of nuclei-free cellular lvsate samples. A 
microtiter plate format based on the Bradford assay was used to determine the protein 
concentrations of the nuclei-free cellular lysate samples (169-172). Ten pi of nuclei-free 
cellular lysate were added to 90 pi of PBS to dilute the protein concentration ten-fold. 
Twenty pi of the 1:10 dilution of cellular lysate were transferred to each of 3 wells of a 96- 
well plate, and 180 pi of Coomassie Plus Protein Assay Reagent (Pierce) were added to 
each well. The 96-well plate was read in a Titertek Multiskan MCC/340 eight-channel 
vertical photometer, and the absorbance of each well was measured at 600 nm (OD600)- A 
standard curve was constructed from OD600 measurements of standards made with BSA 
(Sigma), and the protein concentrations of the samples were quantified using the standard 
curve.
SDS-PAGE of nuclei-free cellular lvsates and electrophoretic transfer of proteins to 
nitrocellulose membranes. Nuclei-free cellular lysate containing 50 pg of protein was 
added to an equal volume of 2x SDS-PAGE sample buffer, and the samples were boiled 
for 5 minutes and then allowed to cool to room temperature. The samples were subjected 
to 7.5% SDS-PAGE, and molecular weights were determined using prestained SDS-PAGE 
standards (154). Proteins were electrophoretically transferred to an Immobilon-NC
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nitrocellulose /  cellulose acetate membrane as previously described (173, 174). The 
transfer buffer consisted of 82.5 mM Tris, 192 mM glycine and 20% (v/v) methanol, and 
the transfer was performed using a Model TE42 Transphor electrophoresis unit with a 
Model TE50 Transphor Power Lid (Hoefer).
Western blot analysis of total cellular SFFVp pp55 protein. A previously described 
procedure was used to detect gp55 that had been transferred onto the Immobilon-NC 
membrane (173). The membrane was soaked in Tris-buffered saline (TBS; 50 mM Tris- 
HCl [pH 7.4], 200 mM NaCl) and then incubated under gentle agitation in a blocking 
solution of 5% (w/v) nonfat dry milk (H. J. Heinz Co., Pittsburgh, PA) in TBS for 2 
hours at room temperature. The blocking solution was removed, and the membrane was 
incubated with goat a-MuLV gp70 polyclonal antiserum (1:250 dilution in 1% [w/v] nonfat 
dry milk in TBS) overnight at 4°C. The membrane was washed 5 times at room 
temperature with TBS-Tween 20 (0.05% [w/v] Tween 20 in TBS) and then once with 
TBS. The membrane was blocked with 5% (w/v) nonfat dry milk for 30 minutes and then 
incubated with 30 pCi of 125I-rProtein A (low specific activity 2-10 pCi/pg, 80 pCi/ml in a 
50 mM sodium phosphate buffer, pH 4.0, containing 35% [v/v] ethanol; Du Pont NEN) in 
30 ml of 1% (w/v) nonfat dry milk for 2 hours at room temperature. The membrane was 
washed as before, and the dried membrane was exposed to Kodak X-Omat AR film at 
-70°C.
Construction of the eukaryotic expression vector pRc/RSV-eo55. The SFFVp 
gp55 cDNA insert was excised from pXM-gp55, a COS cell expression vector containing 
the SFFVp gp55 cDNA, by digestion with the restriction endonucleases Hindlll and PstI 
(Boehringer Mannheim). pXM-gp55 was the generous gift of Dr. Alan D’Andrea, 
Children's Hospital, Boston, MA. The SFFVp gp55 cDNA insert was then subcloned into 
the multiple cloning site of HindlH-Pstl-linearized pBluescript SK (a gift of Dr. Jianming 
Li, Yale University, New Haven, CT) using previously described methods (137, 140). 
pBluescript SK-gp55 was then digested with the restriction endonucleases H indlll and
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Xbal, and the resulting SFFVp gp55 cDNA insert was subcloned in the sense orientadon 
into the multiple cloning site o f pRc/RSV (Invitrogen Corp., San Diego, CA), a 
mammalian expression vector containing a neomycin resistance gene for selection in 
eukaryotic cells. A large scale plasmid preparation of pRc/RSV-gp55 was performed using 
a previously described alkaline lysis method (137,147).
Construction of the antisense gp55 cDNA expression vector pRc/RSV-antisense 
gp55. The SFFVp gp55 cDNA insert was excised from pXM-gp55 by digestion with the 
restriction endonucleases EagI (New England Biolabs, Beverly, MA) and Pstl, and the 
insert was subcloned into the multiple cloning site o f Eagl-Pstl-lincmzed pBluescript SK 
(137). The resulting plasmid was then digested with EagI and Hindlll, and the resulting 
SFFVp gp55 cDNA insert was subcloned in the antisense orientation into the multiple 
cloning site of pRc/RSV. A large scale plasmid preparation of pRc/RSV-antisense gp55 
was performed using a previously described alkaline lysis method (137,147).
Transfection of Friend MEL cells bv electroporation. MEL cells were transfected 
with plasmids expressing the SFFVp gpSS cDNA in the sense or antisense orientation by a 
previously described method for electroporation of suspension culture cells (140, 175- 
178). The expression vectors pRc/RSV, pRc/RSV-gp55 and pRc/RSV-antisense gp55 
were digested with the restriction endonuclease Bglll (New England Biolabs) to generate 
linearized plasmids. The restriction digestion mixtures were extracted with equal volumes 
of SS-phenol: chloroform: isoamyl alcohol (25:24:1, v/v), and the aqueous layers were 
extracted with equal volumes of chloroform: isoamyl alcohol (24:1, v/v). After addition of 
0.1 volumes of 3 M sodium acetate (pH 5.2) followed by ethanol precipitation, the DNA 
pellets was resuspended in TE70 buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.0) (140).
One x 107 logarithmically growing Friend MEL cells were collected by 
centrifugation, washed once with 5 ml of ice-cold PBS, and resuspended at a density of 1 x 
107 cells/ml in 1 ml of ice-cold PBS (140). Eight x 106 cells (0.8 ml) were transferred by 
pipette to a sterile Gene Pulser cuvette (Bio-Rad). Ten pg of linearized pRc/RSV (vector
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alone), pRc/RSV-gp55, pRc/RSV-antisense gp55, or no vector (sham transfection) were 
added, and the cuvette was incubated on ice for 5 minutes. Transfection of the cells was 
performed using a Gene Pulser electroporation apparatus (Bio-Rad) with a capacitance 
extender (Bio-Rad). Electroporated cells were incubated on ice for 10 minutes and then 
transferred to a tissue culture flask containing 30 ml of growth medium. Cells were 
incubated for 48 hours at 37°C in a humidified air atmosphere containing 10% CO2.
Selection and cloning (bv single cell sorting) of transfectants. A sterile stock 
solution of the aminoglycoside antibiotic G-418 Sulfate (Geneticin, GIBCO) was prepared 
by filtering an aqueous solution of 10 mg/ml of G-418 through a 0.22 pm Millex filter unit 
(179-182). The sterile antibiotic solution was divided into aliquots and stored at -20°C. 
Two x 106 cells were reseeded at a density of 8 x 104 cells/ml in 25 ml of fresh growth 
medium supplemented with 800 ng/ml of G-418. Cells were incubated under antibiotic 
selection at 37°C in a humidified air atmosphere containing 10% CO2  for 2 weeks. Cells 
were passaged biweekly with collection of cells by centrifugation and resuspension in fresh 
growth medium containing 800 ng/ml of G-418. Cells were then cloned by single cell 
sorting using a FACS IV flow cytometer with continued selection in growth medium 
containing 800 ng/ml of G-418.
Screening of transfectants bv Western blotting for total cellular gr?55 protein. Three 
x 106 cells were collected by centrifugation, washed twice with ice-cold HBSS, and then 
lysed in 200 pi of ice-cold extraction buffer as previously described. Nuclei were removed 
by centrifugation, and 40 pi of nuclei-free cellular lysate were removed and added to an 
equal volume of 2x SDS-PAGE sample buffer (154). The samples were boiled, allowed to 
cool to room temperature, and then subjected to 7.5% SDS-PAGE followed by 
electrophoretic transfer to Immobilon-NC membranes as previously described (173,174). 
The membranes were probed with goat a-MuLV gp70 polyclonal antiserum at a dilution of 
1:250 in 1% (w/v) nonfat dry milk, and bound primary antibody was detected with 125I- 
rProtein A and autoradiography as previously described (173). Because the protein
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concentrations of the transfectant samples were not determined prior to SDS-PAGE and, 
therefore, had not been normalized from sample to sample, the visualized gp55 band of 
each sample was compared to the F-MuLV gp70 band of the sample to estimate the level of 
total cellular gp55 protein in each transfectant clone.
Immunoprecipitation of SFFVp gp55 and the mEPOR. MEL or DMSO/R1 cells 
were seeded at 4 x 104 cells/ml in the presence or absence of 1.25% (v/v) DMSO and were 
incubated for 4 days at 37°C in a humidified air atmosphere containing 10% CO2 . Cells 
were split on day 2 and reseeded in fresh growth medium to achieve a cell density of 
approximately 1 x 106 cells/ml upon harvesting on day 4. Cells were collected by 
centrifugation, nuclei-free cellular lysates were prepared, and the protein concentrations of 
the nuclei-free cellular lysates were determined as described above (169-172). Ice-cold 
extraction buffer was added to cellular lysate containing 100 pg of protein to bring the total 
volume to 100 pi.
The nuclei-free cellular lysate was incubated overnight at 4°C in the presence of 4 pi 
of goat a-MuLV gp70 polyclonal antiserum (1:25 dilution), 4 pi of rabbit a-mEPOR 
polyclonal antiseram (1:25 dilution), or no antibody. Rabbit polyclonal antiserum C31201 
(Research Genetics, Huntsville, AL) to the murine erythropoietin receptor (mEPOR) was 
generated by immunization of a New Zealand white female rabbit with a synthetic Multiple 
Antigen Peptide (MAP) containing eight copies of the mEPOR N-terminal peptide 
(APSPSLPDPKFESK) (183-187). SFFVp gp55 and mEPOR immunoprecipitates were 
complexed to 20 pi of Protein A-Agarose and washed several times with ice-cold extraction 
buffer as previously described (159-165).
Western blot analysis of coimmunoprecipitated SFFVp gp55 and mEPOR. The 
nuclei-free cellular lysate samples and the SFFVp gp55 and mEPOR immunoprecipitates 
were resuspended in equal volumes of 2x SDS-PAGE sample buffer and boiled for 5 
minutes. The samples were subjected to 7.5% SDS-PAGE as previously described, and 
molecular weights were determined using prestained SDS-PAGE standards (154).
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Proteins were electrophoretically transferred to Immobilon-NC membranes as described 
above (173, 174). The membranes were soaked in TBS and then incubated with a 
blocking solution of 5% (w/v in TBS) nonfat dry milk for 2 hours. The membranes were 
incubated with goat a-MuLV gp70 polyclonal antiserum (1:2000 dilution in 1% [w/v in 
TBS] nonfat dry milk) or rabbit a-mEPOR polyclonal antiserum (1:250 dilution in 1% 
[w/v] nonfat dry milk) overnight at 4°C (173). The membranes were washed as previously 
described and then blocked with 5% (w/v) nonfat dry milk for 30 minutes.
Membranes that had been probed with goat a-MuLV gp70 polyclonal antiserum 
were incubated with a 1:2000 dilution (in 1% [w/v in TBS] nonfat dry milk) of rabbit anti­
goat IgG (whole molecule) conjugated to horseradish peroxidase (317 purpurogallin 
units/ml in 10 mM PBS, pH 7.4, containing 0.01% thimerosal, lot 091H4806; Sigma). 
Membranes that had been probed with rabbit a-mEPOR polyclonal antiserum were 
incubated with a 1:2000 dilution (in 1% [w/v] nonfat dry milk) of goat anti-rabbit IgG 
(whole molecule) conjugated to horseradish peroxidase (300 purpurogallin units/ml in 10 
mM PBS, pH 7.4, containing 0.01% thimerosal, lot 053H4815; Sigma). The membranes 
were probed with secondary antibody for 2 hours at room temperature and then washed as 
described above. The bound horseradish peroxidase-conjugated secondary antibodies were 
visualized using an enhanced chemiluminescence detection system (ECL; Amersham) and 
Kodak RP X-Omat scientific imaging film (188,189).
Chemical crosslinkinp to radioiodinated rhEPO. Radioiodinated rhEPO was 
crosslinked to cell surface proteins using a previously described method (78). Five x 106 
cells were collected by centrifugation and washed with binding medium (DMEM, 15% 
[v/v] FBS, 2 mM L-glutamine, 20 mM HEPES, pH 7.4). Cells were resuspended at a 
density of 5 x 107 cells/ml in 100 pi of binding medium, and 0.5 pmol of ,25I-rhEPO was 
added. Cells were incubated at 10-12°C for 4 hours to allow binding of 125I-rhEPO to cell 
surface EPO receptors. Cells and bound 17̂ I-rhEPO were collected by centrifugation and
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were washed twice with 500 jxl of ice-cold PBS. Cells and bound ,25I-rhEPO were 
resuspended in 99 pi of ice-cold PBS.
One-half pi of a stock solution of 100 mM disuccinimidyl suberate (DSS; Pierce) 
(126,128) and 0.5 pi of a stock solution of 100 mM disuccinimidyl tartarate (DST; Pierce) 
(190, 191) were added to attain final concentrations of 0.5 mM DSS and 0.5 mM DST. 
The stock solutions of 100 mM DSS and 100 mM DST were freshly prepared in DMSO 
prior to their use. Cells were incubated on ice for 90 minutes, and 0.5 pi o f 100 mM DSS 
and 0.5 pi of 100 mM DST were both added after 30 and 60 minutes of incubation. 
A lte rna tive ly , cells w ere incubated in the presence o f  0.5 mM 
bis(sulfosuccinimidyl)suberate (BS^; Pierce) (192-194) or 10 mM l-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide (EDC; Pierce) (195-197) and 20 mM N- 
hydroxysulfosuccinimide (sulfo-NHS; Pierce) (198) for 90 minutes.
Cells and bound and crosslinked I25I-rhEPO were collected by centrifugation and 
were washed twice with 500 pi of ice-cold PBS. The cell pellet was resuspended in 75 pi 
of ice-cold extraction buffer, and nuclei were removed by centrifugation. Seventy-five pi 
of 2x SDS-PAGE sample buffer were added to each sample, and the samples were boiled 
and allowed to cool to room temperature. The samples were subjected to 7.5% SDS- 
PAGE, and molecular weights were determined using prestained molecular weight 
standards (154). The gel was soaked under gentle agitation in a fixing solution of 10% 
(v/v) trichloroacetic acid, 10% (v/v) acetic acid and 30% (v/v) methanol, and the fixed gel 
was dried under heat and vacuum. The dried gel was exposed to Kodak X-Omat AR 
scientific imaging film at -70°C.
Radioiodination of cell surface proteins. Cell surface proteins were radiolabeled 
using a previously described enzymatic method (199-203). A sterile stock solution of 1% 
(w/v) {J-D-glucose (Sigma) was prepared by filtering an aqueous solution through a 0.22 
pm Millex filter unit, and lyophilized Enzymobead Radioiodination Reagent (immobilized 
preparation of lactoperoxidase and glucose oxidase, Bio-Rad) was rehydrated with distilled
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water. Five x 106 cells were collected by centrifugation, washed once with 1 ml of ice-cold 
HBSS, and resuspended in 50 pi of HBSS. Twenty-five pi of 1% p-D-glucose, 50 pi of 
Enzymobead Radioiodination Reagent, and 100 pCi of Na125I (100 mCi/ml in NaOH 
solution, pH 7-11; Amersham) were added. The reaction mixture was incubated for 25 
minutes at room temperature. The mixture was centrifuged, and the supernatant containing 
unreacted Na125I was removed. The pellet was washed with ice-cold HBSS and lysed in 
200 pi of ice-cold extraction buffer. Nuclei and Enzymobead Radioiodination Reagent 
were removed by centrifugation, and the supernatant was designated the nuclei-fiee cellular 
lysate. An aliquot of nuclei-free cellular lysate was removed and added to an equal volume 
of 2x SDS-PAGE sample buffer, and the samples were subjected to 7.5% SDS-PAGE and 
autoradiography as described above (154).
Cell surface labeling o f SFFVp gp55. Nuclei-free cellular lysates were 
immunoprccipitated with 8 pi of goat a-MuLV gp70 polyclonal antiserum (1:25 dilution) at 
4°C overnight. The immunoprecipitates were complexed to 40 pi of Protein A-Agarose 
and washed several times with ice-cold extraction buffer as described above (159-165). 
The samples were added to equal volumes of 2x SDS-PAGE sample buffer and subjected 
to 7.5% SDS-PAGE and autoradiography as described above (154).
Statistical analyses. Experiments were performed in triplicate, and mean values and 
standard errors were determined. Experimental results were expressed as tabular values or 
graphical points representing the results of 3 determinations plus or minus the standard 
error of measurement. The significance of the difference between two experimental groups 
was evaluated using the one-tailed Student's t test. A p  value less than 0.05 was 
considered statistically significant.
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RESULTS
CHARACTERIZATION OF THE DMSO-RESISTANT MEL CLONE DMSO/R1
To assist in an investigation of changes in erythropoietin receptor (EPOR) 
expression during induction of Friend murine erythroleukemia (MEL) cell differentiation by 
dimethylsulfoxide (DMSO), a cell line resistant to the differentiating and EPO-sensitizing 
effects of DMSO was developed by selection in DMSO-containing growth medium. This 
DMSO-resistant subline of MEL cells, DMSO/R1, was obtained without mutagenesis by 
passaging MEL cells in growth medium containing progressively higher concentrations of 
DMSO, up to 1.5% (v/v) DMSO, as described in the Materials and Methods section. 
DMSO/R1 was then cloned by single cell sorting using a FACS IV flow cytometer. After 
cloning, DMSO/R1 was continuously passaged in growth medium containing 1.25% (v/v) 
DMSO.
Growth and differentiation of Friend MEL and DMSO/R1 cells. The growth 
characteristics of Friend MEL cells and DMSO/R1 cells arc represented by growth curves 
in Figure 2. Cells were seeded at a density of 4 x 104 cells/ml in the absence or presence of 
1.25% (v/v) DMSO and were incubated for 4 days in a humidified air atmosphere, as 
described in the Materials and Methods section. An aliquot of the cell suspension was 
removed each day, and cell numbers were determined using a Coulter particle counter. 
Friend MEL cells displayed logarithmic growth with a doubling time of 10 hours, and 
growth reached a plateau at day 3 at a cell density of approximately 3 x 106 cells/ml.
DMSO treatment inhibited the growth of Friend MEL cells slightly, increasing the 
doubling time to 11 hours. However, DMSO-treated MEL cells reached a similar plateau 
phase density of 3 x 10® cells/ml on day 4. DMSO/R1 cells grew more slowly than 
parental MEL cells in the absence of DMSO, displaying a doubling time o f 12 hours. In 
contrast to parental MEL cells, DMSO/R1 cells responded to DMSO treatment with 
increased growth resulting in a doubling time of 11 hours. DMSO-treated DMSO/R1 cells
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Figure 2a. Growth curves of Friend murine erythroleukemia (MED cells incubated in the 
presence or absence of 1.25% (v/v) DMSO.
Friend murine erythroleukemia (MEL) cells were seeded on day 0 at 4 x 104 
cells/ml in the presence or absence of 1.25% (v/v) DMSO. An aliquot was removed each 
day, and cell numbers were determined using a Coulter particle counter. Each point 
represents the results of 3 determinations ±  the standard error.
Figure 2b. Growth curves of DMSO/R1 cells incubated in the presence or absence of 
1.25% (v/v) DMSO.
DMSO-resistant cells (clone DMSO/R1) were seeded on day 0 at 4 x 104 cells/ml in 
the presence or absence of 1.25% (v/v) DMSO. An aliquot was removed each day, and 
cell numbers were determined using a Coulter particle counter. Each point represents the 
results of 3 determinations + the standard error.
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reached a similar plateau phase cell density as Friend MEL cells by day 4, but growth of 
untreated DMSO/R1 cells reached a plateau of 2 x 106 cells/ml by day 4. DMSO induced 
the differentiation of Friend MEL cells, as evidenced by a hemoglobin (Hb) content of 18.7 
+ 2.7 pg Hb/107 cells on day 3 for DMSO-treated cells, as compared to 4.9 + 0.6 pg 
Hb/107 cells for untreated cells. Exposure to DMSO had no effect on Hb production in 
DMSO/R1 cells, and both untreated and DMSO-treated cells contained 4.4 ±  0.4 pg Hb/107 
cells on day 3.
Induction of cell differentiation and restoration of EPO responsiveness bv DMSO in 
Friend MEL cells but not in DMSO/R1 cells. The responsiveness of Friend MEL cells and 
DMSO/R1 cells to EPO after pretreatment with DMSO is examined in Table 2. Cells were 
incubated in culture for 3 days in the absence or presence of 1.25% (v/v) DMSO and were 
then reseeded in the absence or presence of 0.5 units/ml o f recombinant human 
erythropoietin (rhEPO), as described in the Materials and Methods section. After 3 days of 
exposure to rhEPO, cell numbers were determined as a measure of proliferation, and Hb 
content was determined as a measure of the extent of differentiation (20,134). DMSO 
inhibited the growth of Friend MEL cells (73% inhibition from day 3 to day 6) but 
stimulated the growth of DMSO/R1 cells (30% stimulation from day 3 to day 6), as had 
been previously demonstrated in Figure 1. In addition, DMSO induced the differentiation 
of Friend MEL cells, as evidenced by a Hb content of 40.3 pg Hb/107 cells by day 6, but 
not of DMSO/R1 cells, which displayed no increase in Hb content upon exposure to 
DMSO.
RhEPO had no effect on Friend MEL cells that were not pretreated with DMSO 
(data not shown) but stimulated both increased proliferation (+22%) and further 
differentiation (+6.5 pg Hb/107 cells) in DMSO-pretreated MEL cells. Both the increase in 
proliferation and differentiation were statistically significant with p  values less then 0.005. 
In contrast, rhEPO had no effect on either unpretreated (data not shown) or DMSO-
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Table 2. DMSO pretreatment restores sensitivity o f Friend murine 
erythroleukemia (MED cells, but not of the DMSO-resistant clone DMSQ/R1. to 
the growth-stimuiatorv and differentiation-inducing effects of erythropoietin (EPOl
Cell line DMSO EPO Cells/ml x 10~6 tig Hh/107 Cells
Friend MEL - - 2.72 ±0.23 8.1 ±  1.0
+ - 0.74 ±0 .12  40.3 ± 1 .7
+ + 0.90 ±0.13* 46.8 ± 2 .5*
DMSO/R1 - - 1.51 ±0.17 8.3 ± 0 .9
+ - 1.97 ± 0 .32  8.4 ± 0 .9
+ + 2.02 ±  0.28 8.6 ±  0.7
Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence 
of 1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 104 cells/ml in the 
same DMSO concentration in the presence or absence of 0.5 unit/ml of 
recombinant human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research 
Institute). Cell numbers and hemoglobin content were determined on day 6. Each 
value represents the results from 3 to 6 determinations ±  the standard error. 
*p<0.005
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pretreated DMS0/R1 cells, confirming that this subline was resistant to both the 
differentiation-inducing and EPO-sensitizing effects of DMSO.
Stability of the DMSO-resistant ohenotvpe of DMSQ/R1 cells. Since DMSO had 
been shown to stimulate the growth of clone DMSO/R1, it was necessary to determine if 
DMSO/R1 cells would lose their resistance to DMSO upon removal of DMSO from their 
growth medium. To determine whether the DMSO-resistant phenotype was dependent 
upon continuous passage in DMSO-containing growth medium, DMSO/R1 cells were 
removed from growth medium containing 1.25% (v/v) DMSO and were passaged in 
DMSO-free medium for 1 week or 1 month. The same experiment was then repeated for 
DMSO/R1 cells that had been continuously passaged in growth medium containing 1.25% 
(v/v) DMSO or that had been passaged for 1 week or 1 month in DMSO-free medium. The 
growth characteristics and DMSO-resistant phenotype of clone DMSO/R1 did not change 
with removal of the cells from DMSO-containing medium for up to 1 month, as 
summarized in Table 3. DMSO stimulated cell growth (a statistically significant 37 to 44% 
increase from day 3 to day 6) under all three conditions but did not induce Hb production 
under any condition. Additionally, DMSO pretreatment did not confer EPO responsiveness 
under any of the three conditions. Thus, it appears that the DMSO-resistant phenotype of 
clone DMSO/R1 is relatively stable and does not depend on continuous exposure to 
DMSO.
Cross-resistance of DMSO/R1 cells to hexamethvlene bisacetamide (HMBA). To 
determine if DMSO/R1 cells were also resistant to HMBA, another well-characterized 
inducer of MEL cell differentiation, similar experiments were performed with two different 
concentrations of HMBA (51). Cells were exposed to 1.25% (v/v) DMSO, 2 mM HMBA, 
4 mM HMBA, or no inducer in culture as described above. The results are summarized in 
Table 4. Exposure of Friend cells to 2 mM HMBA did not inhibit cell growth (42% 
inhibition from day 3 to day 6) to the same degree as 1.25% (v/v) DMSO (63% growth 
inhibition) but induced nearly the same degree of Hb production (23.1 + 0.9 pg Hb/107
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Table 3. The DMSO-resistant phenotype of DMSO/R1 cells is not dependent upon 
continuous passage of the cells in growth medium containing DMSO
Time following
DMSO exposure DMSO EPO Cells/ml x 10~6 tig Hh/107 Cells
None - 1.41 ±  0.06 7.5 ±  2.2
- + 1.42 ±  0.09 6.8 ±  2.1
+ - 2.04 ±  0.13 5.8 ±  2.6
+ + 2.14 ±0 .09 6.1 ± 2 .1
1 week - 1.46 ± 0 .06 7.1 ±  1.7
- + 1.46 ±  0.06 7.3 ±  1.6
+ - 2.00 ±  0.14 7.3 ± 1 .7
+ + 2.01 ±  0.17 7.8 ±  1.6
1 month - 1.45 ±  0.05 8.8 ± 1 .4
- + 1.39 ±0.07 9.5 ±  1.2
+ - 1.98 ±0.15 9.3 ±  1.3
+ + 2.00 ±0.17 9.0 ±  1.0
DMSO/R1 cells were continuously passaged in growth medium containing 
1.25% (v/v) DMSO or were passaged for 1 week or 1 month in DMSO-free growth 
medium. Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence 
of 1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 104 cells/ml in the 
same DMSO concentration in the presence or absence of 0.5 unit/ml of recombinant 
human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research Institute). Cell 
numbers and hemoglobin content were determined on day 6. Each value represents 
the results from 3 determinations ±  the standard error.
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Table 4. Cross-resistance o f DMSO/R1 cells to the differentiation-inducing and 
erythropoietin fEPOVsensitizing effects of hexamethvlene bisacetamide fHMBAl
Cell line Inducer EPO Cells/ml x 10-6 ug Hb/107 Cells
Friend MEL 2.45 + 0.10 3.9 + 2.0
- + 2.47 ± 0.06 3.9 ± 1 .6
1.25% DMSO _ 0.91 + 0.17 24.5 + 2.3
1.25% DMSO + 1.24 ±  0.09* 29.5 ±0.8*
2mM  HMBA 1.42 + 0.09 23.1 + 0.9
2 mM HMBA + 1.61 ±0.12 27.1 ±  1.0
4 mM HMBA 0.20 + 0.02 59.1 + 4.9
4 mM HMBA + 0.27 ±  0.02 65.6 ± 4 .2
DMSO/R1 1.52 + 0.13 4.0 + 1.8
- + 1.42 ±  0.11 4.2 ±  1.8
1.25% DMSO 2.03 + 0.13 3.5 + 2.0
1.25% DMSO + 2.15 ±0.19 3.6 ± 1 .8
2 mM HMBA * 1.88 ±0.10 2.9 + 1.0
2 mM HMBA + 1.97 ± 0 .22 3.9 ±  1.5
4 mM HMBA 1.57 ±  0.08 2.5 ±1 .1
4 mM HMBA + 1.59 ±0.05 2.9 ±  1.1
DMSO/R1 1.61 ±0.08 3.5 ±  1.3
(4 weeks 
following
“ + 1.52 ±0.10 3.3 ± 1 .4
exposure 1.25% DMSO - 1.99 + 0.12 3.7 + 1.2
to DMSO) 1.25% DMSO + 2.12 ±0.11 3.4 ± 1 .3
2mM HMBA 1.85 ±0.10 4.2 + 1.0
2 mM HMBA + 1.90 ±0 .06 4.1 ±1 .1
4 mM HMBA 1.75 + 0.25 4.1 + 1.9
4 mM HMBA + 1.70 ±0.08 5.3 ±  2.4
Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence of 1.25% 
(v/v) DMSO, 2 mM HMBA, or 4 mM HMBA. On day 3, cells were reseeded at 4 x 104 
cells/ml in the same DMSO or HMBA concentration in the presence or absence of 0.5 
unit/ml of recombinant human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research 
Institute). Cell numbers and hemoglobin content were determined on day 6. Each value 
represents the results from 3 determinations ±  the standard error.
*p<0.05
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cells, compared to 24.5 + 2.3 pg Hb/107 cells). Additionally, EPO treatment of cells 
pretreated with 2 mM HMBA resulted in a smaller percentage increase in cell proliferation 
(+13%) than was observed with DMSO (+36%), but a similar increase in Hb content was 
seen in response to EPO after DMSO or HMBA pretreatment.
An increase in HMBA concentration to 4 mM resulted in a greater inhibition of 
proliferation (92% inhibition from day 3 to day 6) and increased Hb production (59.1 +4.9 
pg Hb/107 cells), indicating a stronger induction of differentiation compared to 1.25% (v/v) 
DMSO (63% growth inhibition and 24.5 + 2.3 pg Hb/107 cells). DMSO/R1 cells that had 
been continuously passaged in the presence of 1.25% (v/v) DMSO as well as resistant cells 
that had been passaged in DMSO-free medium for 4 weeks exhibited a resistant phenotype 
to HMBA (less than 5 pg Hb/107 cells). While DMSO/R1 cells grew faster in the presence 
of 2 mM or 4 mM HMBA than in the absence of the inducer, they did not grow as well as 
resistant cells incubated in the presence of DMSO in culture. Interestingly, while the 
addition of 2 mM HMBA stimulated the growth of DMSO/R1 cells compared to untreated 
cells, an increase in HMBA concentration to 4 mM resulted in a slight inhibition of cell 
proliferation. DMSO/R1 cells were resistant to both the differentiation-inducing ar.d EPO- 
sensitizing effects of HMBA, and this cross-resistance was not dependent upon continuous 
passage in the presence of an inducing agent
Expression of c-m \c  and c-mvb mRNAs in Friend MEL and DMSO/R1 cells. To 
determine if clone DMSO/R1 lacked characteristic transcriptional changes seen in MEL cells 
in response to chemical induction of differentiation in addition to displaying a DMSO- 
resistant phenotype, expression of messenger ribonucleic acids (mRNAs) for the nuclear 
protooncogenes c-myb and c-myc was examined in the Friend MEL PC4 and DMSO/R1 
cell lines. c-Myb mRNA levels have been shown to decrease to undetectable levels within 
2-3 hours after DMSO exposure, return to pretreatment levels at 12-24 hours and fall again 
to undetectable levels by day 3 or 4 (204). Constitutive expression of c-myb in MEL cells 
blocked DMSO-induced differentiation, so the decrease in c-myb is a necessary part of
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chemically induced MEL cell maturation (204,205). Similar changes in c-myc expression 
with induction of differentiation in MEL cells have also been demonstrated (206-208).
Northern blots to detect c-myb and c-myc mRNA levels are shown in Figures 3a 
and 4a, respectively. A constant amount of total cellular RNA was loaded in each lane and 
subjected to electrophoresis, as described in the Materials and Methods section. 
Photographs of ethidium bromide-stained gels, wtih prominent 18S and 28S ribosomal 
RNA (rRNA) bands, are displayed in Figures 3b and 4b to demonstrate that an equal 
amount of total RNA was loaded in each lane. The nitrocellulose membranes onto which 
RNA had been transferred were examined by UV illumination to confirm complete and 
even transfer (data not shown). Friend MEL cells (F) and DMSO/R1 cells (R) were 
incubated in the absence (-) or presence (+) o f 1.25% (v/v) DMSO for 4 days in culture. 
On day 2, cells were split and reseeded in fresh growth medium in the absence or presence 
of 1.25% (v/v) DMSO to allow for a cell density of 1 to 1.5 x 106 cells/ml upon harvesting 
on day 4. As depicted in Figure 3a, Friend MEL and DMSO/R1 cells expressed similar 
levels of c-myb mRNA under untreated conditions. As had been previously reported 
(204), c-myb mRNA was almost undetectable in Friend MEL cells after 4 days of DMSO 
treatment. As expected, given its DMSO-resistant phenotype, clone DMSO/R1 did not 
show a decrease in c-myb mRNA expression after exposure to DMSO.
Friend MEL cells expressed a low level of c-myc mRNA, which decreased to an 
undetectable level after 4 days of treatment with DMSO, as represented in Figure 4a. 
However, DMSO/R1 cells expressed an increased level of c-myc mRNA, compared to 
parental Friend MEL cells, and this expression appeared to increase with DMSO treatment. 
To examine the changes in c-myc mRNA expression in Friend MEL clone PC4 in response 
to DMSO treatment, a Northern blot was performed with total cellular RNA isolated from 
Friend MEL cells exposed to 1.25% (v/v) DMSO for 0 ,1 ,2 , or 4 days in culture. As seen 
in Figure 5a, untreated Friend MEL cells expressed a low level of c-myc mRNA, which 
increased after 1 or 2 days of DMSO treatment but decreased to a nearly undetectable level
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Figure 3a. Northern blot to detect c-mvft messenger ribonucleic acid (mRNA) expression
in Friend murine erythroleukemia (MED and DMSO/R1 cells.
Friend MEL cells (F) or DMSO/R1 cells (R) were incubated in the absence (-) or 
presence (+) of 1.25% (v/v) DMSO for 4 days in culture. Cells were split on day 2 and 
reseeded in fresh growth medium to achieve a cell density of 1 to 1.5 x 106 cells/ml upon 
harvesting on day 4. Total cellular RNA was isolated, and 10 pg of total RNA were 
prepared for electrophoresis, as described in the Materials and Methods section. RNA was 
subjected to electrophoresis through a formaldehye-Agarose gel and then transferred to a 
nitrocellulose membrane. The membrane was probed with a radiolabeled c-myb cDNA 
fragment, as described in the Materials and Methods section.
Figure 3b. Ethidiuro bromide staining of total cellular ribonucleic acid (RNA).
The formaldehyde-Agarose gel in Figure 3a was photographed under ultraviolet 
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S 
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under 
UV illumination to confirm even transfer of RNA; data are not shown.)




2 8 S -  
1 8 S -
F F R R
M a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
56
Figure 4a. Northern blot to detect c-mvc messenger ribonucleic acid (mRNA) expression
in Friend murine erythroleukemia (MEL) and DMSO/R1 ceils.
Friend MEL cells (F) or DMSO/R1 cells (R) were incubated in the absence (-) or 
presence (+) of 1.25% (v/v) DMSO for 4 days in culture. Cells were split on day 2 and 
reseeded in fresh growth medium to achieve a cell density of 1 to 1.5 x 106 cells/ml upon 
harvesting on day 4. Total cellular RNA was isolated, and 10 pg of total RNA were 
prepared for electrophoresis, as described in the Materials and Methods section. RNA was 
subjected to electrophoresis through a formaldehye-Agarose gel and then transferred to a 
nitrocellulose membrane. The membrane was probed with a radiolabeled c-myc cDNA 
fragment, as described in the Materials and Methods section.
Figure 4b. Ethidium bromide staining of total cellular ribonucleic.acid_(R_NA).
The formaldehyde-Agarose gel in Figure 4a was photographed under ultraviolet 
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S 
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under 
UV illumination to confirm even transfer of RNA; data are not shown.)
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Figure 5a. Northern blot to detect changes in c-mvc messenger ribonucleic acid (mRNA)
expression during DMSO-induced differentiation of Friend murine erythroleukemia (MEL)
cells.
Friend MEL cells were incubated in the presence of 1.25% (v/v) DMSO for 1,2 or 
4 days in culture. Control cells were incubated in the absence of DMSO (day 0). Total 
cellular RNA was isolated, and 10 pg of total RNA were prepared for electrophoresis, as 
described in the Materials and Methods section. RNA was subjected to electrophoresis 
through a formaldehye-Agarose gel and then transferred to a nitrocellulose membrane. The 
membrane was probed with a radiolabeled c-myc cDNA fragment, as described in the 
Materials and Methods section.
Figure 5b. Ethidium bromide staining of total cellular ribonucleic acid (RNA).
The formaldehyde-Agarose gel in Figure 5a was photographed under ultraviolet 
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S 
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under 
UV illumination to confirm even transfer of RNA; data are not shown.)
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by day 4. Figure 5b depicts ethidium bromide-stained 18S and 28S rRNA bands to show 
loading of a constant amount of total RNA in each lane. Again, the nitrocellulose 
membrane onto which RNA had been transferred was examined by UV illumination to 
confirm complete and even transfer (data not shown).
CHARACTERIZATION OF THE EPOR ON FRIEND MEL PC4 AND DMSO/R1 CELLS
Expression of EPOR mRNA in Friend MEL and DMSO/Rl cells. To examine 
EPOR mRNA expression in parental Friend MEL (F) and DMSO/R1 (R) cells in response 
to DMSO exposure, Northern blots were performed with total RNA isolated from cells 
incubated in the absence (-) or presence (+) of 1.25% (v/v) DMSO. As shown in Figure 
6a, Friend MEL cells exhibited a low level of EPOR mRNA expression, which increased 
with the induction of differentiation by DMSO. DMSO/R1 cells expressed a higher 
baseline level of EPOR mRNA than parental MEL cells, and this level also increased with 
exposure to DMSO. Loading of an equal amount of total cellular RNA in each lane is 
demonstrated by ethidium bromide staining in Figure 6b. The nitrocellulose membrane 
onto which RNA had been transferred was examined by UV illumination to confirm 
complete and even transfer (data not shown).
To determine whether the presence of EPO in the culture medium resulted in the 
down-regulation of the mRNA expression of its receptor, Northern blots were performed 
with total RNA isolated from MEL and DMSO/R1 cells treated with or without 0.5 unit/ml 
of rhEPO after pre-incubation in the absence (-) or presence (+) of 1.25% (v/v) DMSO 
(Figure 7a). Exposure to rhEPO in culture did not have a significant effect upon the levels 
of EPOR mRNA in Friend MEL or DMSO/R1 cells. Similarly, exposure to rhEPO after 
prctreatment with DMSO did not result in any change in EPOR mRNA expression in the 
parental MEL or resistant subline. Loading of an equal amount of total cellular RNA in 
each lane is demonstrated by ethidium bromide staining in Figure 7b. The nitrocellulose
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Figure 6a. Northern blot to detect erythropoietin receptor (EPOR) messenger ribonucleic
acid ('mRNA') expression in Friend murine ervthroleukemia fMELI and DMSO/R1 cells.
Friend MEL cells (F) or DMSO/R1 cells (R) were incubated in the absence (-) or 
presence (+) of 1.25% (v/v) DMSO for 4 days in culture. Cells were split on day 2 and 
reseeded in fresh growth medium to achieve a cell density of 1 to 1.5 x 106 cells/ml upon 
harvesting on day 4. Total cellular RNA was isolated, and 10 pg of total RNA were 
prepared for electrophoresis, as described in the Materials and Methods section. RNA was 
subjected to electrophoresis through a formaldehye-Agarose gel and then transferred to a 
nitrocellulose membrane. The membrane was probed with a radiolabeled EPOR cDNA 
fragment, as described in the Materials and Methods section.
Figure 6b. Ethidium bromide staining of total cellular ribonucleic add (RNA).
The formaldehyde-Agarose gel in Figure 6a was photographed under ultraviolet 
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S 
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under 
UV illumination to confirm even transfer of RNA; data are not shown.)
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Figure 7a. Northern blot to detect erythropoietin receptor (EPOR) messenger ribonucleic 
acid (mRNAl expression in Friend murine ervthroleukemia (MEL) and DMSO/R1 cells 
exposed to erythropoietin (EPO'I after pretreatment with PMSO.
Friend MEL cells or DMSO/R1 cells were incubated in the absence (-) or presence 
(+) of 1.25% (v/v) DMSO for 3 days in culture. On day 3 cells were reseeded in fresh 
growth medium in the same DMSO concentration and in the absence (-) or presence (+) of 
0.5 unit/ml o f recombinant human erythropoietin (rhEPO, R. W. J. Pharmaceutical 
Research Institute). On day 5, total cellular RNA was isolated, and 10 pg of total RNA 
were prepared for electrophoresis, as described in the Materials and Methods section. 
RNA was subjected to electrophoresis through a formaldehye-Agarose gel and then 
transferred to a nitrocellulose membrane. The membrane was probed with a radiolabeled 
EPOR cDNA fragment, as described in the Materials and Methods section.
Figure 7b. Ethidium bromide staining of total cellular ribonucleic add (RNA).
The formaldehyde-Agarose gel in Figure 7a was photographed under ultraviolet 
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S 
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under 
UV illumination to confirm even transfer of RNA; data are not shown.)
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membrane onto which RNA had been transferred was examined by UV illumination to 
confirm complete and even transfer (data not shown).
Radioiodination of rhEPO using the IOPO-GEN method. To determine whether 
differences in EPOR mRNA expression resulted in changes in functional cell surface 
receptor expression, binding assays using radioiodinated EPO were performed to measure 
receptor numbers and affinity constants in Friend MEL and DMSO/R1 cells treated with or 
without DMSO. Purified, serum albumin-free rhEPO was labeled with Na125I by the 
IODO-GEN method (78, 151-153), and iodination products were separated on an 
excellulose column as described in the Materials and Methods section. Twenty-four eluate 
fractions were collected, and the radioactivity o f each collected fraction was determined 
using a gamma counter. The results are depicted in graphical form in Figure 8a. A peak of 
radioactivity, likely representing 125I-rhEPO, was eluted primarily in fractions 6 to 11, and 
unreacted Na125I was eluted beginning at fraction 18.
To determine that 125I-rhEPO was, in fact, eluted with the peak of radioactivity 
seen in Figure 8a, eluate fractions were analyzed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) as described in the Materials and Methods section (154). 
As demonstrated in Figure 8b, the primary product of the radioiodination procedure was 
125I-rhEPO; this band was shown to comigrate with both pure, serum albumin-free rhEPO 
and tissue culture-grade rhEPO on SDS-PAGE (data not shown). Radioiodination 
produced a small amount of labeled product o f higher molecular weight, which was 
originally thought to be labeled albumin due to inadequate quenching of the iodination 
reaction. However, this second product did not comigrate with serum albumin on SDS- 
PAGE (data not shown) and was interpreted to be to a radioiodinated dimer of rhEPO, as 
its molecular weight was consistent with the expected size of such a dimer. In addition, 
SDS-PAGE and silver staining (209,2i0) of rhEPO used in radioiodination revealed only 
a single protein band comigrating with the labeled product seen in Figure 8b, and there was 
no other band which might have represented a contaminant (data not shown).
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Figure 8a. Radioactivity of eluate fractions collected after application of iodination 
products onto an excellulose column.
Recombinant human erythropoietin (rhEPO) was radiolabeled with Na125I using 
the IODO-GEN reagent, as described in the Materials and Methods section. The iodination 
reaction was quenched with excess KI, and the radioiodination products were applied onto 
a Pierce Excellulose GF-5 Desalting Column. An initial fraction of 300 pi and subsequent 
fractions of 5 drops (approximately 60 pi) were collected. One pi was removed from each 
fraction, and radioactivity was determined using an LKB 1282 universal gamma counter.
Figure 8b. Analysis of radioiodination products bv sodium dodecvl sulfate- 
polvacrvlamide gel electrophoresis (PAGE! and autoradioeraphv.
Recombinant human erythropoietin (rhEPO) was radiolabeled with Na125I using 
the IODO-GEN reagent, and the radioiodination products were applied to an excellulose 
column, as described in the Materials and Methods section. Fractions of eluate were 
collected as described in Figure 8a, and 1 pi was removed from each fraction and subjected 
to 7.5% SDS-PAGE. The gel was fixed and then dried under heat and vacuum, and the 
dried gel was exposed to Kodak X-Omat AR film.
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To ensure that only the band corresponding to I2^I-rhEPO would bind to cells, 
preliminary binding assays were performed and the binding proteins were analyzed by 
SDS-PAGE and autoradiography (data not shown). Only a single band corresponding to 
125I-rhEPO was shown to bind to Friend MEL and DMSO/R1 cells. If the higher 
molecular weight band was, in fact, a radiolabeled dimer of rhEPO, cell surface EPORs did 
not possess a high enough binding affinity for the dimer for the presence of the dimer to 
contaminate subsequent binding assays.
Determination of the biological activity of the radioiodination product. Fractions 6 
to 10 were combined and used in subsequent binding assays. As can be seen from Figure 
8b, however, 12̂ l-rhEPO was not eluted from the column in a sharp, clean peak. An 
unknown but significant amount of 125I-rhEPO was not eluted during collection of 
fractions 6 to 10, and 125I-rhEPO was still eluted with the last collected fraction (fraction 
24). In order to confirm the biological activity of the radiolabeled 125I-rhEPO product and 
to determine the actual quantity of 125I-rhEPO collected in fractions 6 to 10, the biological 
activity of the combined fractions was assessed using a quantitative colorimetric assay for 
cellular proliferation, as described in the Materials and Methods section (155). Ba/F3- 
EPOR cells, which are dependent upon interleukin (IL)-3 or EPO, were used in this assay 
(104). The biological activities of tissue culture-grade and iodination-grade rhEPO were 
first assessed to confirm that the two sources of rhEPO possessed equal biological activity. 
As shown in Figure 9a, both sources of rhEPO demonstrated equal bioactivity, with 50% 
maximal biological response occurring at approximately 0.04 units/ml of rhEPO. Figure 
9b depicts the bioactivity curve in response to 125l-rhEPO in combined fractions 6 to 10; 
from this curve, the amount of 125I-rhEPO in the combined fractions was determined and 
used in subsequent binding assays.
Binding studies of the EPOR of Friend MEL and DMSO/R1 cells. Whole cell 
binding assays were performed as described in the Materials and Methods section (78), and 
the results are shown in Figures 10 to 14. Friend MEL cells were incubated in the absence
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Figure 9a. Comparison of biological activities of two sources of erythropoietin (EPO).
Tissue culture-grade recombinant human erythropoietin (rhEPO, stabilized with 
serum albumin) was obtained from R.W. Johnson Pharmaceutical Research Institute, and 
iodination-grade recombinant human erythropoietin (rhEPO, albumin-free) was obtained 
from Amgen (or R.W.J.) as described in the Materials and Methods section. Biological 
activity was determined by an MTT reduction assay, as described in the Materials and 
Methods section, and the results are expressed as % of maximum cell growth (of tissue 
culture grade rhEPO). Each point represents the results of 3 determinations + the standard 
error.
Figure 9b. Biological activity of radioiodinated erythropoietin.
Recombinant human erythropoietin (rhEPO) was radioiodinated as described in the 
Materials and Methods section. The biological activity of the radioiodination product was 
determined by an MTT reduction assay, as described in the Materials and Methods section, 
and the results are expressed as % of maximum cell growth. Each point represents the 
results of 3 determinations + the standard error.
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Figure 10a. Binding of radioiodinated erythropoietin to Friend murine ervthroleukemia
(MED cells.
Binding experiments using radioiodinated erythropoietin were performed as 
described in the Materials and Methods section. Total binding and nonspecific binding 
were determined in the absence or presence, respectively, of greater than 40-fold excess of 
unlabeled erythropoietin. Specific binding was obtained by subtraction o f nonspecific 
binding from total binding. Each point represents the results of 3 determinations + the 
standard error. The standard error for specific binding represents the sum of the standard 
errors for total and nonspecific binding.
Figure 10b. Scatchard plot for binding of radioiodinated erythropoietin to Friend murine 
ervthroleukemia (MED cells.
Binding experiments using radioiodinated erythropoietin were performed as 
described in the Materials and Methods section. Values for bound and free radioiodinated 
erythropoietin were determined from the amount of radioiodinated erythropoietin 
specifically bound to cells and the amount of radioligand added to the binding mixture. 
Each point represents the results of 3 determinations.
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Figure 11a. Binding of radioiodinated erythropoietin to Friend murine ervthroleukemia
(MEL) cells treated with 1.25% (v/v) DMSO for 2 davs.
Friend murine erythroleukemia (MEL) cells were incubated in the presence of 
1.25% (v/v) DMSO for 2 days. Binding experiments using radioiodinated erythropoietin 
were performed as described in the Materials and Methods section. Total binding and 
nonspecific binding were determined in the absence or presence, respectively, of greater 
than 40-fold excess of unlabeled erythropoietin. Specific binding was obtained by 
subtraction of nonspecific binding from total binding. Each point represents the results of 
3 determinations ±  the standard error. The standard error for specific binding represents 
the sum of the standard errors for total and nonspecific binding.
Figure 1 lb . Scatchard plot for binding of radioiodinated erythropoietin to Friend murine 
ervthroleukemia (MEL) cells treated w ith1.25% (v/v) DMSO for 2 davs.
Friend murine erythroleukemia (MEL) cells were incubated in the presence of 
1.25% (v/v) DMSO for 2 days. Binding experiments using radioiodinated erythropoietin 
were performed as described in the Materials and Methods section. Values for bound and 
free radioiodinated erythropoietin were determined from the amount of radioiodinated 
erythropoietin specifically bound to cells and the amount of radioligand added to the 
binding mixture. Each point represents the results of 3 determinations.
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Figure 12a. Binding of radioiodinated erythropoietin to Friend murine erythroleukemia
(MEL-) cells treated with 1.25% (v/v) DMSO for 4 davs.
Friend murine erythroleukemia (MEL) cells were incubated in the presence of 
1.25% (v/v) DMSO for 4 days. Binding experiments using radioiodinated erythropoietin 
were performed as described in the Materials and Methods section. Total binding and 
nonspecific binding were determined in the absence or presence, respectively, of greater 
than 40-fold excess of unlabeled erythropoietin. Specific binding was obtained by 
subtraction of nonspecific binding from total binding. Each point represents the results of 
3 determinations ±  the standard error. The standard error for specific binding represents 
the sum of the standard errors for total and nonspecific binding.
Figure 12b. Scatchard plot for binding of radioiodinated emhropoietinto Friend_ro\irine 
ervthroleukemia (MEL) cells treated with 1.25% (v/v) DMSO for 4 davs.
Friend murine erythroleukemia (MEL) cells were incubated in the presence of 
1.25% (v/v) DMSO for 4 days. Binding experiments using radioiodinated erythropoietin 
were performed as described in the Materials and Methods section. Values for bound and 
free radioiodinated erythropoietin were determined from the amount of radioiodinated 
erythropoietin specifically bound to cells and the amount of radioligand added to the 
binding mixture. Each point represents the results of 3 determinations.
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Figure 13a. Binding of radioiodinated erythropoietin to PMSO/R1 ceils passaged in the 
continuous presence o f !  ,2g% (v/v) d m § q .
DMSO-resistant cells (clone DMSO/R1) were passaged in the continous presence of 
1.25% (v/v) DMSO. Binding experiments using radioiodinated erythropoietin were 
performed as described in the Materials and Methods section. Total binding and 
nonspecific binding were determined in the absence or presence, respectively, of greater 
than 40-fold excess of unlabeled erythropoietin. Specific binding was obtained by 
subtraction of nonspecific binding from total binding. Each point represents the results of 
3 determinations + the standard error. The standard error for specific binding represents 
the sum of the standard errors for total and nonspecific binding.
Figure 13b. Scatchard plot for binding of radioiodinated erythropoietin to DMSO/R1 cells 
passaged in the continuous presence of 1.25% (vM DMSO.
DMSO-resistant cells (clone DMSO/R1) were passaged in the continous presence of 
1.25% (v/v) DMSO. Binding experiments using radioiodinated erythropoietin were 
performed as described in the Materials and Methods section. Values for bound and free 
radioiodinated erythropoietin were determined from the amount of radioiodinated 
erythropoietin specifically bound to cells and the amount of radioligand added to the 
binding mixture. Each point represents the results of 3 determinations.
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Figure 14a. Scatchard plot for binding of radioiodinated erythropoietin to DMSO/R1 cells 
passaged in the continuous presence of 1.25% (v/v) DMSO.
DMSO-resistant cells (clone DMSO/R1) were passaged in the continous presence of 
1.25% (v/v) DMSO. Binding experiments using radioiodinated erythropoietin were 
performed as described in the Materials and Methods section. Values for bound and free 
radioiodinated erythropoietin were determined from the amount of radioiodinated 
erythropoietin specifically bound to cells and the amount of radioligand added to the 
binding mixture. Each point represents the results of 3 determinations.
Figure 14b. Scatchard plot for binding of radioiodinated erythropoietin to DMSO/R1 cells 
passaged in the absence ofDMSO for 2 weeks.
DMSO-resistant cells (clone DMSO/R1) were passaged in the absence ofDMSO for 
2 weeks. Binding experiments using radioiodinated erythropoietin were performed as 
described in the Materials and Methods section. Values for bound and free radioiodinated 
erythropoietin were determined from the amount o f radioiodinated erythropoietin 
specifically bound to cells and the amount of radioligand added to the binding mixture. 
Each point represents the results of 3 determinations.
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(Figure 10) or presence of 1.25% (v/v) DMSO for two (Figure 11) or four days (Figure 
12) in culture. Cells were split at day 2 to allow for logarithmically growing cells at day 4. 
Total binding and nonspecific binding were determined from measurements of radioactivity 
contained in cell pellets after binding and washing, and specific binding was determined 
from the difference between total binding and nonspecific binding. Results of binding 
measurements are represented in part a of the figures, and Scatchard plots are depicted in 
part b of the figures.
A similar binding assay was performed with DMSO/R1 cells that had been 
continuously passaged in growth medium containing 1.25% (v/v) DMSO, and the results 
are shown in Figure 13. Because DMSO is a polar solvent with known membrane- 
permutating effects, the presence of a small amount o f DMSO in the medium used to 
maintain DMSO/R1 cells had the potential to influence EPO binding (211). Consequently, 
DMSO/R1 cells were removed from growth medium supplemented with DMSO and were 
passaged in DMSO-free medium for 2 weeks, and the binding assay was repeated. The 
Scatchard plots for DMSO/R1 cells passaged in the presence (part a) or absence (part b) of 
DMSO are represented in Figure 14.
The results of several binding assays are summarized in Table 5, which shows 
affinity constants and receptor numbers per cell for the experiments represented in Figures 
10 to 14. In contrast to a previously reported study with MEL cell clone B8, which had 
demonstrated a two-fold increase in EPORs per cell but no change in binding affinity over 
5 days of DMSO treatment, induction of differentiation of Friend MEL cell clone PC4 by 
DMSO resulted in a decrease in EPOR number followed by an increase in binding affinity. 
Untreated Friend MEL cells expressed 180 receptors of a single class with an affinity 
constant of 1.0 nM, classifying these receptors in the low-affinity range of described 
EPORs. The values for both receptor number and affinity constant are within the range of 
previously reported values (55). Exposure to 1.25% (v/v) DMSO for 2 days resulted in 
basically no change in binding affinity (0.9 nM) and a decrease in receptor number from
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Table 5. Affinity constants and receptor numbers per cell for Friend murine 
ervthroleukemia cells and DMSO-resistant clone DMSO/R1.
Cell line KnfnMl Receptors per cell
MEL (clone PC4)
Control 1.0 180
2 days DMSO 0.9 130
4 days DMSO 0.6 110
DMSO/R1
Maintained in DMSO 0.46 62
10 days out of DMSO 0.41 61
Binding experiments using radioiodinated erythropoietin were performed 
as described in the Materials and Methods section. Values for affinity constants 
and receptors numbers were determined from Scatchard plots.
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180 to 130 receptors per cell. Exposure to DMSO for 2 more days (4 days total) resulted in 
a small decrease in receptor number from 130 to 110 receptors per cell. A single class of 
EPOR with increased binding affinity (0.6 nM) was observed, and no receptors of affinity 
constant 0.9-1.0 nM were seen. Despite the increased binding affinity, the affinity constant 
remained in the low-affinity range. No positive cooperativity was seen with DMSO 
induction of differentiation.
DMSO/R1 cells maintained in DMSO-containing growth medium expressed 62 
receptors per cell of a single class with an affinity constant of 0.46 nM. The presence of 
DMSO in the growth medium was of great concern, as the decreased EPOR number and 
higher binding affinity seen in DMSO/R1 cells could be due to the presence of DMSO, 
rather than intrinsic properties of the subline. The decrease in receptor number and affinity 
constant seen with DMSO treatment of Friend MEL cells added to this concern. To address 
this issue, DMSO/R1 cells were passaged in DMSO-free growth medium for 2 weeks, and 
the binding assay was repeated. The removal ofDMSO from the growth medium resulted 
in no change in binding affinity (0.41 nM) or receptor number (61 receptors per cell). 
Thus, the changes in EPOR characteristics in DMSO/R1 did not appear to be dependent on 
the presence ofDMSO in culture.
INCREASED EXPRESSION OFGP55 PROTEIN IN DMSO/R1 CELLS
Synthesis of gp55 protein in Friend MEL and DMSO/Ri cells. Metabolic labeling 
with L-[35S]-methionine (156-158) followed by cell lysis and immunoprecipitation with an 
antiserum recognizing both F-MuLV gp70 and SFFVp gp55 was employed to examine the 
synthesis of gp55 protein in Friend MEL cells induced to differentiate by 1.5% (v/v) 
DMSO or 5 mM HMBA. Immunoprecipitates from a constant number of cells were loaded 
in each lane for 7.5% SDS-PAGE (154). As depicted in Figure 15, the synthesis of both 
F-MuLV gp85-90, the precursor of gp70, and SFFVp gp55 (marked by arrow) in Friend 
cells decreased over a period of 3 days in culture, likely due to a saturation of cell density
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Figure 15. 35S;Metabolic labeling of F-MuLV gp7J and SFFVp gp55 in Friend 
murine ervthroleukemia (MEL) ceils induced to differentiate with 1.5% (v/v) 
DMSO or 5 mM HMBA
Friend murine erythroleukemia (MEL) cells were seeded at day 0 in the 
absence (Friend) or presence of 1.5% (v/v) DMSO or 5 mM HMBA. After 1,2 or 
3 days in culture, cells were labeled with L-[35S]-methionine for 1 hour. Cellular 
lysates were immunoprecipitated with a goat polyclonal antiserum to F-MuLV gp70 
that also recognizes SFFVp gp55 (marked by arrow), and immunoprecipitates were 
subjected to 7.5% SDS-PAGE and autoradiography.
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with a plateau in cell growth. Induction of differentiation by DMSO resulted in no apparent 
change in F-MuLV gp85-90 synthesis but appeared to result in increased synthesis of gp55 
on day 3. In contrast, HMBA treatment resulted in decreased synthesis of SFFVp gp55 
and a more marked decrease in F-MuLV gp85-90 synthesis over the same time period. In 
addition, HMBA-treated cells exhibited almost undetectable levels of actin synthesis; actin 
was nonspecifically immunoprecipitated by goat whole serum (data not shown) and 
migrated as a 42-44 kDa protein on SDS-PAGE.
To determine if DMSO/R1 cells demonstrated changes in gp55 synthesis compared 
to parental MEL cells, the metabolic labeling experiment was repeated with both Friend 
MEL (F) and DMSO/R1 cells (R) that were grown in the absence (-) or presence (+) of 
1.25% (v/v) DMSO for 1, 2 or 3 days in culture (Figure 16). As observed before, the 
synthesis of both F-MuLV gp85-90 and SFFVp gp55 (marked by arrow) in Friend cells 
decreased over 3 days in culture. Exposure of Friend cells to DMSO increased both F- 
MuLV gp85-90 and SFFVp gp55 synthesis compared to uninduced cells on the same day. 
However, the level o f synthesis in DMSO-induced cells of both envelope glycoproteins 
also decreased slightly over 3 days in culture. DMSO/R1 cells appeared to exhibit a higher 
ratio of gp55 synthesis to gp85-90 synthesis, compared to parental MEL cells. This 
increase was particularly evident on day 3. In contrast to its effect upon parental MEL 
cells, DMSO treatment did not induce as much of an increase in envelope glycoprotein 
synthesis, particularly of F-MuLV gp85-90, in DMSO/R1 cells.
Western blot analysis of total cellular go55 protein content. Friend MEL and 
DMSO/R1 cells were grown in the absence or presence of 1.25% (v/v) DMSO for 1,2 or 3 
days in culture. Total cellular gp55 protein content was examined by Western blot analysis 
using a goat polyclonal antiserum recognizing both F-MuLV gp70 and SFFVp gp55, as 
described in the Materials and Methods section (Figure 17). In contrast to metabolic 
labeling experiments, which demonstrated synthesis of gp55 equal to or greater than that of 
F-MuLV gp85-90, Western blot analysis detected a much greater amount of F-MuLV gp85
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Figure 16. 35S-Metabo1ic labeling of F-MuLV pp70 and SFFVp  gp55_in_Friend 
muring. grythrplguKgmia (MEL) gglls and PMSO/P ) cells treated with PMSO
Friend murine erythroleukemia (MEL) cells (F) or DMSO/R1 cells (R) were 
seeded at day 0 in the absence (-) or presence (+) of 1.5% (v/v) DMSO. After 1,2 
or 3 days in culture, cells were labeled with L-[35S]-methionine for 1 hour. 
Cellular lysates were immunoprecipitated with a goat polyclonal antiserum to F- 
MuLV gp70 that also recognizes SFFVp gp55 (marked by arrow). 
Immunoprecipitates were subjected to 7.5% SDS-PAGE and autoradiography.
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Figure 17. Western blotting of F-MuLV gp70 and SFFVp gp55 in Friend murine
grythroleukemia (MEL) gglls.and.PMSQ/Rl cells treated with PM SQ
Friend murine erythroleukemia (MEL) cells (Friend) or DMSO/R1 cells 
(Resistant) were seeded at day 0 in the absence or presence (+DMSO) of 1.5% 
(v/v) DMSO. After 1, 2 or 3 days in culture, cellular lysates were subjected to 
7.5% SDS-PAGE, and proteins were transferred to an Immobilon-NC membrane. 
The membrane was probed with a goat polyclonal antiserum to F-MuLV gp70 that 
also recognizes SFFVp gp55 (marked by arrow). Proteins were detected using 
125I-Protein A.
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than of SFFVp gp55 (marked by arrow) in Friend cells. Both total cellular gp85 and gp55 
decreased from day 2 to day 3, and it appeared that the level of total cellular SFFVp gp55, 
but not of F-MuLV gp85, decreased in Friend cells exposed to DMSO, compared to 
uninduced cells. DMSO/R1 cells exhibited a large increase in the amount of total cellular 
gp55, compared to parental MEL cells, and a smaller increase in the amount of F-MuLV 
gp85. A band corresponding to F-MuLV gp70, the processed form of the gp85 precursor, 
was also observed in the resistant subline. As with MEL cells, the amounts of F-MuLV 
gp85 (and gp70) and SFFVp gp55 in DMSO/R1 cells decreased over 3 days in culture, and 
exposure to DMSO appeared to decrease the level of gp55 protein. However, the amount 
of gp55 protein observed in DMSO/R1 cells exposed to DMSO was still considerably 
increased over the level observed in uninduced parental MEL cells.
Eulse-chase metabolic labeling and endoglvcosidase H treatment of SFFVp gp55 
immunoprecipitates. To determine if slower degradation of synthesized gp55 in DMSO/R1 
cells was responsible for the observed increase in the level of total cellular gp55 protein in 
the resistant subline, pulse-chase experiments using endoglycosidase H (endo H) treatment 
of gp55 immunoprecipitates were performed (166-168). Friend MEL cells (Figure 18) and 
DMSO/R1 cells (Figure 19) were metabolically labeled with L-[35S]-methionine for 15 
minutes, and incorporated label was chased for up to 6 hours. In Friend cells, F-MuLV 
gp70 was synthesized as an immaturely glycosylated, endo H-sensitive polypeptide of a 
molecular size of 80-85 kDa (Figure 18). Endo H treatment decreased the molecular 
weight of the F-MuLV envelope glycoprotein to two bands of 60-62 kDa and 67-68 kDa. 
After a 3 hour chase period, the maturely glycosylated, endo H-resistant 70 kDa form was 
the primary band seen on SDS-PAGE, indicating that F-MuLV gp70 had undergone 
oligosaccharide processing and passed through the Golgi complex. In addition, most of 
the radiolabeled F-MuLV envelope glycoprotein had undergone degradation within 3 hours 
after synthesis, as evidenced by the decreased intensities of the gp70 bands at 3 hours. The 
results after 6 hours were essentially unchanged from the observations at 3 hours.
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Figure 18. Pulse-chase metabolic labeling and endoelvcosidase H treatment of F- 
MuLV go70 and SFFVp gp55 in Friend murine ervthroleukemia (MEL) cells 
induced to differentiate with 1.25% (v/v) DMSO
Friend murine erythroleukemia (MEL) cells were seeded in the absence or 
presence of 1.25% (v/v) DMSO. After 2 days in culture, cells were labeled with L- 
[35S]-methionine for 15 minutes. Cells were washed twice and then incubated in 
growth medium for 0, 3 or 6 hours (chase). Cellular lysates were 
immunoprecipitated with a goat polyclonal antiserum to F-MuLV gp70 that also 
recognizes SFFVp gp55 (marked by aiTOWs). Immunoprecipitates were incubated 
in the absence (-) or presence (+) of endoglycosidase H (endo H) and then 
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Figure 19. Pulse-chase metabolic labeling and endoglvcosidase H treatment of F- 
MnLV pp70 and SFFVp gp55 in DMSO/R1 ceils incubated in culture in the absence
QLBressncg.Qf 1,25% (v/v) DMSQ
DMSO/R1 cells were seeded in the absence or presence of 1.25% (v/v) 
DMSO. After 2 days in culture, cells were labeled with L-[35S]-methionine for 15 
minutes. Cells were washed twice and then incubated in growth medium for 0 ,3  
or 6 hours (chase). Cellular lysates were immunoprecipitated with a goat polyclonal 
antiserum to F-MuLV gp70 that also recognizes SFFVp gp55 (marked by arrows). 
Immunoprecipitates were incubated in the absence (-) or presence (+) of 
endoglycosidase H (endo H) and then subjected to 7.5% SDS-PAGE and 
autoradiography.
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In contrast, the primary form of the SFFVp envelope glycoprotein that was 
observed at all time points was the immaturely glycosylated, endo H-sensitive 55 kDa form 
(marked by upper arrow). Endo H treatment decreased the size of SFFVp gp55 to the 
unglycosylated 45 kDa polypeptide chain (marked by lower arrow). Interestingly, a 
significant amount of gp45 was observed in the absence of endo H after 3 and 6 hour chase 
periods, suggesting that a fraction of synthesized gp55 undergoes deglycosylation in 
Friend cells. In contrast to the observed degradation of gp70, the intensities o f the gp45 
and gp55 bands did not diminish after 3 or 6 hour chase periods, indicative of the longer 
half-life of gp55. DMSO-treated Friend cells demonstrated faster degradation of newly 
synthesized F-MuLV gp70, as the intensities of the gp70 decreased more rapidly than in 
uninduced cells. It also appeared that synthesized SFFVp gp55 underwent a small degree 
of degradation after 6 hours, as the intensities of the gp45 and gp55 bands at this time point 
seemed slightly diminished. In vivo deglycosylation of synthesized gp55 appeared to 
occur more slowly in DMSO-treated cells.
Similar results were observed with DMSO/R1 cells (Figure 19). Essentially no 
degradation of synthesized gp55 was seen over a 6 hour chase period. In contrast to 
parental MEL cells, exposure of resistant cells to DMSO resulted in no diminution of gp45 
and gp55 band intensities at the 6 hour timepoint. As was observed in DMSO-treated MEL 
cells, however, DMSO treatment of DMSO/R1 cells delayed the appearance of gp45 in 
untreated immunoprecipitates, again suggesting that DMSO somehow retards the in vivo 
deglycosylation of synthesized gp55.
Transfection of pRc/RSV-gp55 and pRc/RSV-antisense tro55 into Friend ceils. To 
determine whether SFFVp gp55 is responsible for the block in EPO-induced differentiation 
of Friend cells and whether the increase in gp55 protein observed in DMSO/R1 cells is 
responsible for the subline's resistant phenotype, expression vectors containing the SFFVp 
gp55 cDNA in both sense and antisense configurations were transfected into Friend MEL 
cells (140). The SFFVp gp55 cDNA insert was ligated in the sense or antisense orientation
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into the multiple cloning site of the stable eukaryotic expression vector pRc/RSV (Figure
20). The vector alone, pRc/RSV, was introduced into cells by electroporation (140,176, 
177), and a clone (FI) was derived from vector-transfected cells. FI cells demonstrated no 
significant difference in cell growth characteristics or in sensitivity to the effects of DMSO 
from parental MEL cells (Table 6). DMSO inhibited cell growth, induced differentiation, 
and restored responsiveness to EPO to the same degrees in both parental MEL and FI cells.
DMSO treatment of MEL cells resulted in a 73% growth inhibition and an increase 
in Hb content to 40.3 + 1.7 pg Hb/107 cells, and EPO stimulated cell proliferation by 22% 
and Hb production by an additional 6.5 pg Hb/107 cells. In comparison, DMSO treatment 
of FI cells resulted in a 74% growth inhibition and an increase in Hb content to 34.8 + 1.4 
pg Hb/107 cells, and EPO stimulated cell proliferation by 27% and Hb production by an 
additional 9.2 pg Hb/107 cells. pRc/RSV-gp55 and pRc/RSV-antisense gp55 transfectants 
were selected in medium containing 800 ng/ml of G-418 (180-182), and clones were 
screened by Western blot analysis to measure the level of total cellular gp55 protein (data 
not shown). Sense-transfected clones expressing increased total gp55 content and 
antisense-tranfected clones expressing decreased gp55 content were chosen for further 
examination of their biological responsiveness to the differentiation-inducing and EPO- 
sensitizing effects of DMSO.
A clone derived from MEL cells transfected with gp55 cDNA expressed in the 
sense orientation (Tf-gp55), which exhibited a level of total cellular gp55 protein similar to 
the relatively high level observed in DMSO/R1 cells, was selected for further study (Figure
21). Tf-gp55 cells exhibited similar growth characteristics as parental MEL cells (Table 7). 
Exposure of clone Tf-gp55 to 1.25% (v/v) DMSO resulted in a 77% inhibition of cell 
growth and an increase in cellular Hb content to 33.2 + 1.3 pg Hb/107 cells. The 
magnitudes of growth inhibition and differentiation were similar to those produced by 
DMSO in parental MEL cells (81% growth inhibition and 39.7 ± 2 .0 p g  Hb/107 cells). 
However, in contrast to parental MEL cells, DMSO treatment did not sensitize Tf-gp55
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
93
Figure 20. Construction of plasmids to express SFFVp gp55 cPNA in the sense or 
antisense orientation in Friend murine ervthroleukemia (MED cells
The cDNA insert for SFFVp gp55 was subcloned, in either the sense or 
antisense configuration, into the multiple cloning site of the stable eukaryotic 
expression vector pRc/RSV. Expression of the insert cDNA was under the 
transcriptional control o f a Rous sarcoma virus promoter (RSV LTR), and the 
vector also contained a neomycin resistance gene (Neo) under control of the SV40 
early promoter.
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Table 6. Effects of erythropoietin fEPO! on proliferation and hemoglobin (Hb) 
content of Friend MEL cells and pRc/RSV-transfected MEL cells (clone FI) treated 
with DMSO
Cell line DMSO EPO Cells/ml x 10~6 n f Hb/107 Cells
Friend MEL - 2.72 ±0.23 8.1 ±  1.0
+ - 0.74 ±0.12 40.3 ±  1.7
+ + 0.90 ±0.13* 46.8 ±  2.5*
FI - 2.56 ±  0.39 7.6 ± 0 .5
- + 2.60 ±0.33 8.2 ± 0 .5
+ - 0.66 ±0.07 34.8 ± 1 .4
+ + 0.84 ±  0.07 44.0 ±  2.3*
Cells were seeded on day 0 at 4 x 10* cells/ml in the presence or absence of 
1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 104 cells/ml in the same 
DMSO concentration in the presence or absence of 0.5 unit/ml of recombinant 
human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research Institute). Cell 
numbers and hemoglobin content were determined on day 6. Each value represents 
the results from 3 to 6 determinations ±  the standard error.
*p<0.005
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Figure 21. Western blotting of F-MuLV gp70 and SFFVp gp55 in pRc/RSV-gp55- 
transfected MEL clone Tf-gn55
Friend murine erythroleukemia (MEL) cells (Friend), DMSO/R1 cells 
(Resistant), or pRc/RSV-gp55-transfected MEL cells (clone Tf-gp55) were seeded 
at day 0 in the absence or presence (+DMSO) of 1.25% (v/v) DMSO. After 1,2 or 
3 days in culture, cellular lysates were subjected to 7.5% SDS-PAGE, and proteins 
were transferred to an Immobilon-NC membrane. The membrane was probed with 
a goat polyclonal antiserum to F-MuLV gp70 that also recognizes SFFVp gp55 
(marked by arrows). Proteins were detected using ,25I-Protein A.
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Table 7. Effects of erythropoietin CEpo") on proliferation and hemoglobin (Hh-) 
CQntenLflLEriend MEL cells and pRc/RSV-fgp55 cDNAVtransfected MEL cells 
(clone Tf-gp55) treated with DMSO
Cell line DMSO EPO Cells/ml x 10~6 ug Hb/107 Cells
Friend MEL - 2.40 ±0.17 6.8 ±  0.4
- + 2.44 ±  0.19 7.0 ± 0 .7
+ - 0.45 ±0.04 39.7 ±  2.0
+ 0.57 ±  0.02 46.1 ±  2.3*
Tf-gp55 - 2.29 ±  0.20 5.0 ±  1.1
- + 2.30 ±0.18 5.6 ± 1 .3
+ - 0.53 ±  0.03 33.2 ±  1.3
+ + 0.69 ±  0.05 32.5 ±  1.6
Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence of 
1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 104 cells/ml in the same 
DMSO concentration in the presence or absence of 0.5 unit/ml of recombinant 
human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research Institute). Cell 
numbers and hemoglobin content were determined on day 6. Each value represents 
the results from 3 to 6 determinations ±  the standard error.
*p<0.0005
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Figure 22. Western blotting of F-MuLV pp70 and SFFVp cd55 in dRc/RSV- 
antisense gp55-transfected MEL clone B7
Friend murine erythroleukemia (MEL) cells (clone PC4), DMSO/R1 cells 
(R l)f pRc/RSV-antisense gp55-transfected MEL cells (clone B7), or pRc/RSV- 
gp55-transfected MEL cells (TO were seeded at day 0 in the absence (-) or presence 
(+) of 1.25% (v/v) DMSO. After 2 days in culture, cellular lysates were subjected 
to 7.5% SDS-PAGE, and proteins were transferred to an Immobilon-NC 
membrane. The membrane was probed with a goat polyclonal antiserum to F- 
MuLV gp70 that also recognizes SFFVp gp55. Proteins were detected using 125I- 
Protein A.
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Table 8. Increased sensitivity of pRc/RSV-fantisense e p 55 cPNAVtransfected 
MEL-Clone B7 to both the differentiation-inducing and erythropoietin fEPOV 
sensitizing effects of DMSO
Cell line DMSO EPO Cells/ml x IQ-6 up Hb/107 Cells
Friend MEL - 3.26 + 0.31 6.8 ±  0.4
- + 3.22 + 0.31 7.0 ±  0.7
+ - 1.00 ±  0.09 39.7 ±  2.0
+ + 1.26 ±0.03 46.1 ±  2.3*
B7 - 3.15 ±  0.26 6.0 ±  0.7
- + 3.04 ±0.28 7.8 ±  1.4
+ - 0.37 ±  0.06 59.5 ± 4 .0
+ + 0.60 ±  0.05 78.3 ±  5.3*
Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence of 
1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 10* cells/ml in the same 
DMSO concentration in the presence or absence of 0.5 unit/ml of recombinant 
human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research Institute). Cell 
numbers and hemoglobin content were determined on day 6. Each value represents 
the results from 3 to 6 determinations ±  the standard error.
*p<0.001
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cells to the differentiating effects of EPO, although EPO stimulated cell proliferation by 
30% (compared to 27% in MEL cells). While the increased level of SFFVp gp55 protein in 
Tf-gp55 cells did not result in resistance to the differentiating effects of DMSO, the 
increased amount o f gp55 appeared to render these cells nonresponsive to the 
differentiating effects of EPO.
A clone derived from MEL cells transfected with SFFVp gp55 cDNA in the 
antisense orientation (B7) exhibited a decreased level of gp55 protein compared to parental 
MEL cells (Figure 22). B7 cells showed growth characteristics similar to those of parental 
MEL cells in the absence of DMSO, but exhibited increased sensitivity to both the growth 
inhibitory and differentiating effects o f DMSO (Table 8). DMSO treatment o f B7 cells 
resulted in an 88% growth inhibition and an increase in Hb content to 59.5 + 4.0 pg 
Hb/107 cells. In comparison, DMSO treatment of parental MEL cells resulted in a 69% 
growth inhibition and an increase in Hb content to 39.7 ±  2.0 pg Hb/107 cells. In addition, 
EPO caused a greater percentage increase in cell number, as well as a greater increase in Hb 
production, in DMSO-treated B7 cells (62% growth stimulation and +18.8 pg Hb/107 
cells) than in parental MEL cells (26% growth stimulation and +6.4 pg Hb/107 cells). 
Thus, transfection with a vector expressing gp55 cDNA in the antisense orientation resulted 
in greater sensitivity to both the differentiation-inducing and EPO-sensitizing effects of 
DMSO.
INTERACTION BETWEEN GP55 AND THE EPOR
Chemical crosslinking to radioiodinated EPO. 125I-rhEPO was crosslinked to 
Friend MEL and DMSO/R1 cells using 0.5 mM disuccinimidyl suberate (DSS) as 
described in the Materials and Methods section, and the results are shown in Figure 23 
(126-128). Bound 125I-rhEPO migrated at an approximate size of 40 kDa by SDS-PAGE, 
and specific binding of the radiolabeled ligand was competed by an excess of cold EPO 
(lane 1). Radioiodinated EPO was crosslinked to a protein of 60-65 kDa in both Friend
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Cold Epo: +
Figure 23. Chemical crosslinking of radioiodinated erythropoietin to Friend murine 
ervthroleukemia (MEL’) cells and DMSO/R1 cells hv disuccinimidvl suberate fDSS)
Friend murine erythroleukemia (MEL) cells (F) or DMSO/R1 cells (R) were seeded 
at 4 x 104 cells/ml in the absence (-) or presence (+) of 1.25% (v/v) DMSO. After 2 days 
in culture, cells were collected, and ,25I-rhEPO was allowed to bind to cells in the absence 
or presence (+) of excess cold EPO for 4 hours at 10-12°C. 125I-rhEPO was crosslinked 
to cellular proteins for 90 minutes at 4°C using 0.5 mM disuccinimidyl suberate (DSS). 
Cellular lysates were subjected to 7.5% SDS-PAGE and autoradiography.
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MEL and DMSO/R1 cells, and crosslinking to this protein was not observed in the 
presence of excess cold EPO. Exposure of Friend MEL or DMSO/R1 cells to DMSO 
appeared to increase the intensity of the crosslinked protein band but did not result in the 
appearance of any new bands. In both cell lines, only a small amount of bound 125I- 
rhEPO was crosslinked to protein, as evident by the much stronger signal intensity of the 
125I-rhEPO band compared to the crosslinked band.
To determine if the use of different chemical reagents would result in more efficient 
crosslinking or in crosslinking of different proteins, radioiodinated EPO was crosslinked to 
Friend MEL cells using a variety of reagents (Figure 24). Cells were incubated with 12̂ I- 
rhEPO in the presence of 0.5 mM DSS (lane 1), 0.5 mM disuccinimidyl tartarate (DST) 
and 0.5 mM DSS (lane 2), 10 mM l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
and 20 mM N-hydroxysulfosuccinimide (sulfo-NHS) (lane 3), or 0.5 mM 
bis(sulfosuccinimidyl)suberate (BS3) (lane 4). No crosslinking was observed with the 
combination of EDC and sulfo-NHS (195-198), and BS3 (192-194) proved to be a less 
efficient crosslinker than DSS. However, the combination of DSS (126-128) and DST 
(190,191) resulted in more efficient crosslinking of 123I-rhEPO to the 60-65 kDa protein 
than did DSS alone.
The combination of DSS and DST was used to crosslink radiolabeled EPO to 
Friend MEL and DMSO/R1 cells, and the results are shown in Figure 25. As observed 
above, crosslinking of bound 125I-rhEPO was very inefficient, with the intensities of the 
crosslinkcd protein bands being of much lower intensities than the radiolabeled ligand 
alone. However, a second protein of approximately 120 kDa appeared to be crosslinked to 
125I-rhEPO, in addition to the aforementioned 60-65 kDa protein, which remained the 
primary crosslinked band. The intensities of both crosslinked protein bands did not appear 
to significantly change with exposure of either cell line to DMSO.
CelLsurface labeling of SFFVp gp55. Cell surface labeling was used to examine 
the expression of the SFFVp envelope glycoprotein at the surface of Friend MEL and










Figure 24. Chemical crosslinking of radioiodinated erythropoietin to Friend murine
gmhrolguRgroia.(M EU cclls
Friend murine erythroleukemia (MEL) cells were crosslinked to ,25I-rhEPO for 90 
minutes at 4°C using 1) 0.5 mM disuccinimidyl suberate (DSS), 2) 0.5 mM DSS and 0.5 
mM disuccinimidyl tartarate, 3) 10 mM l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
and 20 mM N-hydroxysulfosuccinimide, or 4) 0.5 mM bis(sulfosuccinimidyl)suberate. 
Cellular lysates were subjected to 7.5% SDS-PAGE and autoradiography.
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Figure 25. Chemicalcrossl inking of radioiodinated erythropoietin to Friend MEL cells and 
DMSQ/R1 cells bv disuccinimidyl suberate (DSS) and disuccinimidyl tartarate (DST)
Friend murine erythroleukemia (MEL) cells (F) orDMSO/Rl cells (R) were seeded 
at 4 x 104 cells/ml in the absence (-) or presence (+) of 1.25% (v/v) DMSO. After 2 days 
in culture, cells were collected, and 125I-rhEPO was allowed to bind to cells for 4 hours at 
10-12°C. 125I-rhEPO was crosslinked to cellular proteins for 90 minutes at 4°C using a 
combination of 0.5 mM disuccinimidyl suberate (DSS) and 0.5 mM disuccinimidyl tartarate 
(DST). Cellular lysates were subjected to 7.5% SDS-PAGE and autoradiography.
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DMSO/R1 cells and to determine if exposure to DMSO or EPO changed this expression. 
Cells were incubated in the absence (-) or presence (+) of 1.25% (v/v) DMSO in culture, 
and cell surface proteins were labeled with NaI25I using an immobilized preparation of 
lactoperoxidase and glucose oxidase, as described in the Materials and Methods section 
(199-203). Total labeled cell surface proteins are shown in Figure 26. In both parental 
MEL and DMSO-resistant cells, exposure to DMSO resulted in an increase in radiolabeling 
of cell surface proteins, although this increase appeared to be more pronounced in DMSO- 
treated Friend cells. In both cell lines, the predominant labeled protein migrated at a 
molecular weight of approximately 47-48 kDa, with less intense bands migrating at 
approximately 35 kD a, 65 kDa and 80 kDa.
Labeled cell surface F-MuLV gp70 and SFFVp gp55 proteins are depicted in Figure 
27. Immunoprecipitation of the cellular lysates of cell surface labeled Friend MEL cells 
with goat a-MuLV gp70 polyclonal antiserum primarily detected an approximately 70 kDa 
band corresponding to F-MuLV gp70 that had been processed and transported to the cell 
surface. In addition, a very faint band was seen at approximately 60-65 kDa, which 
presumably represented SFFVp gp55 which had undergone carbohydrate processing and 
transport to the cell surface. Also observed was a 47-48 kDa band that comigrated with the 
primary band seen with total labeled cell surface proteins; this band probably represented 
nonspecific binding to the goat antiserum. DMSO/R1 cells exhibited a markedly decreased 
amount of labeled F-MuLV gp70, compared to parental MEL cells, and no detectable 
amount of labeled gp55.
Exposure to DMSO greatly increased cell surface labeling of F-MuLV gp70 in both 
cell lines, and the degree of increase in band intensity exceeded the increase in band 
intensities observed in total cell surface proteins (Figure 26). DMSO treatment of both cell 
lines also increased labeling of the 47-48 kDa protein thought to nonspecifically bind to the 
goat antiserum. Additionally, DMSO treatment of both cell lines markedly increased cell 
surface labeling of the 60-65 kDa protein thought to be the maturely glycosylated envelope
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Cells: Friend DMSO/R1
DMSO: -  +  ■ +
Figure 26. Labeling of total cell surface proteins in Friend murine ervthroleukemia 
(MED cells and DMSO/R1 cells treated with DMSO
Friend murine erythroleukemia (MEL) cells or DMSO/R1 cells were seeded 
at day 0 at 4 x 104 cells/ml in the absence (-) or presence (+) of 1.25% (v/v) 
DMSO. On day 2, cells were reseeded at 4 x 104 cells/ml. On day 4, cell surface 
proteins were labeled with Na,25I using immobilized lactoperoxidase and glucose 
oxidase (Enzymobead Reagent). Cellular lysates were subjected to 7.5% SDS- 
PAGE and autoradiography.








Figure 27. Labeling o f cell surface F-MuLV gp70 and SFFVp en55 in Friend 
murine erythroleukemia (MEL) cells and PMSO/R1 cells treated with DMSO
Friend murine erythroleukemia (MEL) cells or DMSO/R1 cells were seeded 
at day 0 at 4 x 104 cells/ml in the absence (-) or presence (+) of 1.25% (v/v) 
DMSO. On day 2, cells were reseeded at 4 x 104 cells/ml. On day 4, cell surface 
proteins were labeled with Na,25I using immobilized lactoperoxidase and glucose 
oxidase (Enzymobead Reagent). Cellular lysates were immunoprecipitated with a 
goat polyclonal antiserum to F-MuLV gp70 that also recognizes SFFVp gp55. 
Immunoprecipitates were subjected to 7.5% SDS-PAGE and autoradiography.
Friend DMSO/R1 
-  +  -  +
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form of SFFVp gp55 (Figure 27). Interestingly, a labeled protein of 52-55 kDa was 
observed in DMSO-treated MEL cells but not in DMSO-resistant cells exposed to DMSO. 
This protein band was not seen in uninduced MEL cells nor in DMSO-treated DMSO/R1 
cells, even upon longer exposure of the dried gel to radiographic film (data not shown).
Cell surface labeling of SFFVp gp55 in pRc/RSV-gp55 and oRc/RSV-antisense 
gp55-transfected cell lines. Cell surface labeling studies were performed to examine 
expression of the SFFVp env gene product at the cell surface of cells derived from 
pRc/RSV-gp55 cDNA-transfected MEL cells (clone Tf-gp55) and pRc/RSV-antisense gp55 
cDNA-transfected MEL cells (clone B7). The results are shown in Figure 28. Similar to 
the results observed in parental MEL cells, immunoprecipitation of the cellular lysates of 
cell surface labeled Tf-gp55 cells and B7 cells detected primarily F-MuLV gp70 and a very 
small amount of a 60-65 kDa protein corresponding to the mature, cell surface form of 
SFFVp gp55. A small amount of the 47-48 kDa protein was observed in all three cell 
lines, but no 52-55 kDa protein was seen. DMSO treatment of Tf-gp55 and B7 cells, as 
well of Friend and DMSO/R1 cells, resulted in markedly increased labeling of F-MuLV 
gp70 as well as of the 60-65 kDa protein. Exposure to DMSO also resulted in the 
appearance of the 52-55 kDa band, which was readily detectable in the parental MEL lines 
and the two transfected cell lines, but faintly detectable in the resistant subline. The 
increase in labeling of the 47-48 kDa band was less pronounced than the increases in the 
other three bands.
Attempts to detect cell surface EPOR by immunoprecipitation of cellular lysates of 
lactoperoxidase-glucose oxidase labeled cells with a rabbit polyclonal o-mEPOR antiserum 
were unsuccessful. This lack of success appeared to be due to the low cell surface 
expression of EPORs on MEL cells, as demonstrated by the results of the binding assays, 
and the poor ability of the rabbit a-mEPOR antiserum to precipitate EPOR in cellular lysate 
samples. Similarly, attempts to detect mctabolically labeled EPOR by immunoprecipitation 
also proved disappointing.









Figure 28. Labeling of cell surface F-MuLV pp70 and SFFVp gp55 in murine 
erythroleukemia (MEL) cell lines treated with erythropoietin following pretreatment 
with DMSO
Friend murine erythroleukemia (MEL) cells, DMSO/R1 cells (Resist), 
pRc/RSV-gp55-transfected MEL cells (clone Tf-gp55), or pRc/RSV-antisense 
gp55-transfected MEL cells (clone B7) were seeded at day 0 at 4 x 104 cells/ml in 
the absence (-) or presence (+) o f 1.25% (v/v) DMSO. On day 3, cells were 
reseeded at 4 x 104 cells/ml in the absence (-) or presence (+) of 0.5 unit/ml of 
erythropoietin (EPO). On day 5, cell surface proteins were labeled with Na125I 
using immobilized lactoperoxidase and glucose oxidase (Enzymobead Reagent). 
Cellular lysates were immunoprecipitated with a goat polyclonal antiserum to F- 
MuLV gp70 that also recognizes SFFVp gp55. Immunoprecipitates were subjected 
to 7.5% SDS-PAGE and autoradiography.
FRIEND B7 Tf(gp55) RESIST 
- + -  +  -  +  -  +
* +  " +  ■ +  " +  * +  “ +  • +  “ +
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Western .blot analysis of coimmunoprecipitated SFFVp  gp55 and mEPOR. To 
directly determine if induction of differentiation by DMSO resulted in dissociation of gp55 
from the EPOR, coimmunoprecipitation studies of unlabeled cellular lysates of Friend MEL 
and DMSO/R1 cells were performed. Nuclei-free cellular lysates of Friend MEL cells (F) 
and DMSO/R1 cells (R) were obtained as described above. The lysates were subjected to 
immunoprecipitation by a rabbit antiserum to the mEPOR (anti-EpoR) or by a goat 
antisemm to F-MuLV gp70 which also recognizes SFFVp gp55 (anti-gp70). Samples of 
cellular lysates and of the immunoprecipitates were resolved by SDS-PAGE and transferred 
to nitrocellulose membranes (173, 174). The membranes were probed with antiserum 
against gp55/gp70 (Figure 29) or the mEPOR (Figure 30) to detect both 
immunoprecipitated and coimmunoprecipitated proteins, and bound primary antibodies 
were detected with the appropriate peroxidase-conjugated secondary antibodies (188,189).
The Western blot of gp55/gp70 is shown in Figure 29. In Friend MEL cells (F), 
the F-MuLV env gene product existed primarily in the maturely glycosylated, cell surface 
gp70 form; however, a small fraction o f the immature 80 kDa form of the glycoprotein was 
detected. The env gene product o f the SFFVp existed primarily in the immaturely 
glycosylated 55 kDa form in the RER, although a small amount underwent oligosaccharide 
processing to the mature 65 kDa form. Similar amounts of F-MuLV gp70 and gp80 were 
observed in DMSO/R1 cells (R), but the resistant cells exhibited increased levels of gp55 
and, in particular, gp65. Western blotting of anti-gp55/gp70 immunoprecipitates (lanes 3 
and 4) showed that the polyclonal antiserum against F-MuLV gp70 bound the F-MuLV and 
SFFVp envelope glycoproteins with different affinities under immunoprecipitation and 
Western blot conditions. A much smaller proportion of gp70 was seen by Western blotting 
in lanes 3 and 4 than in lanes 1 and 2, indicating a lower affinity for gp70 under 
immunoprecipitation conditions. Western blotting of anti-EpoR immunoprecipitates (lanes 
5 and 6) demonstrated that the gp55 and gp65 forms of SFFVp, but not the gp70 and gp80
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Immunoppt: None anti-gp70 anti-EpoR
Cells: F R F R F R
Figure 29. Western blotting of SFFVp gp55 coimmunoprecipitated with the 
erythropoietin receptor in Friend murine ervthroleukemia (MEL) cells and 
PMSO/R1 cells
Cellular lysates of Friend murine erythroleukemia (MEL) cells (F) or 
DMSO/R1 cells (R) were subjected to immunoprecipitation with a goat polyclonal 
antiserum to F-MuLV gp70 that also recognizes SFFVp gp55 (anti-gp70) or with a 
rabbit polyclonal antiserum to the murine erythropoietin receptor (anti-EpoR). 
Cellular lysates and immunoprecipitates were subjected to 7.5% SDS-PAGE, and 
proteins were transferred to an Immobilon-NC membrane. The membrane was 
probed first with goat anti-gp70 antiserum (primary andbody) and then with rabbit 
anti-goat IgG conjugated to horseradish peroxidase (secondary andbody). Proteins 
were detected using an enhanced chemiluminescence (ECL) system.
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forms o f F-MuLV, physically associated with the EPOR. This association was seen in 
both Friend (F) and DMSO/R1 (R) cells.
Immunoprecipitated and coimmunoprecipitated mEPOR was more difficult to detect 
by this assay (Figure 30). The antiserum to the mEPOR primarily recognized a protein of 
approximately 105 kDa, but fainter bands of approximately 60 and 65 kDa were also 
observed in both Friend (F) and DMSO/R1 (R) cell lines (lanes 1 and 2). Western blotting 
of anti-gp55/gp70 immunoprecipitates demonstrated that the 60 and 65 kDa forms of the 
EPOR, but not the 105 kDa protein, associated with SFFVp gp55 and gp65 (lanes 3 and 4) 
in both cell lines. Western blotting of anti-EpoR immunoprecipitates resulted in a very 
dense band of approximately 55 kDa.
To determine whether this band was the result of secondary antibody recognizing 
antibody in the immunoprecipitation that had been subjected to SDS-PAGE and transferred 
to the membrane, a Western blot was performed in which a membrane was probed only 
with the secondary antibody. Goat anti-rabbit IgG conjugated to horseradish peroxidase 
was used to probe a membrane, as shown in Figure 31. The antibody was probed against 
Friend MEL cell lysate (lane 1), goat anti-gp70 immunoprecipitate of lysate (lane 2), rabbit 
anti-EpoR immunoprecipitate of lysate (lane 3), goat anti-gp70 antiserum alone (lane 4), 
and rabbit anti-EpoR antiserum alone (lane 5). The secondary antibody readily detected a 
band o f approximately 55 kDa in lanes 3 and 5, indicating that the goat anti-rabbit 
secondary antibody bound to the rabbit antiserum used to immunoprecipitate the mEPOR. 
A similar experiment determined that the rabbit anti-goat secondary antibody did not bind to 
the goat antiserum used to immunoprecipitate SFFVp gp55 (data not shown).
Effect of DMSO upon the association of SFFVp gp55 and the EPOR. Friend MEL 
and DMSO/R1 cells were incubated for 4 days in culture in the absence (-) or presence (+) 
of 1.25% (v/v) DMSO, and nuclei-free cellular lysates were obtained as described in the 
Materials and Methods section. The lysates were immunoprecipitated with goat antiserum 
to F-MuLV gp70 (anti-gp70) or with rabbit antiserum to the mEPOR (anti-EpoR). The
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Immunoppt: None anti-gp70 anti-EpoR
Cells: F R F R F R
Figure 30. Western blotting of ervthropoietin.receDtor coimmunoprecipitated with 
SFFVp gp55 in Friend murine ervthroleukemia (MEL) cells and DMSQ/R1 cells
Cellular lysates of Friend murine erythroleukemia (MEL) cells (F) or 
DMSO/R1 cells (R) were subjected to immunoprecipitation with a goat polyclonal 
antiserum to F-MuLV gp70 that also recognizes SFFVp gp55 (anti-gp70) or with a 
rabbit polyclonal antiserum to the murine erythropoietin receptor (anti-EpoR). 
Cellular lysates and immunoprecipitates were subjected to 7.5% SDS-PAGE, and 
proteins were transferred to an Immobilon-NC membrane. The membrane was 
probed first with rabbit anti-EpoR antiserum (primary antibody) and then with goat 
anti-rabbit IgG conjugated to horseradish peroxidase (secondary antibody). 
Proteins were detected using an enhanced chemiluminescence (ECL) system.
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Figure 31. Western blotting with anti-rabbit secondary antibody alone
Cellular lysate of Friend murine erythroleukemia (MEL) cells was subjected 
to immunoprecipitation with a goat polyclonal antiserum to F-MuLV gp70 that also 
recognizes SFFVp gp55 (anti-gp70) or with a rabbit polyclonal antiserum to the 
murine erythropoietin receptor (anti-EpoR). Cellular lysate (lane 1), anti-gp70 
immunoprecipitate (lane 2), anti-EpoR immunoprecipitate (lane 3), anti-gp70 alone 
(lane 4), and anti-EpoR alone (lane 5) were subjected to 7.5% SDS-PAGE. 
Proteins were transferred to an Immobilon-NC membrane. The membrane was 
probed with goat anti-rabbit IgG conjugated to horseradish peroxidase. Proteins 
were detected using an enhanced chemiluminescence (ECL) system.
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ImmppL anti-gp70 Immppt anti-EpoR 
Cells: Friend Resist Friend Resist
DMSO: +
*   *  —  -  -  —  *
1 0 6 -
8 0 -
Figurc 32. Western blotting of SFFVp gp55 coimmunoprecipitated with the 
erythropoietin receptor in Friend muiine ervthroleukemia (MEL) cells and 
DMSO/R1 cells treated with DMSO
Friend murine erythroleukemia (MEL) cells or DMSO/R1 cells (Resist) 
were seeded at day 0 at 4 x 104 cells/ml in the absence (-) or presence (+) or 1.25% 
(v/v) of DMSO. On day 2, cellular lysates were subjected to immunoprecipitation 
with a goat polyclonal antiserum to F-MuLV gp70 that also recognizes SFFVp 
gp55 (anti-gp70) or with a rabbit polyclonal antiserum to the murine erythropoietin 
receptor (anti-EpoR). Immunoprecipitates were subjected to 7.5% SDS-PAGE, 
and proteins were transferred to an Immobilon-NC membrane. The membrane was 
probed first with goat anti-gp70 antiserum (primary antibody) and then with rabbit 
anti-goat IgG conjugated to horseradish peroxidase (secondary antibody). Proteins 
were detected using an enhanced chemiluminescence (ECL) system.
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Cellular lysates Immunoppt. anti-gp70 
Cells: Friend Resist Friend Resist
DMSO: _ - 4 . - 4 .
106 -
49.5 -
Figure 33. _Westem_blotting of erythropoietin reccotor coimmunoprecipitated with 
SEEyp-gp55_in_Eriendjnurine ervthroleukemia (MEL) cells and PMSQ/RLcells 
treated with PMSO
Friend murine erythroleukemia (MEL) cells or DMSO/R1 cells (Resist) 
were seeded at day 0 at 4 x 104 cells/ml in the absence (-) or presence (+) or 1.25% 
(v/v) of DMSO. On day 2, cellular lysates were subjected to immunoprecipitation 
with a goat polyclonal antiserum to F-MuLV gp70 that also recognizes SFFVp 
gp55 (anti-gp70). Cellular lysates and anti-gp70 immunoprecipitates were 
subjected to 7.5% SDS-PAGE, and proteins were transferred to an Immobilon-NC 
membrane. The membrane was probed first with rabbit polyclonal antiserum to the 
murine erythropoietin receptor (primary antibody) and then with goat anti-rabbit 
IgG conjugated to horseradish peroxidase (secondary antibody). Proteins were 
detected using an enhanced chemiluminescence (ECL) system.
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immunoprecipitates were subjected to SDS-PAGE and transferred to nitrocellulose 
membranes. The membranes were probed with goat anti-gp70 antiserum (Figure 32) or 
rabbit anti-EpoR antiserum (Figure 33). Western blotting with antiserum to gp55/gp70 
(Figure 32) confirmed the results observed in Figure 29; immunoprecipitation with 
antiserum to mEPOR coprecipitated the gp55 and gp65 forms o f the SFFVp envelope 
glycoprotein in both Friend and DMSO/R1 cells. DMSO treatment of Friend cells appeared 
to increase the amount of SFFVp gp65 coimmunoprecipitated with the EPOR, whereas 
DMSO treatment appeared to decrease the amounts o f SFFVp gp55 and gp65 
coimmunoprecipitated with the EPOR.
Western blotting with antiserum to the mEPOR (Figure 33) demonstrated cleaner 
results than were shown previously in Figure 30. Immunoprecipitation with antiserum to 
gp55/gp70 coprecipitated mEPOR with an apparent molecular weight of approximately 60 
kDa by SDS-PAGE. The same amount of EPOR was coimmunoprecipitated in both Friend 
MEL and DMSO/R1 cells, and exposure of both cell lines to DMSO did not appear to 
change the amount of EPOR that was associated with SFFVp gp55 and gp65.
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DISCUSSION
The focus of the first part of these investigations has been the examination of 
changes in the expression of erythropoietin receptor (EPOR) messenger ribonucleic acid 
(mRNA) and protein during induction of Friend murine erythroleukemia (MEL) cell 
differentiation by the polar solvent dimethylsulfoxide (DMSO). Friend MEL cells, which 
are derived from proerythroblast-like cells isolated from the spleens of mice infected with 
the Friend SFFVp viral complex, are independent of erythropoietin (EPO), the principal 
humoral regulator of erythropoiesis (27,28, 30, 38). Unlike normal committed erythroid 
progenitor cells, Friend cells are blocked in their differentiation and are unresponsive to 
EPO (27,30,42). As has been previously reported, DMSO induces Friend MEL cells to 
undergo changes in cellular morphology and function similar to those occurring during 
differentiation of proeiythroid cells to orthochromatophilic normoblasts (20, 45). More 
importantly to these investigations, however, induction of MEL cell differentiation by 
DMSO is accompanied by restoration of sensitivity to both the growth-stimulatory and 
differentiation-inducing effects of EPO. These studies have attempted to examine whether 
this restoration of sensitivity to EPO is mediated through an increase in cell surface EPORs, 
through the expression of a new class of high-affinity receptors, or through the induction 
of positive cooperativity among the receptors.
CHARACTERIZATION OF THE DMSO-RESISTANT MEL CLONE DMSO/R1 
Measurement of EPO responsiveness of MEL cells pretreated with DMSO. A 
concentration of 1.25% (v/v) DMSO was chosen to induce MEL cell differentiation after 
careful preliminary screening of a wide range, from 0.25% (v/v) to over 2% (v/v), of 
DMSO concentrations (data not shown). A range of concentrations of DMSO was tested to 
determine the level of inducer necessary to optimize studies of the restoration by DMSO of 
both the proliferation- and differentiation-inducing effects of EPO (20). A dose of 1.25%
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(v/v) DMSO was selected because pretreatment of MEL cells with this concentration of the 
agent resulted in maximal increases in cell growth and Hb content by EPO (data not 
shown). Lower concentrations resulted in smaller increases in cell growth and Hb content, 
due to dilution of EPO's effects on differentiating cells by the larger pool of 
nondifferentiated MEL cells.
Higher concentrations also resulted in smaller measured increases in growth and Hb 
production, as these doses appeared to induce MEL cells to mature beyond the stage of 
EPO sensitivity. EPO primarily stimulates CFU-E cells; however, as erythroid progenitor 
cells differentiate beyond the nondividing late basophilic erythoblast stage, they become 
independent of EPO for terminal maturation (38,54,57). At higher doses of DMSO, the 
DMSO-iesponsive population of cells progressed far enough down the differentiation 
pathway that they had no remaining proliferative capacity or had become independent of 
EPO for further differentiation.
Measurement of MEL cell differentiation. A well-characterized spectrophotometric 
assay to determine cellular Hb content by measuring the amount of Hb contained in several 
million cells was the method chosen to measure the degree of MEL cell differentiation in 
these studies (134). Benzidine staining, another commonly used assay o f MEL cell 
differentiation that measures the number of cells staining positively for Hb (20), was not 
performed for several reasons. Although benzidine staining yields valuable information 
about the percentage of cells that are induced to differentiate, the assay is highly dependent 
upon the subjective judgment of the human observer. Experimental reproducibility of 
results with the benzidine staining assay was of concern. Of particular concern was the 
ability to replicate results between different observers, or interobserver reproducibility. 
The degree of staining varies subtly along a continuum from individual cell to cell, and 
there is no clear demarcation between a "negative" and a "positive" cell. Unlike the 
benzidine staining assay, the spectrophotometric assay depends, not on a human observer 
but, on an instrument that generates objective measurements (134). Additionally, the
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spectrophotometric assay yields quantitative results, and interobserver reproducibility is 
excellent.
The one disadvantage of the spectrophotometric assay, however, is its inability to 
provide information about the percentage of the cell population undergoing differentiation 
and the amount of Hb production in those cells that actually differentiate. This limitation 
must be considered in the interpretation of any results generated from this assay, as only a 
certain percentage of cells differentiate in response to a particular concentration of inducer, 
as has been demonstrated by careful use of the benzidine staining assay (20). The 
spectrophotometric assay can not distinguish between a situation in which the entire cell 
population differentiates and produces Hb and a situation in which a smaller subpopulation 
differentiates and produces a greater amount of Hb per individual cell. Both conditions 
would yield the same result in the spectrophotometric assay.
Cell numbers and determination of the amount of growth inhibition in the presence 
of a differentiation inducer compensate, at least to some degree, for this limitation of the 
spectrophotometric assay. Cells which enter the differentiation pathway eventually lose 
their capacity to proliferate (1), so that cell counts can theoretically serve as crude estimates 
of the relative numbers of cells that have not differentiated and still possess proliferative 
capacity. For example, an equal increase in the Hb content of two populations of MEL 
cells in response to DMSO can be accompanied by a lesser or greater degree of growth 
inhibition. A lesser degree of growth inhibition suggests that a smaller percentage of cells 
undergoes differentiation but produces more Hb per individual cell. In contrast, greater 
growth inhibition suggests that a larger percentage of cells differentiates but produces less 
Hb per cell, as a larger number of cells in the overall population produce the same amount 
of total Hb.
Growth and_differentiation of Friend MEL and PMSO/Rl_cells. In order to 
facilitate these investigations, a Friend MEL subline resistant to the differentiating and 
EPO-sensitizing effects of DMSO was developed by passaging MEL cells in progressively
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higher concentrations of DMSO and then cloning resistant cells by single cell sorting. This 
DMSO-resistant subline, DMSO/R1, was used in all subsequent studies. Clone DMSO/R1 
displayed somewhat slower growth in the absence of DMSO in culture than did the parental 
Friend MEL clone PC4, with a doubling time of 12 hours compared to 10 hours for the 
parental line (Figure 2). In addition, DMSO/R1 cells reached plateau phase at a lower 
density than did parental MEL cells, with a plateau phase density of 2 x 10® cells/ml 
compared to 3 x 10® cells/ml for Friend cells. However, the growth of Friend MEL and 
DMSO/R1 cells in the presence of 1.25% (v/v) DMSO was similar for the first 4 days of 
tissue culture growth, with similar doubling times and plateau phase cell densities for both 
lines. In contrast to Friend MEL cells, in which DMSO inhibited growth and induced 
increased Hb production, DMSO/R1 cells responded to DMSO with increased proliferation 
but no differentiation, as evidenced by no change in Hb production in DMSO-treated cells.
Thus, clone DMSO/R1 was demonstrated to be resistant to the differentiation- 
inducing effect of DMSO. Clone DMSO/R1 was then further characterized to determine if 
resistance to the maturation-inducing effect of DMSO was accompanied by resistance to the 
EPO-sensitizing effect of DMSO (20). Unlike parental Friend MEL cells, in which DMSO 
pretreatment restored EPO responsiveness, DMSO-treated DMSO/R1 cells showed no 
change in cell proliferation or Hb content in response to EPO (Table 2). Therefore, clone 
DMSO/R1 was resistant to both the differentiating and EPO-sensitizing properties of 
DMSO.
Stability of the DMSO-resistant phenotype of clone DMSO/R1. Of concern, 
however, was the observation that DMSO stimulated the growth of DMSO/R1 cells, 
especially given that this subline was being continuously passaged in the presence of 
1.25% (v/v) DMSO. Since clone DMSO/R1 had been developed without the use of a 
mutagenizing agent, the possibility that the resistant phenotype was not stable and was, in 
fact, dependent upon constant exposure to DMSO had to be considered. Of additional, 
though less likely, concern was the possibility that clone DMSO/R1 had become dependent
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upon DMSO and would not be able to grow in the absence of the polar solvent To address 
these two concerns, DMSO/R1 cells were removed from DMSO-supplemented growth 
medium and were passaged in DMSO-free growth medium for 1 week or 1 month. The 
cellular responses to DMSO treatment and to EPO exposure following DMSO pretreatment 
were then assessed (Table 3).
Clone DMSO/R1 exhibited a DMSO-resistant phenotype that was stable for at least 
1 month and maintained resistance to both the maturation-inducing and EPO-sensitizing 
properties of DMSO over this month. In addition, while DMSO/R1 cells were able to grow 
in the absence of DMSO during the month, DMSO still exerted a growth-stimulatory effect 
on DMSO/R1 cells that had not been exposed to the polar solvent for 1 month. The degree 
of growth stimulation seen with DMSO in these cells was similar to that observed with 
DMSO/R1 cells continuously passaged in DMSO-containing medium, and DMSO/R1 cells 
exhibited nearly identical growth characteristics whether they were passaged in the constant 
presence of DMSO or after 1 month in culture without DMSO. These results indicated that 
the DMSO-resistant property of DMSO/R1 cells was inherent to the subline and was not a 
transient response to the presence of DMSO.
However, it is unclear whether this population of DMSO-resistant cells was 
achieved through the selection of a preexisting subpopulation of parental Friend MEL cells 
already resistant to the action of DMSO or through the induction of changes, whether 
genetic or cellular, in the parental line which then generated a resistant subline upon further 
selection in DMSO. The first explanation is certainly plausible, as there is a distribution of 
sensitivities to DMSO among any population of Friend MEL cells (20). A very small 
fraction of this population may be resistant to the concentration of inducer used to generate 
DMSO-resistant cells and may eventually account for the entire MEL cell population, as 
DMSO-sensitive cells differentiate and lose all proliferative potential. An increasing 
concentration of DMSO was used, instead of mutagenesis, to develop a resistant subline in
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this hope that selection and expansion of a preexisting, resistant subpopulation could be 
achieved.
Cross-resistance of DMSO/R1 cells to hexamethvlene bisacetamide (HMBA). As 
summarized in Table 4, exposure of Friend MEL cells to 2 mM HMBA resulted in a 
comparable amount of Hb production (23.1 + 0 .9  pg Hb/107 cells) as did exposure to 
1.25% (v/v) DMSO (24.5 ±2 .3  pg Hb/107 cells), but 2 mM HMBA inhibited cell growth 
to a lesser extent (42% inhibition) than did DMSO (63% inhibition). This statistically 
significant difference in growth inhibition suggested that 2 mM HMBA induced a smaller 
percentage of MEL cells to enter the differentiation pathway than did 1.25% (v/v) DMSO. 
However, 2 mM HMBA appeared to induce a greater amount of Hb production in 
differentiation-induced cells than did DMSO. Thus, while HMBA (51) and DMSO (20) are 
both commonly used as inducers of the differentiation of MEL cells, they have similar, but 
not equivalent, biological effects in these cells. An increase in the HMBA concentration to 
4 mM resulted in both increased inhibition of cell growth (92% inhibition) as well as 
increased Hb production (59.1 +4.9 pg Hb/107 cells. The increased Hb production may 
have resulted from an increased percentage of differentiated cells in culture, increased Hb 
production by individual differentiated cells, or a combination of both effects.
DMSO/R1 cells were shown to be resistant to both the differentiation-inducing and 
EPO-sensitizing effects of HMBA. DMSO/R1 cells were resistant to 4 mM HMBA, which 
induced cellular Hb content in parental MEL cells to increase to an amount 2.4-fold the 
level induced by 1.25% (v/v) DMSO. Exposure to 4 mM HMBA induced a greater 
percentage of parental MEL cells to differentiate or stimulated higher production of Hb 
within the same percentage of cells, compared to 1.25% (v/v) DMSO or 2 mM HMBA. It 
is thought that DMSO and HMBA may induce MEL cell differentiation through similar 
mechanisms (1), so it was not surprising that DMSO/R1 cells also expressed a resistant 
phenotype to the differentiating effects of HMBA. It was somewhat surprising that, while 
both 2 mM and 4 mM HMBA stimulated the growth of DMSO/R1 cells, the increase
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observed with 4 mM was less than that seen with 2 mM HMBA. From preliminary studies 
in this laboratory, HMBA appeared to have more cytotoxic effects than DMSO in culture, 
and it is possible that these cytotoxic effects had a larger effect on cell growth at the higher 
concentration of HMBA.
A possibility which had to be considered, however, was that DMSO/R1 cells were 
being induced to differentiate in response to DMSO but were deficient in the synthetic 
machinery to generate Hb, which has been widely used as the marker for erythroid 
maturation (20). Cells treated with imidazole and DMSO failed to activate iron transport, 
synthesize heme, or produce globin mRNA, but they underwent all the other cellular 
changes, such as a decrease in cell size and nuclear condensation, characteristic of terminal 
differentiation. Thus, imidazole inhibited Hb synthesis but did not disrupt other maturation 
processes in MEL cells exposed to DMSO (132,206,212). The possiblity that the method 
in use was not detecting differentiation was addressed by examining clone DMSO/R1 for 
other cellular changes which are known to occur in response to induction of MEL cell 
differentiation by DMSO.
Expression of c-mvc and c-mvb mRNAs in Friend MEL and DMSO/R1 cells. The 
nuclear protooncogenes c-myb and c-myc have been implicated in MEL cell maturation, 
and mRNA levels of these two protooncogenes are known to undergo characteristic 
changes during chemically induced differentiation (204-208). c-Myb and c-myc mRNA 
levels decrease almost immediately in response to DMSO and then return to baseline levels 
by day 1 or 2 before undergoing a second, final decrease by day 3 or 4. This final decrease 
to nearly undetectable levels is necessary for maturation to occur and is a hallmark of MEL 
cell differentiation.
Friend MEL and DMSO/R1 cells were incubated for 4 days in culture in the absence 
or presence of 1.25% (v/v) DMSO, and c-myb and c-myc mRNA levels were examined by 
Northern blotting. While Friend MEL cells exhibited a characteristic decrease in c-myb 
mRNA to an almost undetectable level after 4 days' exposure to DMSO, DMSO treatment
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of DMS0/R1 cells had no effect on c-myb mRNA expression (Figure 3). A similar 
decrease in c-myc mRNA expression was observed in Friend MEL cells after exposure to 
DMSO, but DMSO/R1 cells displayed an increased baseline level of c-myc mRNA 
compared to parental Friend cells (Figure 4). This level of c-myc mRNA appeared to 
increase in DMSO/R1 cells upon DMSO treatment.
Thus, DMSO/R1 cells were resistant to DMSO on a transcriptional, as well as on a 
functional, level, and the resistant phenotype seen in biological assays was not due only to 
a block in the functional enzymes being measured for assessment of maturation. While 
increased c-myc expression may be a possible mechanism for the DMSO-resistant 
phenotype of clone DMSO/R1, it is impossible to conclude that this increase was causally 
related to the phenotype of this subline. This question may be addressed, however, by 
overexpressing c-myc in parental Friend MEL cells and assessing whether such increased 
expression results in a DMSO-resistant phenotype.
CHARACTERIZATION OF THE EPOR ON FRIEND MEL PC4 AND DMSO/R1 CELLS
Unfortunately, studies of EPOR protein expression and transport have been limited 
by the extremely low level of cell surface receptors exhibited on erythroid cell lines (100- 
1000 receptors per cell) (55). Because of this limitation, much of the work to date on the 
EPOR has been conducted on non-erythroid cells transfected with vectors to overexpress 
the receptor (104,122). The EPOR is easier to study in such transfected lines due to the 
high number of receptors which are expressed in these lines. A sizeable body of data on 
the activation of cell growth through the EPOR has been obtained through studies of such 
transfected cell lines. However, it must be kept in mind that the findings from such 
investigations in non-erythroid lines may not necessarily reflect the cellular processes 
involved with the native EPOR in erythroid cells. This caveat is especially true if the goal 
is the investigation of erythroid differentiation, as non-erythroid cells seem an even less 
appropriate system in which to conduct such studies. Thus, while studying the EPOR in
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erythroid cells is technically difficult due to the low number of receptors on these cells, 
such investigations are necessary for a better understanding of the EPOR and its role in 
inducing the differentiation of erythroid progenitor cells.
Expression o f EPOR mRNA in Friend MEL and PMSO/R1 cells. Having 
characterized the DMSO-resistant phenotype of the DMSO/R1 subline, a Northern blot was 
performed to determine whether changes in EPOR mRNA expression occurred after 4 days 
of DMSO treatment in parental Friend and DMSO/R1 cells (Figure 6a). DMSO/R1 cells 
exhibited a higher baseline level of EPOR mRNA expression than parental MEL cells, but 
the level of EPOR mRNA increased with DMSO exposure in both cell lines. This increase 
was not surprising in the Friend MEL line, as the cells became EPO-responsive with 
DMSO-induced maturation. Additionally, it had been shown in B8 cells that the number of 
specific binding sites for EPO increased with induction of differentiation (90).
However, DMSO/R1 cells were resistant to DMSO and did not express the changes 
in nuclear protoonogene expression and Hb production normally observed during 
maturation. Thus, it was intriguing to detect an increase in EPOR mRNA in a subline 
which exhibited no other expected change of maturation and which remained EPO- 
unresponsive after treatment with DMSO. The increase in EPOR mRNA expression 
observed with DMSO treatment of clone DMSO/R1 suggested that the subline’s resistance 
to the EPO-sensitizing effects of DMSO was dependent on a cellular change or event 
subsequent to transcription of EPOR mRNA. The level of EPOR mRNA was not 
downregulated by exposure of uninduced or DMSO-treated Friend MEL or DMSO/R1 cells 
to EPO (Figure 7a).
To better examine the changes in EPOR expression during chemical induction of 
differentiation, binding assays were performed (78, 88). While Nonhem blots are often 
used to assess gene expression, a biochemical assay to measure protein expression is 
desirable, as a knowledge of the level of end product is more informative. Measurements 
such as enzyme assays or binding studies are often more informative than Western blots of
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total protein or metabolic labeling studies of protein synthesis, as the former measurements 
yield information on functional expression. Although both Friend MEL and DMSO/R1 
cells had been shown to respond to DMSO treatment with increased expression of EPOR 
mRNA, it was important to determine if such an increase at the mRNA level translated into 
increased expression of functional receptor at the cell surface.
Radioiodination o f rhEPO and determination of the biological activity of the 
radioiodination product. Recombinant human erythropoietin (rhEPO) was radioiodinated 
using a well-accepted IODO-GEN procedure (151-153), which is the commonly used 
method to label EPO for binding or crosslinking studies (78). As can be observed from 
Figure 8, it was impossible to determine how much rhEPO was recovered in the form of 
125I-rhEPO from the results of gamma counting or SDS-PAGE analysis of fraction 
samples. Clearly, a large but unmeasurable amount of 125I-rhEPO remained on the column 
or was collected in eluate fractions which were not included in the pooled fractions used in 
subsequent binding assays (fractions 6 to 10). It addition, it was necessary to ensure that 
125I-rhEPO generated by this radioiodination possessed biological activity, as iodination of 
more than one tyrosine residue per EPO molecule destroys biological function of the 
hormone (88).
To address this issue and to determine the amount of 125I-rhEPO that was 
recovered from the excellulose column in fractions 6 to 10, the combined radioiodination 
fractions (6 to 10) were tested for bioactivity using a quantitative colorimetric assay (Figure 
9) (155). This assay employed Ba/F3-EPOR cells, murine lymphoid cells which had been 
stably transfected with an expression vector containing MEL EPOR cDNA and which are 
dependent upon interleukin (IL)-3 or EPO for growth in culture (104). While these 
transfected lymphoid cells have been commonly employed to study the murine EPOR, it 
must be emphasized that Ba/F3 cells, being of lymphoid rather than erythroid lineage, may 
not possess all the requisite cellular machinery to transduce an identical signal in response
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to EPO as do erythroid cells. However, the Ba/F3-EPOR cell line was quite suitable for 
the purpose for which it was being used in these investigations.
Effect of DMSO upon receptor number and binding affinity of_the EPOR of Friend 
MEL cells. After determination of the biological activity of 125I-rhEPO and quantitation of 
125I-rhEPO present in the pooled eluate fractions, binding assays were performed to 
examine possible changes in EPOR protein expression on the cell surface in response to 
DMSO-induced differentiation. Binding experiments were conducted with both Friend 
MEL and DMSO/R1 cells, and the results are represented in Figures 10 to 14 and 
summarized in Table 5. Friend MEL cells growing in culture expressed approximately 180 
receptors of a single class with an affinity constant of 1.0 nM, placing these receptors 
within the Iow-affinity range of described EPORs. The values for both receptor number 
and affinity constant are within the range of previously reported values (55).
Exposure to 1.25% (v/v) DMSO for 2 days produced no significant change in 
binding affinity (0.9 nM), but the receptor number decreased from 180 to 130 receptors per 
cell. Continued exposure to DMSO for 2 more days (4 days total) produced a small 
decrease in receptor number from 130 to 110 receptors per c e ll. A single class of EPOR 
with increased binding affinity (0.6 nM) was observed after 4 days of DMSO treatment, 
but no receptors of the original affinity constant of 0.9-1.0 nM were seen. While these 
receptors exhibited somewhat higher affinity for EPO, the affinity constant remained in the 
low-affinity range (55). No positive cooperativity was seen in Friend cells with DMSO 
induction of differentiation.
These results were surprising for several reasons. First, a previous report had 
shown that DMSO treatment of MEL cell clone B8 resulted in a two-fold increase in 
receptor number but no change in binding affinity (90). Secondly, Friend MEL cells had 
been shown, during these investigations, to regain EPO responsiveness after 3 days of 
exposure to DMSO (Table 2). Thirdly, these investigations had demonstrated increased 
EPOR mRNA expression in response to DMSO treatment (Figures 6 and 7). However,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
128
binding assays demonstrated that this increased level of mRNA did not result in increased 
expression of functional receptor at the cell surface. Several possible explanations could 
account for this observation.
Possible explanations for the decreased number and increased binding affinity .of 
EPORs on Friend MEL cells exposed to DMSO. First, the increased level of EPOR 
mRNA in DMSO-treated MEL cells may be translated at a slower rate than in untreated 
cells, resulting in a decreased synthetic rate of the protein. Alternatively, the protein may 
be synthesized at an equal or faster rate, but newly synthesized EPORs may be retained in 
the rough endoplasmic reticulum (RER) or degraded at a faster rate, resulting in a shorter 
half-life and increased EPOR protein turnover. Pulse-chase metabolic labeling experiments 
followed by immunoprecipitation with antibodies against the EPOR could address these 
questions, as such studies would provide information about EPOR protein synthesis and 
subsequent degradation. Treatment with endoglycosidase H or fractionation of the plasma 
membrane from total cell extracts could provide information about the processing and 
transport of EPORs to the cell surface.
Of interest was the increase in EPOR binding affinity observed during day 2 to 4 of 
DMSO treatment, which had not been previously reported in MEL cells. The detection of 
only a single class of receptors of a different binding affinity on day 4 was surprising, as 
induction of a new class of receptors during the time interval from day 2 to day 4 would be 
expected to produce two classes of EPORs in the Scatchard plot. Two explanations may 
account for this observation. First, MEL cells may stop all cell surface expression of the 
first class of EPOR (kd of 0.9-1.0 nM) and express only receptors of a new, second class 
(kd of 0.6 nM) from day 2 to 4 of DMSO treatment. However, the biological utility of 
expressing a new class of EPOR with only a 60-80% increase in binding affinity is not 
obvious. Secondly, the presence of DMSO in the culture medium may perturb the cell 
membrane to such an extent that the conformation of the EPOR is altered to such a degree 
that the binding affinity of the receptor for its ligand is changed somewhat. Of particular
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concern was the possibility that the observed change in binding affinity in response to 
DMSO was due, not to induction of differentiation but rather, to perturbation of membrane 
properties (211).
Decreased number and increased binding affinity of EPORs on PMSO/R1 cells. To 
help address these questions, binding assays were performed with DMSO/R1 cells. 
DMSO/R1 cells maintained in DMSO-containing growth medium expressed 62 receptors 
per cell of a single class with an affinity constant of 0.46 nM. Thus, the DMSO-resistant 
subline expressed approximately a third of the number of receptors exhibited by the 
parental Friend MEL cell line, and these receptors exhibited twice the binding affinity of the 
parental line's EPORs. These results were surprising, given the higher level of EPOR 
mRNA expression in DMSO/R1 cells compared to Friend MEL cells. As has been 
discussed above, a number of mechanisms may play a role in the decrease in cell surface 
EPORs despite an increased EPOR mRNA level.
An additional possibility is that increased SFFVp gp55 in DMSO/R1 cells may 
retain EPOR within the RER and retard transport of the receptor to the cell surface. Gp55, 
the viral envelope glycoprotein of SFFVp, has been demonstrated to associate with the 
EPOR and cause retention of the receptor within the RER (30,103, 109-111, 122). The 
association of gp55 with the EPOR has also been shown to confer factor independence 
upon Ba/F3 cells cotransfected with vectors expressing cDNAs for both gp55 and EPOR 
(104). This possibility will be further addressed in a later part of the Discussion section.
The presence of DMSO in the growth medium used to passage DMSO/R1 cells was 
of concern, as the decreased EPOR number and particularly the higher binding affinity of 
DMSO/R1 cells could be due to the presence of DMSO, rather than intrinsic properties of 
the subline. This concern was increased by the observation that DMSO treatment of Friend 
MEL cells resulted in both decreased cell surface receptor and affinity constant. It was 
necessary to determine if the results seen with clone DMSO/R1 were due to continual 
exposure to a polar solvent or if they reflected stable differences in this subline. Such
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information was also necessary to help determine if the changes in receptor number and 
affinity constant seen with DMSO treatment of Friend cells resulted from induction of 
differentiation or from the presence of the solvent
To address this issue, DMSO/R1 cells were passaged in DMSO-free growth 
medium for 2 weeks, and the binding assay was repeated. The removal of DMSO from 
growth medium resulted in no change in binding affinity (0.41 nM) or receptor number (61 
receptors per cell) compared to DMSO/R1 cells which were continuously exposed to 
DMSO in culture. Thus, the changes in EPOR number and binding affinity in DMSO/R1 
cells, as compared to parental MEL cells, did not appear to be dependent on the constant 
presence of DMSO in culture. It can also be inferred, since the presence of DMSO did not 
affect the values determined for DMSO/R1 cells, that the changes in the cell surface 
expression and binding affinity of the EPOR observed with DMSO treatment of Friend 
MEL cells were due to induction of cell differentiation, rather than to the physical presence 
of the chemical agent. However, it is entirely unclear whether the decreased receptor 
number and affinity constant of the EPOR had any causal relationship with the DMSO- 
resistant phenotype of DMSO/R1 cells.
It was interesting to note again that a change in EPOR mRNA expression was not 
reflected by a similar change in cell surface receptor expression. Removal of DMSO/R1 
cells from DMSO-containing medium resulted in a decreased level of EPOR mRNA, but no 
change resulted in receptor binding assays. These results indicate that post-transcriptional 
controls are important in regulation of the expression of the EPOR on the surface of MEL 
cells. Such controls, as discussed above, may involve translational control or post- 
translational regulation, such as protein transport or degradation.
Proposed future binding studies of the EPOR on Friend MEL and DMSO/R1 cells. 
The first part of these investigations, unfortunately, have not led to a clear model of EPOR 
expression during the DMSO-induced differentiation of Friend MEL cells, but they have 
raised intriguing questions. While DMSO induction resulted in decreased cell surface
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expression of the EPOR, Friend MEL cells became responsive to EPO upon this induction. 
Thus, DMSO must act upon some mechanism downstream of the EPOR, as the decreased 
number of receptors in DMSO-treated cells are able to respond to EPO. One attractive 
hypothesis is that DMSO causes dissociation of the EPOR from SFFVp gp55 in Friend 
MEL cells, allowing the cytokine receptor to transduce its signal upon binding of EPO. 
This possible explanation must be considered, as SFFVp gp55 has been shown to be the 
part of the Friend viral genome required to confer tumorigenicity (30, 103, 213). This 
hypothesis will be addressed in a later part of the Discussion section.
Such a model of DMSO’s actions is conceivable, given the membrane-perturbing 
effects of DMSO (211). However, a major problem with DMSO or any other polar 
compound used to examine leukemia cell differentiation is the degree of nonspecific activity 
with any of these chemical agents. These compounds induce tumor cell maturation in a 
wide number of, but not in all, leukemia cell lines, and their polar properties endow them 
with a variety of membrane- and cell-disrupting effects (211). Unfortunately, they remain 
the most useful group of agents with which to study leukemia cell differentiation and will 
remain so, until new, more specific inducers of differentiation are discovered.
Two useful sets of additional binding experiments may help to address whether the 
changes in EPORs observed in MEL cells after exposure to 1.25% (v/v) DMSO for 2 or 4 
days resulted from cell differentiation or from the physical presence of a polar solvent The 
first set of studies involves treatment of MEL cells with a lower concentration of DMSO, to 
which approximately equal numbers of cells do and do not respond by entering the 
differentiation pathway. Two populations of MEL cells, one differentiating and the other 
not, should arise in culture after treatment with this lower concentration of DMSO. If MEL 
cell differentiation was responsible for the aforementioned changes in EPOR expression, 
binding studies of the entire cell population should theoretically observe two discrete 
population of EPORs, one from each population of MEL cells, with different affinity 
constants. If solvent effects were responsible for the changes in EPOR expression,
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however, the same changes in EPOR number and binding affinity should theoretically 
occur in both differentiating and nondifferentiating cells, as these changes would be due to 
membrane perturbation effects of DMSO and would not be specific for one or the other 
group of cells. In this latter case, a single population of EPORs with a single binding 
affinity should theoretically be observed in both cell populations.
The second set of studies involves treatment of Friend MEL cells and DMSO/R1 
cells with a differentiation inducer that has fewer membrane perturbation effects. 
Unfortunately, the other commonly used inducer of MEL cell differentiation, HMBA (51), 
also alters membrane potential (211). However, the amount of HMBA used to induce 
MEL cell differentiation in vitro is smaller than the concentrations of DMSO (1-2%, v/v) 
necessary to induce differentiation. Thus, solvent effects on the cell membrane may be less 
of a problem with HMBA than at the conentration of 1.25% (v/v) DMSO used in these 
studies. If similar changes in the EPOR number and binding affinity were observed with 
treatment with an inducer that exhibited fewer membrane disrupting effects, such results 
would suggest that the receptor changes seen with DMSO resulted from the induction of 
differentiation. Alternatively, if no changes were seen with the new inducer, such results 
would suggest that membrane perturbation effects of DMSO were responsible.
It remains puzzling that so many different values for the binding affinity of the 
mEPOR have been reported, when only one murine EPOR cDNA has been cloned to date 
(60). These differences may reflect differences in methodology or errors in measurement, 
or they may reflect slightly different post-translational modifications of the receptor by 
different murine cell types expressing the EPOR. Alternatively, other cellular proteins may 
be important in the mEPOR complex needed to bind EPO, and the absence or presence of 
these proteins may affect the affinity of the cytokine receptor for EPO. It is quite 
conceivable that these accessory proteins may be different from cell line to cell line. In a 
way, values from one report can not be compared to results from another report, as 
investigators have used different cell lines and binding conditions to obtain their results.
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The binding of EPO to its receptor and the changes in this binding with induction of MEL 
cell differentiation remain areas which need further investigation.
INCREASED EXPRESSION OF GP55 PROTEIN IN DMSO/R1 CELLS
The hypothesis that DMSO causes dissociation of the EPOR from SFFVp gp55 in 
Friend MEL cells, allowing the receptor to transduce its signal upon binding of EPO, was 
discussed earlier in this section. This hypothesis proposes that the envelope protein of the 
SFFVp plays a role, not only in the constitutive activation of the EPOR with resultant EPO 
independence (104) but also, in the block in EPO-induced differentiation observed in 
Friend MEL cells (20, 29). This question was first approached by examining whether 
DMSO induction of maturation resulted in changes in gp55 expression and whether 
DMSO/R1 cells demonstrated different expression of gp55. Attention was therefore turned 
upon the synthesis and processing of the SFFVp env gene product in Friend MEL and 
DMSO/R1 cells and upon the effects of induction of differentiation upon gp55 expression.
Increased SFFVp pp55 protein content, but not gp55 synthesis, in DMSO/R1 cells. 
Metabolic labeling experiments (156-158) were conducted to examine the synthesis of 
SFFVp gp55 in Friend MEL and DMSO/R1 cells, and the effect of DMSO treatment on this 
synthesis was also examined (Figures 15 and 16). Western blot analysis (173) was 
performed to measure the amount of total cellular gp55 in these cells (Figure 17). The 
results of these studies strongly suggested that, while the SFFVp envelope glycoprotein 
was not synthesized at a greater rate in DMSO/R1 cells than in parental MEL cells, gp55 
was being degraded at a slower rate in the resistant subline, leading to accumulation of a 
much higher level of total cellular gp55 protein in DMSO/R1 cells. This increased level of 
gp55 in a DMSO-resistant MEL subline and the observation that DMSO-treated DMSO/R1 
cells expressed more total gp55 protein than uninduced MEL cells were interesting 
findings, given our hypothesis that gp55 plays a role in the block in EPO-induced 
differentiation of Friend MEL cells.
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While there was no obvious explanation for the increased stability of synthesized 
gp55 in DMSO/R1 cells, the increased amount of total cellular gp55 protein suggested a 
possible explanation for the decreased number of cell surface EPORs observed on these 
cells during binding studies. SFFVp gp55 has been shown to associate with the EPOR in 
the RER, causing retendon of the cytokine receptor within the RER and increasing the half- 
life of newly synthesized receptor (122). Since more than 95% of the SFFVp env gene 
product in Friend MEL cells remains in the RER due to defective intracellular transport of 
the glycoprotein (27,116), DMSO/R1 cells, in most likelihood, contain a higher number of 
gp55 polypeptides in their RERs. A higher number o f gp55 molecules may increase 
retention of EPORs in the RERs of DMSO/R1 cells and thereby inhibit transport of the 
receptors to the cell surface.
To determine if  such a retention was occurring, the synthesis and intracellular 
transport of EPORs in Friend MEL and DMSO/R1 cells were examined by pulse-chase 
metabolic labeling and endoglycosidase H (endo H) treatment (166-168) of a-mEPOR 
immunoprecipitates. Unfortunately, the rabbit polyclonal a-mEPOR antiserum that was 
used did not prove an effective precipitator of the receptor in cellular lysate samples, despite 
the trial of a number of antibody dilutions. This ineffectiveness may have been due to low 
numbers of EPORs in the lysates or to inadequate binding affinity of the antiserum for the 
mEPOR. However, the antiserum was synthesized to the same peptide antigen that had 
been reported to generate immunoprecipitation-usable antiserum (122).
SloaLrisgiadatign.Qf.SFFVp gp55 in Frignd.M El  and .P M S Q/R 1 ,cells- Pulse- 
chase metabolic labeling and endo H treatment (166-168) of anti-gp55/gp70 
immunoprecipitates demonstrated that the SFFVp env gene product existed primarily as an 
immaturely glycosylated, endo H-sensitive 55 kDa glycoprotein which underwent little, if 
any, detectable degradation during a 6 hour chase period following metabolic labeling 
(Figures 18 and 19). There appeared to be some degradation of gp55 after a 6 hour chase 
period in DMSO-treated MEL cells, suggesting that the decrease in total gp55 protein seen
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with Western blot analysis of these cells was due to faster degradation of synthesized gp55. 
If synthesized gp55 protein in DMSO/R1 cells has^reater stability and a longer half-life 
than in parental MEL cells, a much longer chase period will be necessary to detect such a 
difference in degradative rates of the envelope glycoprotein. The duration of the chase 
period in this set of experiments was too short to detect any degradation of gp55, much less 
any difference between the stabilities of gp55 in the two cell lines.
Interestingly, F-MuLV gp70 appeared to be synthesized at an equal or slower rate 
in both cell lines than was SFFVp gp55 and, unlike gp55, underwent significant 
degradation during the chase period (Figures 18 and 19). Yet, Western blot analysis with 
the same antiserum used in immunoprecipitation studies detected a markedly higher amount 
of gp70 than of gp55 in both Friend and DMSO/R1 cells (Figure 17). Since a greater 
quantity of one protein can not accumulate when it is synthesized at an equal or slower rate 
and possesses a shorter half-life than the second protein, one of the observations is 
probably the result of experimental artifact. The most likely explanation is that the 
polyclonal antiserum used in these investigations exhibits different binding affinities for 
gp55 and gp70 under immunoprecipitation conditions and Western blot conditions. The 
antiserum may immunoprecipitate gp70 less efficiently than gp55, or the antiserum may 
bind gp70 more efficiently than gp55 on a Western blot. This question will be addressed 
later in this section.
Transfection of pRc/RSV-gp55 and pRc/RSV-antisense gp55 into Friend cells. 
Although DMSO/R1 cells had been demonstrated to contain a greater amount of gp55 
protein than parental MEL cells, it was unclear whether this increased level of the SFFVp 
env gene product produced the DMSO-resistant phenotype in clone DMSO/R1, whether 
these two phenomena were correlated but not causally related, or whether these two 
phenomena were entirely unrelated. To test the hypothesis that the envelope protein of the 
SFFVp plays a role, not only in the constitutive activation of the EPOR (104, 115) but 
also, in the block in EPO-induced differentiation observed in Friend MEL cells,
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transfection studies were performed to increase or decrease the level of total gp55 protein in 
MEL cells. Electroporation (140,175-178) was used to stably transfect Friend cells with 
vector alone (no insert), vector expressing the SFFVp gp55 cDNA in the sense orientation, 
or vector expressing the gp55 cDNA in the antisense orientation (Figure 20). Cells were 
selected in growth medium containing G-418 (180-182) and cloned by single cell sorting.
Western blot analysis (173) of SFFVp gp55 was used to screen clones for 
increased or decreased cellular content of gp55 protein. This method of screening was 
chosen because the relationship of interest was the one between the level of total cellular 
gp55 protein, not of mRNA expression or protein synthesis, and responsiveness to the 
effects of DMSO. A clone (Tf-gp55) of pRc/RSV-gp55-transfected cells expressing an 
increased level of gp55 protein similar to that seen in DMSO/R1 cells was chosen for 
further study (Figure 21). Similarly, a clone (B7) of pRc/RSV-antisense gp55-transfected 
cells expressing a decreased level of gp55 was selected for further study (Figure 22).
Transfection of the expression vector alone containing no DNA insert had no 
significant effect on the growth characteristics or responsiveness to DMSO (Table 6). As 
summarized in Table 6 and in the Results section, Tf-gp55 cells exhibited similar growth 
characteristics as Friend cells, and exposure of Tf-gp55 cells to DMSO resulted in a similar 
amount of growth inhibition as in parental MEL cells. In addition, DMSO-pretreated Tf- 
gp55 cells responded to EPO with a similar increase in cell proliferation as was observed 
with parental Friend cells. However, unlike its action upon Friend MEL cells, DMSO 
treatment of Tf-gp55 cells did not confer cellular responsiveness to the differentiation- 
inducing effects of EPO (Table 7). These results suggested that the increased level of 
SFFVp gp55 in DMSO/R1 cells was responsible for the cells' resistance to the restoration 
by DMSO of cellular sensitivity to EPO's differentiation-inducing effects. However, these 
results indicated that the increased level of gp55 in DMSO/R1 cells was not responsible for 
the cells’ resistance to the differentiation-inducing effects of DMSO and to the restoration 
by DMSO of sensitivity to the growth-stimulatory effects of EPO. Some other
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mechanism(s) must account for these two aspects of the resistant phenotype of clone 
DMSO/R1.
Separation of the growth-stimulatory and differentiation-inducing effects of EPO. 
These results demonstrated that the stimulation of proliferation and the induction of 
differentiation by EPO are two separate processes. EPO was able to stimulate cell growth, 
but not increased differentiation, in Tf-gp55 cells that had been pretreated with DMSO, 
indicating that these two cellular pathways are not necessarily linked. It makes 
physiological sense for these two pathways to be connected, as the biological function of 
EPO is to increase the number of circulating erythrocytes and, thus, the oxygen carrying 
capacity of the blood (38,54). EPO increases the erythrocyte population by stimulating the 
proliferation of erythroid progenitor cells, thereby increasing the erythroid cell pool as well 
as replacing differentiating progenitors, and inducing the maturation of erythroid precursor 
cells to mature, functional red blood cells (1,54). However, these results have shown that 
the proliferation and maturation pathways downstream of the EPOR can be disconnected. 
This separation had been suggested by the ability of gp55 to associate with and 
constitutively activate a mitogenic signal, but not a differentiating signal, from the EPOR.
Interestingly, as evidenced by the ability of DMSO to induce the differentiation of 
Tf-gp55 cells, but not to confer sensitivity to the maturation-inducing effects of EPO in the 
same cells, the block in the EPO-induced differentiation of Friend cells does not seem to be 
due simply to a block in tumor cell maturation. Tf-gp55 cells were induced to differentiate 
to the same apparent extent as Friend cells, as evidenced by growth inhibition and Hb 
production (20, 134, 206). Nevertheless, these transfected cells were unable to further 
differentiate in response to EPO. Thus, the ability of a DMSO-treated MEL cell to respond 
to EPO does not appear to be dependent solely upon the stage of differentiation of the 
tumor cell. In normal erythroid progenitor cells, responsiveness to EPO does appear to be 
dependent upon a cell's stage of development and the distance which the cell has traveled 
along the pathway from pluripotent stem cell to mature erythrocyte (38,54). The increase
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
138
in the level of gp55 protein in Tf-gp55 cells, however, resulted in continued blockage of 
EPO-induced maturation despite DMSO-induced differentiation.
Transfection of MEL cells with pRc/RSV-antiscnsc tn?55 cDNA. Of greater interest 
than transfection studies to increase gp55 protein content was the attempt to decrease the 
level of gp55 by the transfection of a vector expressing gp55 cDNA in the antisense 
direction. If the hypothesis that the gp55-EPOR interaction results in a block in EPO- 
induced differentiation is true, a significant decrease in cellular gp55, and thereby gp55- 
EPOR interactions, should allow MEL cells to differentiate in response to EPO in the 
absence of pretreatment with DMSO. However, the results obtained from these antisense 
transfection studies did not fully support nor refute this hypothesis.
Clone B7, derived from MEL cells transfected with pRc/RSV-antisense gp55, was 
hypersensitive to both the differentiadon-inducing and EPO-sensitizing effects of DMSO, 
compared to parental Friend cells (Table 8). DMSO-pretreated B7 cells responded to EPO 
with increased stimuladon of both cell proliferation and further differentiation. However, 
these cells contained only a partially decreased level of gp55 protein and were unresponsive 
to EPO in the absence of DMSO. All further attempts to isolate pRc/RSV-antisense gp55- 
transfected clones with more greatly decreased levels of gp55 were unsuccessful. 
Whatever the role of SFFVp gp55 in blocking MEL cell differentiation may be, gp55 is 
known to be required for EPO independence of MEL cells (104,115). Thus, transfectants 
in which the expression of gp55 is decreased to very low or nonexistent levels are likely to 
be unable to grow in culture in the absence of EPO.
To address this concern, EPO was added to the selection medium and to the 
medium in which clones were expanded after single cell sorting. Unfortunately, this 
modification proved fruitless. Several clones which, in preliminary tests, appeared to 
increase Hb production in response to EPO in the absence of DMSO (data not shown), 
could not be maintained in culture despite repeated attempts. After a limited number of 
passages, these very promising clones stopped growing and could not be maintained in
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culture. While this inability to maintain viable populations of these clones was 
disappointing, this failure was not surprising given the dual effects of EPO upon cells of 
the erythroid lineage (38, 54). EPO that was added to support cell viability and 
proliferation in transfectants with greatly decreased gp55 protein levels may have induced 
these same cells to enter the maturation pathway and lose their capacity to self-replicate (1). 
Thus, it was not unexpected that only cells in which gp55 expression remained above a 
certain threshold level were able to be isolated from the antisense transfection studies.
These results indicated that SFFVp gp55 may play a role in blocking EPO-induced 
differentiation, possibly through its association with the EPOR (104, 122). The question 
of possible relationships between gp55 expression and cellular responsiveness to EPO- 
induced growth stimulation or DMSO-induced differentiation remains unclear. While no 
changes were observed upon increased expression of gp55, increased sensitivity to the 
maturation-inducing and EPO-sensitizing effects of DMSO accompanied a decrease in the 
level of gp55 protein in clone B7. Clones Tf-gp55 and B7 may prove useful tools for the 
study of the signal transduction pathways used by the EPOR to generate mitogenic and 
differentiation signals in the erythroid cell (38, 54, 55). Clone Tf-gp55, in particular, 
offers a cell system in which the differentiating response to EPO has been dissociated from 
the proliferative response to EPO. Studies may be conducted to examine if exposure to 
EPO after DMSO pretreatment results in the activation of different intracellular messenger 
systems than in Friend cells. In particular, activation of a certain messenger pathway in 
Friend cells, but not in Tf-gp55 cells, may be valuable in identifying the possible 
involvement of this pathway in the generation of a differentiation signal.
INTERACTION BETWEEN GP55 AND THE EPOR
Chemical crosslinking to_radioiodinated EPO. Chemical crosslinking was 
performed with a number of different reagents, but none proved to be an efficient 
crosslinker of radiolabeled EPO. Only a small fraction of the radiolabeled EPO that was
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bound to cells was crosslinked to protein, despite the use of several different reagents and 
numerous attempts to optimize crosslinking conditions and minimize any hydrolysis of the 
crosslinker. The binding of radiolabeled EPO was demonstrated to be specific by the 
ability of excess cold EPO to compete for binding (Figure 23). Homobifunctional N- 
hydroxysuccinimide (NHS) esters (DSS, DST, BS^), which react with primary amines on 
lysine or available amino-terminal amines, and a carbodiimide (EDC), which crosslinks an 
amine to a carboxylic acid group, were tested (126-128, 190-198). The tested reagents 
included both water-insoluble, membrane-permeable compounds (DSS, DST) and water- 
soluble, membrane-impermeable compounds (BS^, EDC /  sulfo-NHS). None of these 
compounds, however, crosslinked more than a small fraction of receptor-bound 12̂ I- 
rhEPO to cellular protein.
The ability of a chemical crosslinker to covalently join a radiolabeled ligand to its 
receptor or to a receptor-associated protein depends upon the chemical specificity and the 
spacer arm length of the reagent. The chemical specificity of a crosslinking reagent resides 
in the functional reactive group or groups which are contained in the reagent (214). 
Different reactive groups couple to different amino acid residues, and only reagents with 
the appropriate functional group(s) can crosslink two proteins. Additionally, the distance 
between the targeted amino acid residues on the two proteins must be bridged by the 
crosslinker in order for covalent linkage to occur (214). The inability of myriad attempts to 
covalently link radioiodinated EPO to its receptor is, in all probability, due to a lack of 
suitable amino acid residues on the two proteins that are in close enough physical proximity 
to be joined by available crosslinking reagents. The crosslinking of radiolabeled EPO to 
SFFVp gp55 in a Friend MEL cell line (115,123) indicated that gp55 must be associated 
with the EPOR and that the spatial relationship of the bound EPO molecule and gp55 
allowed the intermolecular distance to be bridged by a crosslinker.
As shown in Figures 23 to 25, radiolabeled EPO was crosslinked primarily to a 
protein of a molecular weight of 60-65 kDa, which has been previously identified by other
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investigators as SFFVp gp55 and not the EPOR (123). A protein of approximately 120 
kDa was also crosslinked to 125I-rhEPO when a combination of DSS and DST was used 
(Figure 25). This second protein may represent a dimer of gp55, as gp55 has been shown 
to form disulfide-linked homodimers in Friend MEL cells (27,107, 115,117). Attempts 
to positively identify the smaller and larger proteins by immunoprecipitation of 125I-rhEPO- 
crosslinked proteins from cellular lysates were unsuccessful. This lack of success was 
likely due to the very small amount of EPO-crosslinked proteins present in the binding 
mixture and the resultant inability to immunoprecipitate detectable amounts of proteins.
Induction of MEL cell differentiation did not result in disappearance of either the 
60-65 kDa or 120 kDa crosslinked protein. On the contrary, the amounts of the two EPO- 
crosslinked proteins appeared to have increased upon DMSO treatment, although this was 
difficult to determine due to the faintness of the crosslinked bands. In addition, similar 
amounts of both crosslinked proteins were observed in DMSO/R1 cells, and DMSO 
treatment seemed to have a similar effect on EPO-crosslinking in resistant cells as in 
parental MEL cells.
These results were surprising for several reasons. First, these findings 
demonstrated that induction of differentiation by DMSO was not accompanied by 
dissociation of SFFVp gp55 from the EPOR, as the putative gp55 protein was still 
crosslinked to EPO after 4 days of DMSO treatment. Secondly, the amount of ^1-rhEPO- 
crosslinked gp55 appeared to increase upon DMSO induction of differentiation, although 
the number of receptors was shown to decrease from 180 to 110 receptors per cell over the 
same time period. Similarly, comparable levels of EPO-crosslinking to DMSO/R1 cells 
were observed, although binding studies demonstrated that DMSO/R1 cells express one- 
third the number of EPORs expressed by parental MEL cells. Thus, while DMSO 
induction of differentiation does not result in dissociation of SFFVp gp55 from the EPOR, 
some other change in the EPOR complex may be occurring, as a model in which the EPOR 
complex remains static does not fit the crosslinking results. In any case, crosslinking of
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EPO to gp55 must occur through interaction of EPO to the EPOR, since it has been 
demonstrated that EPO does not bind to cells expressing gp55 but not the EPOR (57,115).
Differences between water-insoluble and water-soluble crosslinkers. Interestingly, 
the amount of ^ j^ E P O -c ro ss lin k e d  gp55 was greater when a water-insoluble, 
membrane-permeable reagent was used, either alone (DSS) or in combination with another 
compound of a similar class (DSS and DST), rather than a water-soluble, membrane- 
impermeable reagent (BS3 or the combination of EDC and sulfo-NHS). O f note, the 
reported crosslinking of radiolabeled EPO to SFFVp gp55 in MEL cells had been achieved 
with DSS (123). Classically, surface membrane proteins are crosslinkable by both water- 
soluble and water-insoluble reagents, whereas integral membrane proteins are conjugable 
by water-insoluble, but not water-soluble, reagents (214). The reason is obvious; water- 
soluble compounds are not able to permeate the membrane. Such an explanation does not 
seem plausible in this situation, however, since EPO is known to bind to the exoplasmic 
domain of its receptor (55,57). Thus, bound EPO must be on the exoplasmic surface of 
the plasma membrane, rather than imbedded in the membrane, and should be reachable by 
water-soluble crosslinkers. In addition, although little if any crosslinking was observed 
with the combination of EDC and sulfo-NHS, the other water-soluble crosslinker, BS3, 
was able to conjugate 125I-rhEPO to gp55.
Two other characteristics of the tested water-soluble reagents may explain their 
inferior ability to crosslink radiolabeled EPO to gp55. First, EDC, being a carbodiimide 
(195-197), is in an altogether different class of reagents from DSS, DST and BS3, which 
are all homobifunctional NHS esters (126-128, 190-193). EDC can only crosslink an 
amine on one protein to a carboxylic acid group on a second protein, whereas the NHS 
esters crosslink a primary amine on one protein to a primary amine on a second (214). 
Thus, an exposed carboxylic acid at the right distance from an amine may not be present on 
the second protein. Secondly, the spacer arm length of DST, 6.4 angstroms, is 
considerably shorter than the spacer arm lengths of DSS or BS3, which are both 11.4
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angstroms (214). Thus, the combination of DSS and DST may be able to each form one 
crosslink, incorporating twice as much label as BS3 alone.
Cell surface labeling of SFFVp gp55. Since the crosslinking of EPO to gp55 
appeared to increase with induction of differentiation, cell surface labeling studies (199- 
203) were conducted to determine if cell surface expression of SFFVp gp55 increased with 
DMSO treatment. A small amount of SFFVp gp60-65 was seen in Friend MEL cells, 
indicative of the low percentage (2-5%) of the SFFVp env gene product that is transported 
to the cell surface (Figure 27) (27, 116). Markedly decreased labeling of F-MuLV gp70, 
and no SFFVp gp60-65, was observed in DMSO/R1 cells. Not only did the increased 
level of SFFVp gp55 in DMSO/R1 cells not result in increased cell surface expression of 
SFFVp gp60-65, DMSO/R1 cells exhibited markedly less surface gp60-65 than parental 
MEL cells. The decrease in surface F-MuLV gp70 in DMSO/R1 cells was unexpected, as 
this glycoprotein is not throught to have any role in the mitogenic activation of the EPOR or 
in blockage of EPO-induced differentiation (27). However, the decreases in the the cell 
surface expression of the two viral envelope glycoproteins in DMSO/R1 cells appeared 
specific, as total labeled surface proteins did not change remarkably from parental MEL 
cells (Figure 26).
While total cell surface labeled proteins increased upon exposure of Friend MEL or 
DMSO/R1 cells to DMSO (Figure 26), DMSO treatment of both cell lines resulted in 
greater increases in surface labeling of both F-MuLV gp70 and the 60-65 kDa protein 
thought to be the maturely glycosylated envelope form of SFFVp gp55 (Figure 27). In 
addition, cell surface labeled protein gp55 was observed in DMSO-treated MEL cells but 
not in DMSO-resistant cells exposed to DMSO. This result was quite surprising, as the 55 
kDa form of the SFFVp env gene product normally represents immaturely glycosylated 
protein that has not traversed the Golgi complex (27, 107, 116). This Finding suggested 
that DMSO treatment may disrupt normal intracellular transport, resulting in transport of 
immaturely glycosylated gp55 to the cell surface without carbohydrate processing.
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To explore alternative explanations for this observation, the mechanism of action of 
lactoperoxidase-glucose oxidase radioiodination must be reviewed (199-203). In the 
Enzymobead preparation used in these studies, the two enzymes are immobilized on 
hydrophilic spheres several microns in diameter. The glucose oxidase generates hydrogen 
peroxide from p-D-glucose, and lactoperoxidase catalyzes the peroxide oxidation of labeled 
iodide to 125l2 . 125l2 reacts with cellular proteins to produce radioiodinated proteins. 
Given the membrane perturbing effects of DMSO (211), it is conceivable that exposure of 
MEL cells to DMSO may disrupt the plasma membrane to such an extent that a molecule 
such as 12̂ l2  may diffuse through the plasma membrane to radioiodinate proteins that are 
intracellular. The size of the Enzymobead spheres precludes the possiblity of 
intemalizadon of the spheres.
What argues against both proposed explanations, however, is the apparent relative 
specificity of this increase in cell surface labeling of SFFVp gp55 and F-MuLV gp70. If 
disruption of membrane protein transport or diffusion of 12̂ l2 into the cell was occurring, 
then labeling of other immaturely glycosylated proteins or labeling of proteins not normally 
expressed on the cell surface would be expected. However, although total cell surface 
labeling increased with DMSO treatment, the same labeled bands were prominent in both 
control and treated cells. Additionally, the increase in the viral envelope glycoproteins was 
more pronounced than the increase in total surface proteins.
Similar experiments with clones Tf-gp55 and B7 demonstrated the apparent lack of 
a relationship between total SFFVp gp55 content and surface expression of the envelope 
protein (Figure 28). Both sense and antisense gp55-transfected cells exhibited similar 
surface labeling of F-MuLV gp70 and SFFVp gp65 as did parental MEL cells. Although 
both DMSO/R1 and Tf-gp55 cells showed increased total cellular SFFVp envelope 
glycoprotein, the amount of cell surface gp65 was quite different in the two cell lines, with 
clone Tf-gp55 expressing a similar amount as the parental Friend MEL clone as well as 
clone B7. Similar to its effects upon Friend cells, DMSO increased labeling of both F-
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MuLV gp70 and SFFVp gp65 and induced the labeling of SFFVp gp55 in both transfected 
clones. These results demonstrated no relationship between the level of cell surface SFFVp 
gp60-65 and responsiveness to the differentiation-inducing and EPO-sensitizing effects of 
DMSO.
Coimmunoprecipitation studies of SFFVp gp55 and the EPOR. To more directly 
determine if induction of MEL cell differentiation results in dissociation of SFFVp gp55 
from the EPOR, coimmunoprecipitation experiments were performed (Figures 29-33). 
These studies took advantage of the difference between the sizes of the SFFVp env gene 
product expressed on the cell surface (65 kDa) and in the RER (55 kDa) to determine which 
of the two forms associated with the EPOR (27,116). The goat polyclonal a-MuLV gp70 
antiserum more efficiently immunoprecipitated SFFVp gp55 than F-MuLV gp70, as 
Western blotting demonstrated a higher ratio of gp55 to gp70 in immunoprecipitates than in 
cellular lysates (Figure 29). This finding provided a possible explanation for the higher 
ratio of gp70 to gp55 detected in Western blots than in immunoprecipitation of 
metabolically labeled cellular lysates, despite the shorter half-life of gp70.
Figures 29 demonstrated that only the SFFVp env gene product, and not F-MuLV 
gp70, associated with the EPOR, as immunoprecipitation of the EPOR did not coprecipitate 
gp70. Both the cell surface gp65 form and the RER gp55 form coimmunoprecipitated with 
the EPOR, and the amounts of the two forms that associated in parental MEL and 
DMSO/R1 cells appeared to be similar. While only 2-5% of the SFFVp env gene product 
is expressed on the MEL cell surface in its mature 65 kDa form (27,116), approximately 
equal amounts of gp65 and gp55 were coimmunoprecipitated with the EPOR, indicative 
that the small amount of cell surface protein accounted for a significant fraction of the 
SFFVp env gene product's interaction with the EPOR. Western blotting of MEL and 
DMSO/R1 cellular lysates with rabbit a-mEPOR antiserum detected a prominent band at 
approximately 105 kDa (Figure 30). Whether this band represented an immunologically 
related protein, perhaps a covalently linked homodimer of the receptor, or a protein
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nonspecifically recognized by rabbit antiserum was not determined. Such a determination 
can be made by performing Western blot analysis of cellular lysate with rabbit preimmune 
serum. Whatever the identity of this band, it was not recognized by the same rabbit a- 
mEPOR antiserum in immunoprecipitation studies and was not coprecipitated during 
immunoprecipitation of SFFVp gp55.
Interestingly, bands of 60 kDa and 65 kDa, corresponding to the reported molecular 
sizes of newly synthesized and maturely glycosylated EPOR, were far more prominent in 
Western blots of a-mEPOR immunoprecipitates than of cellular lysates. This finding that 
the rabbit a-mEPOR antiserum appeared to efficiently recognize and bind the EPOR in 
cellular lysate samples was interesting, given the inability to detect significant levels of 
metabolically labeled or cell surface labeled EPOR in earlier experiments. It is possible that 
labeling of the EPOR with 35S-methionine or radioiodination with Na125I interfered, in 
some way, with recognition of the receptor by the antiserum, resulting in this apparent 
discrepancy in affinity of the a-mEPOR antiserum. The results depicted in Figure 31 
demonstrated that the goat anti-rabbit secondary antibody directly recognized the denatured 
immunoglobulin (Ig) heavy chain of the rabbit a-mEPOR antibody, used in 
immunoprecipitations, that had been subjected to SDS-PAGE and transferred to membrane. 
It was somewhat surprising that a similar experiment showed that the rabbit anti-goat 
secondary antibody did not recognize the denatured Ig heavy chain of the goat a-MuLV 
gp70 antibody that had been subjected to SDS-PAGE and transferred (data not shown).
The results depicted in Figures 32 and 33 suggested that SFFVp gp55 and gp65 did 
not dissociate from the mEPOR upon induction of MEL cell differentiation, as both forms 
of the SFFVp env gene product were still coimmunoprecipitated with the EPOR (Figure 
32). The amount of EPOR coimmunoprecipitated with the SFFVp envelope glycoproteins 
did not change with exposure of Friend MEL or DMSO/R1 cells to DMSO, also suggestive 
that the amount of association between the receptor and gp55 (and gp65) did not change 
upon DMSO treatment. However, an important limitation of these coimmunoprecipitation
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studies must be kept in consideration when interpreting these results. The ability of the a- 
mEPOR anti serum to coimmunoprecipitate SFFVp gp65 in a cellular lysate may represent a 
true association of the two proteins ir. the living cell but may also represent an experimental 
artifact arising from association in vitro after cellular lysis. The only true way to answer 
this question is through careful fractionation of plasma membrane away from other 
membrane compartments, including the RER, prior to examination of the SFFVp gp65- 
EPOR interaction. Such an experiment has not been reported in the literature, probably due 
to the extremely low number of EPORs expressed on the surface of MEL cells and the 
accompanying technical difficulties associated with careful fractionation of cell membranes.
GP55 AND THE BLOCK IN EPO-INDUCED DIFFERENTIATION OF MEL CELLS
These investigations have attempted to examine the role of the SFFVp env gene 
product, gp55 (27, 107, 111, 112), in the block in the EPO-induced differentiation of 
Friend MEL cells. The ability of DMSO to induce maturation of Friend MEL cells (20) has 
been studied to determine the effects of this maturation upon the relationship and interaction 
between SFFVp gp55 and the EPOR. An MEL subline that was resistant to the 
differentiation-inducing and EPO-sensitizing effects of DMSO, and that expressed greatly 
increased amounts o f total cellular SFFVp gp55, was developed and studied to help 
determine the changes in the interaction of gp55 with the EPOR.
Increased expression of total cellular gpSS protein resulted in blockage of the ability 
of DMSO to restore sensitivity to EPO-induced differentiation. Such an increase, however, 
did not result in blockage of the abilities of DMSO to induce maturation or to restore 
sensitivity to EPO-induced proliferation. These distinctions are subtle but important points. 
First, the induction of MEL cell differentiation and the restoration of responsiveness to 
EPO, or at least to the maturation-inducing effects of EPO, by DMSO are two separable 
processes, indicating that the pathways are not identical. Thus, DMSO does not restore 
EPO responsiveness merely by stimulating Friend cells to progress down the maturation
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pathway to a certain stage in development. Instead, DMSO must act on some other level to 
permit the differentiation-induced cell to respond to EPO with further maturation.
Secondly, the abilities of EPO to stimulate proliferation and induce differentiation of 
DMSO-treated Friend MEL are also separable events. If extrapolated to the function of 
EPO in normal erythropoiesis, his latter distinction has wider implications, as EPO serves 
dual, and seemingly contradictory, roles as mitogenic factor and differentiation inducer (38, 
54). As discussed earlier in this section, the roles of EPO as growth stimulant and 
maturation inducer fit physiologically, as proliferation and self-renewal of the erythroid 
progenitor population is needed to replace precursors that have committed to terminal 
differentiation and production of functional, end-stage erythrocytes (1). The SFFVp 
envelope glycoprotein, gp55, binds to the EPOR and induces cell growth (104) but not 
differentiation, indicative of the separation of the signaling pathways for these two 
biological pathways. Clone Tf-gp55 represents an example in which that separation of 
cellular events downstream of the EPOR is seen, not with a transforming viral envelope 
glycoprotein but, with the natural ligand for the receptor, EPO.
The role of SFFVp gp55 in the block in the EPO-induced differentiation of Friend 
cells is, however, unclear. Coimmunoprecipitation and crosslinking studies indicated that 
dissociation of gp55 or gp65, the cell surface form of the SFFVp env gene product, from 
the EPOR does not appear to occur. These investigations have disproved the model that 
had originally been proposed, that of DMSO’s acting upon the EPOR complex to dissociate 
SFFVp gp55 from the receptor and thus "free" the receptor to transduce the mitogenic and 
differentiating signals of EPO. However, DMSO may still alter the EPOR complex in such 
a way that transduction of a maturation-inducing signal from the receptor can occur. 
DMSO may perturb the plasma membrane, changing the gp55-EPOR complex enough that 
a third protein, necessary to generate a differentiation signal, can bind to the EPOR. Such a 
model is possible, especially given the change in receptor binding affinity seen upon
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DMSO treatment of Friend cells, which may be due to perturbation o f the plasma 
membrane and EPOR conformation by DMSO.
Alternatively, DMSO may circumvent the gp55-EPOR complex entirely and induce 
differentiation and restore EPO responsiveness at a different cellular site altogether. While 
it is likely that DMSO induces MEL cell maturation through this manner, the restoration of 
EPO responsiveness by this manner is more speculative, given the known interaction of 
gp55 with the EPOR (104, 122) and the results observed with clone Tf-gp55. What that 
cellular site may be is open to speculation, as DMSO has been demonstrated to exert a wide 
range of effects upon cells, from membrane perturbations (211) to induction of a number of 
second messenger systems, as reviewed in the Introduction section (46-53). DMSO may, 
in fact, act upon several cellular systems which are all important in the induction of 
differentiation. The study of DMSO as an inducer of MEL cell differentiation, and as a 
restorer of EPO responsiveness, is greatly complicated by this range of nonspecific actions.
Thus, while SFFVp gp55 appears to be important in blocking the EPO-induced 
differentiation of Friend MEL cells, the mechanism by which DMSO restores EPO 
responsiveness remains unclear. The Friend cell system, while a fascinating model of 
tumorigenesis and differentiation, is a system in which differentiation, particularly EPO- 
induced maturation, is difficult to study for a number of reasons. The low expression of 
EPORs (55), the low level of cell surface SFFVp gp65 (27, 116), and the promiscuous 
effects of the differentiation inducer DMSO (46-49,51-53,211) all contribute to complicate 
the study of Friend MEL cell differentiation. However, unlike the study of EPO-induced 
proliferation, which is readily studied in non-erythroid cell lines transfected to overexpress 
the EPOR (104, 115), the investigation of erythroid differentiation must be performed in 
erythroid cells, including the Friend system.
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SUMMARY
These studies have provided evidence that DMSO induces Friend cell differentiation 
and restores EPO responsiveness at a cellular site downstream of EPOR expression and the 
binding of EPO to its receptor. The results of the binding assays demonstrated that DMSO 
does not restore EPO sensitivity through increased receptor expression, induction of a new 
high-affinity class of receptor, or induction of cooperative binding. As demonstrated by 
the transfection studies with clone Tf-gp55, restoration of responsiveness to the 
differentiating effects of EPO does not necessarily accompany DMSO-induced Friend cell 
maturation and is not dependent solely upon the stage of maturation of the cell. Thus, 
DMSO must restore EPO responsiveness through some mechanism other than induction of 
differentiation. The same transfection studies provided evidence that EPO can induce a 
mitogenic signal in the absence of a differentiation signal, demonstrating that these dual 
effects of EPO are separable processes.
While clone DMSO/R1 exhibited an increased level of total cellular gp55 protein, 
this increase did not appear to be the cause of the subline's resistance to the differentiating 
effects of DMSO. However, the transfection studies demonstrated that this increased 
amount of gp55 is sufficient to maintain the block in EPO-induced differentiation despite 
pretreatment of cells with DMSO. Although these investigations have provided evidence 
that SFFVp gp55 plays a role in the block in the EPO-induced differentiation of Friend 
MEL cells, the mechanism by which this block occurs and the mechanism by which DMSO 
removes this block remain unclear. These studies have shown, however, that DMSO does 
not induce the dissociation of gp55 from the EPOR in Friend cells.
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